<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001992.pub3" GROUP_ID="PREG" ID="427199102014142561" MERGED_FROM="" MODIFIED="2015-05-21 12:17:05 +0100" MODIFIED_BY="Leanne Jones" REVIEW_NO="0199" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2015-05-21 12:17:05 +0100" MODIFIED_BY="Leanne Jones">
<TITLE MODIFIED="2014-01-15 15:13:12 +0000" MODIFIED_BY="Frances Kellie">Cyclo-oxygenase (COX) inhibitors for treating preterm labour</TITLE>
<CONTACT MODIFIED="2015-05-21 12:17:05 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="z1309180919290569750731827844581" ROLE="AUTHOR"><FIRST_NAME>Hanna</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Reinebrant</LAST_NAME><POSITION>Research Officer</POSITION><EMAIL_1>hanna.reinebrant@mater.uq.edu.au</EMAIL_1><EMAIL_2>hanna.reinebrant@gmail.com</EMAIL_2><MOBILE_PHONE>+61 415 485742</MOBILE_PHONE><ADDRESS><DEPARTMENT>Translating Research Into Practice (TRIP) Centre</DEPARTMENT><ORGANISATION>Mater Research Institute - The University of Queensland (MRI-UQ)</ORGANISATION><ADDRESS_1>Level 2 Aubigny Place, Mater Health Services</ADDRESS_1><ADDRESS_2>Annerley Road, Woolloongabba</ADDRESS_2><CITY>Brisbane</CITY><ZIP>4102</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 31632119</PHONE_1><FAX_1>+61 7 31632550</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-05-21 12:17:05 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="z1309180919290569750731827844581" ROLE="AUTHOR"><FIRST_NAME>Hanna</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Reinebrant</LAST_NAME><POSITION>Research Officer</POSITION><EMAIL_1>hanna.reinebrant@mater.uq.edu.au</EMAIL_1><EMAIL_2>hanna.reinebrant@gmail.com</EMAIL_2><MOBILE_PHONE>+61 415 485742</MOBILE_PHONE><ADDRESS><DEPARTMENT>Translating Research Into Practice (TRIP) Centre</DEPARTMENT><ORGANISATION>Mater Research Institute - The University of Queensland (MRI-UQ)</ORGANISATION><ADDRESS_1>Level 2 Aubigny Place, Mater Health Services</ADDRESS_1><ADDRESS_2>Annerley Road, Woolloongabba</ADDRESS_2><CITY>Brisbane</CITY><ZIP>4102</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 31632119</PHONE_1><FAX_1>+61 7 31632550</FAX_1></ADDRESS></PERSON><PERSON ID="6C9749EC82E26AA20075541C0765C73F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cynthia</FIRST_NAME><LAST_NAME>Pileggi-Castro</LAST_NAME><POSITION>Medical Doctor, PhD</POSITION><EMAIL_1>cynthiapileggi@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Ribeirão Preto Medical School, University of São Paulo</ORGANISATION><ADDRESS_1>Av. Bandeirantes, 3900</ADDRESS_1><CITY>Ribeirão Preto, SP</CITY><ZIP>14049-900</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON><PERSON ID="z1311281027127379509754674845562" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Carla</FIRST_NAME><MIDDLE_INITIALS>LT</MIDDLE_INITIALS><LAST_NAME>Romero</LAST_NAME><POSITION>Medical Student</POSITION><EMAIL_1>carla.lionela@hotmail.com</EMAIL_1><EMAIL_2>carla.romero@usp.br</EMAIL_2><MOBILE_PHONE>+55 16 997955333</MOBILE_PHONE><ADDRESS><DEPARTMENT>Ribeirão Preto Medical School</DEPARTMENT><ORGANISATION>University of São Paulo</ORGANISATION><ADDRESS_1>Avenida Bandeirantes 3900</ADDRESS_1><CITY>Ribeirão Preto</CITY><ZIP>14049-900</ZIP><REGION>Sao Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 16 32894391</PHONE_1></ADDRESS></PERSON><PERSON ID="z1312051022035027023519859683587" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Rafaela</FIRST_NAME><MIDDLE_INITIALS>AN</MIDDLE_INITIALS><LAST_NAME>dos Santos</LAST_NAME><POSITION>Medical Student</POSITION><EMAIL_1>fafa_neman@hotmail.com</EMAIL_1><EMAIL_2>rafaela.augusto.santos@usp.br</EMAIL_2><MOBILE_PHONE>+55 16 981679433</MOBILE_PHONE><ADDRESS><ORGANISATION>Ribeirão Preto Medical School, University of São Paulo</ORGANISATION><ADDRESS_1>Avenida Bandeirantes 3900</ADDRESS_1><CITY>Ribeirão Preto</CITY><ZIP>14049-900</ZIP><REGION>Sao Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON><PERSON ID="z1405021138231273790996663641410" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Sailesh</FIRST_NAME><LAST_NAME>Kumar</LAST_NAME><EMAIL_1>sailesh.kumar@mater.uq.edu.au</EMAIL_1><ADDRESS><ORGANISATION>Mater Health Services</ORGANISATION><CITY>Brisbane</CITY><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="743BC47E82E26AA2017F61BB54093172" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>João Paulo</FIRST_NAME><LAST_NAME>Souza</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>jpsouza@fmrp.usp.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Social Medicine</DEPARTMENT><ORGANISATION>Ribeirão Preto Medical School, University of São Paulo</ORGANISATION><ADDRESS_1>Avenida dos Bandeirantes, 3900. Campus Universitário - Bairro Monte Alegre</ADDRESS_1><CITY>Ribeirão Preto</CITY><ZIP>14049-900</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 (16) 3602 2536</PHONE_1></ADDRESS></PERSON><PERSON ID="4620" ROLE="AUTHOR"><FIRST_NAME>Vicki</FIRST_NAME><LAST_NAME>Flenady</LAST_NAME><SUFFIX>PhD, MMedSc (ClinEpid)</SUFFIX><POSITION>Director</POSITION><EMAIL_1>vflenady@mmri.mater.org.au</EMAIL_1><ADDRESS><DEPARTMENT>Translating Research Into Practice (TRIP) Centre</DEPARTMENT><ORGANISATION>Mater Research Institute - The University of Queensland (MRI-UQ)</ORGANISATION><ADDRESS_1>Level 2 Aubigny Place, Mater Health Services</ADDRESS_1><ADDRESS_2>Annerley Road, Woolloongabba</ADDRESS_2><CITY>Brisbane</CITY><ZIP>4102</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 38401591</PHONE_1><FAX_1>+61 7 38401588</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-10-28 09:05:33 +0000" MODIFIED_BY="Lynn Hampaon">
<UP_TO_DATE>
<DATE DAY="24" MONTH="8" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="8" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="24" MONTH="8" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2014-10-28 09:06:00 +0000" MODIFIED_BY="Lynn Hampaon">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-10-28 09:05:53 +0000" MODIFIED_BY="Lynn Hampaon">
<DATE DAY="24" MONTH="8" YEAR="2014"/>
<DESCRIPTION>
<P>With the addition of seven studies with a total of 684 women, this review now includes outcome data from 20 studies including 1509 women. The conclusions of the previous review remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-10-28 09:06:00 +0000" MODIFIED_BY="Lynn Hampaon">
<DATE DAY="24" MONTH="8" YEAR="2014"/>
<DESCRIPTION>
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trial Register and identified additional studies for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-01-14 12:50:41 +0000" MODIFIED_BY="Jill V Hampson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-01-14 12:50:41 +0000" MODIFIED_BY="Jill V Hampson">
<DATE DAY="1" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated. Seven reports added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> (Bartfield 1998a; Borna 2007a; Caballero 1979a; Gamissans 1984a; Groom 2005a; Jain 2006a; Shrivastava 2008a).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-27 10:30:53 +0000" MODIFIED_BY="Jill V Hampson">
<DATE DAY="12" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Centre for Clinical Studies - Women's and Children's Health, Mater Mothers' Hospital, South Brisbane, Queensland</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of Perinatal Medicine, Royal Women's Hospital, Melbourne, Victoria</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of Biological Sciences, University of Warwick, Coventry</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Health and Ageing, Commonwealth Government, Canberra - Supporting the Centre for Clinical Studies, Mater Hospital</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-05-21 12:13:11 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-04-13 13:54:35 +0100" MODIFIED_BY="Heather Maxwell">
<TITLE MODIFIED="2008-05-12 15:41:53 +0100" MODIFIED_BY="[Empty name]">Cyclo-oxygenase (COX) inhibitors for treating preterm labour</TITLE>
<SUMMARY_BODY MODIFIED="2015-04-13 13:54:35 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not enough evidence on whether COX inhibitors administered to women in threatened premature labour may reduce the risk of babies being born too early.</P>
<P>Babies born too early are at increased risk of serious illness, and often do not survive. COX inhibitors inhibit uterine contractions, so may postpone birth to allow the administration of steroids to the mother to help mature the baby's lungs. COX inhibitors may have adverse effects on the baby's heart, lungs and kidneys, and on the mother. Other drugs given for premature labour also have side effects. This review found that COX inhibitors may be better than no treatment, or other drugs, in reducing the number of babies born too early; however, there is insufficient evidence on possible adverse effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-04-27 11:10:00 +0100" MODIFIED_BY="Leanne V Jones">
<ABS_BACKGROUND MODIFIED="2015-04-13 18:05:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>Preterm birth is a major cause of perinatal mortality and morbidity. Cyclo-oxygenase (COX) inhibitors inhibit uterine contractions, are easily administered and appear to have few maternal side effects. However, adverse effects have been reported in the fetus and newborn as a result of exposure to COX inhibitors.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-09-04 05:48:21 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>To assess the effects on maternal and neonatal outcomes of COX inhibitors administered as a tocolytic agent to women in preterm labour when compared with (i) placebo or no intervention and (ii) other tocolytics. In addition, to compare the effects of non-selective COX inhibitors with COX-2 selective inhibitors.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-04-01 13:28:38 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (24 August 2014). We also contacted recognised experts and searched reference lists of retrieved studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-10-23 02:38:06 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>All published and unpublished randomised trials in which COX inhibitors were used for tocolysis for women in labour between 20 and 36 completed weeks' gestation.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-04-13 18:05:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>Two review authors independently evaluated methodological quality and extracted data. We sought additional information from study authors. Results are presented using risk ratio (RR; dichotomous data) and mean difference (MD; continuous data) with 95% confidence interval (CI). The number needed to treat for benefit (NNTB) and the number needed to treat for harm (NNTH) were calculated for statistically different categorical outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-04-27 11:10:00 +0100" MODIFIED_BY="Leanne V Jones">
<P>With the addition of seven studies with a total of 684 women, this review now includes outcome data from 20 studies including 1509 women. The non-selective COX inhibitor indomethacin was used in 15 studies. The overall quality of the included studies was considered moderate to low.</P>
<P>Three small studies (102 women), two of which were conducted in the 1980's, compared COX inhibition (indomethacin only) with placebo. No difference was shown in birth less than 48 hours after trial entry (average RR 0.20, 95% CI 0.03 to 1.28; two studies with 70 women). Indomethacin resulted in a reduction in preterm birth (before completion of 37 weeks of gestation) in one small study (36 women) (RR 0.21, 95% CI 0.07 to 0.62; NNTB 2, 95% CI 2 to 4); and an increase in gestational age at birth (average MD 3.59 weeks, 95% CI 0.65 to 6.52; two studies with 66 women) and birthweight (MD 716.34 g, 95% CI 425.52 to 1007.16; two studies with 67 infants). No difference was shown in measures of neonatal morbidity or neonatal mortality.</P>
<P>Compared with betamimetics, COX inhibitors resulted in a reduction in birth less than 48 hours after trial entry (RR 0.27, 95% CI 0.08 to 0.96; NNTB 7, 95% CI 6 to 120; two studies with 100 women) and preterm birth (before completion of 37 weeks of gestation) (RR 0.53, 95% CI 0.28 to 0.99; NNTB 6, 95% CI 4 to 236; two studies with 80 women) although no benefit was shown in terms of neonatal morbidity or mortality. COX inhibition was also associated with fewer maternal adverse affects compared with betamimetics (RR 0.19, 95% CI 0.11 to 0.31; NNTB 3, 95% CI 2 to 3; five studies with 248 women) and maternal adverse effects requiring cessation of treatment (average RR 0.09, 95% CI 0.02 to 0.49; NNTB 5, CI 95% 5 to 9; three studies with 166 women).</P>
<P>No differences were shown when comparing COX inhibitors with magnesium sulphate (MgSO<SUB>4</SUB>) (seven studies with 792 women) or calcium channel blockers (CCBs) (two studies with 230 women) in terms of prolonging pregnancy or for any fetal/neonatal outcomes. There were also no differences in very preterm birth (before completion of 34 weeks of gestation) and no maternal deaths occurred in the one study that reported on this outcome. However COX inhibitors resulted in fewer maternal adverse affects when compared with MgSO<SUB>4</SUB> (RR 0.39, 95% CI 0.25 to 0.62; NNTB 11, 95% CI 9 to 17; five studies with 635 women).</P>
<P>A comparison of non-selective COX inhibitors versus any COX-2 inhibitor (two studies with 54 women) did not demonstrate any differences in maternal, fetal or neonatal outcomes.</P>
<P>No data were available to assess COX inhibitors compared with oxytocin receptor antagonists (ORAs). Further, no data were available on extremely preterm birth (before 28 weeks of gestation), longer-term infant outcomes or costs.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-11-07 10:18:45 +0000" MODIFIED_BY="[Empty name]">
<P>In this review, no clear benefit for COX inhibitors was shown over placebo or any other tocolytic agents. While some benefit was demonstrated in terms of postponement of birth for COX inhibitors over placebo and betamimetics and also maternal adverse effects over betamimetics and MgSO<SUB>4</SUB>, due to the limitations of small numbers, minimal data on safety, lack of longer-term outcomes and generally low quality of the studies included in this review, we conclude that there is insufficient evidence on which to base decisions about the role of COX inhibition for women in preterm labour. Further well-designed tocolytic studies are required to determine short- and longer-term infant benefit of COX inhibitors over placebo and other tocolytics, particularly CCBs and ORAs. Another important focus for future studies is identifying whether COX-2 inhibitors are superior to non-selective COX inhibitors. All future studies on tocolytics for women in preterm labour should assess longer-term effects into early childhood and also costs.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-05-20 14:48:57 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-04-13 18:07:32 +0100" MODIFIED_BY="Heather Maxwell">
<CONDITION MODIFIED="2014-09-05 02:57:51 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Preterm birth, defined as birth occurring between 20 and 36 weeks of gestation is a major contributor to perinatal mortality and morbidity.</P>
<P>The rate of preterm birth is increasing across low- and middle-income countries, affecting 8.6% of births in high-income countries and between 7.4% to 13.3% in low- and middle-income countries (<LINK REF="REF-WHO-2012" TYPE="REFERENCE">WHO 2012</LINK>). Preterm birth is a leading cause of perinatal morbidity including respiratory distress syndrome, chronic lung disease, intraventricular haemorrhage, sepsis, cerebral palsy and other forms of neuro-developmental impairment (<LINK REF="REF-Gladstone-2011" TYPE="REFERENCE">Gladstone 2011</LINK>), blindness and deafness. The birth of a preterm infant who requires intensive care for survival is a crisis, not only for the infant, but also for the parents (<LINK REF="REF-McCain-1993" TYPE="REFERENCE">McCain 1993</LINK>). The costs to the parents, community and society as a whole, both economic and emotional, are substantial (<LINK REF="REF-Petrou-2011" TYPE="REFERENCE">Petrou 2011</LINK>).<BR/>
</P>
<P>Approximately 65% to 70% are spontaneous preterm births either following spontaneous preterm labour (40% to 45%) and those following preterm rupture of membranes (25% to 30%) (<LINK REF="REF-Goldenberg-2008" TYPE="REFERENCE">Goldenberg 2008</LINK>). While the cause of spontaneous preterm birth is often unclear, some risk factors have been identified including: maternal age (adolescence and advanced age); history of preterm birth; race; multiple pregnancy, short inter-pregnancy interval; infections; medical conditions; poor nutrition; psychological factors and genetic predisposition (<LINK REF="REF-Goldenberg-2008" TYPE="REFERENCE">Goldenberg 2008</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-04-13 18:06:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>Despite improvements in standards in obstetric and neonatal care over recent years, no progress has been made over the last two decades in reducing the incidence of preterm birth in high-income countries. In fact, rates of preterm birth are rising, in part due to increasing obstetric intervention (<LINK REF="REF-Goldenberg-2008" TYPE="REFERENCE">Goldenberg 2008</LINK>; <LINK REF="REF-Norman-2009" TYPE="REFERENCE">Norman 2009</LINK>). Some benefits have been identified from prolongation of pregnancy, which theoretically allows time for corticosteroids to be administered to the mother to hasten fetal lung maturation (<LINK REF="REF-Roberts-2006" TYPE="REFERENCE">Roberts 2006</LINK>), to effect transfer to a centre with neonatal intensive care facilities (<LINK REF="REF-Powell-1995" TYPE="REFERENCE">Powell 1995</LINK>) and magnesium sulphate (MgSO<SUB>4</SUB>) administration to reduce risk of cerebral palsy (<LINK REF="REF-Doyle-2009" TYPE="REFERENCE">Doyle 2009</LINK>). For these reasons, short-term tocolytic therapy is commonly used to inhibit preterm labour and postpone preterm birth.</P>
<P>A range of pharmacological agents (tocolytics) have been used to inhibit preterm labour in order to allow time for such co-interventions to occur (short-term tocolytic therapy) and are the topics of Cochrane systematic reviews including: nitric oxide donors (glyceryl trinitrate) (<LINK REF="REF-Duckitt-2014" TYPE="REFERENCE">Duckitt 2014</LINK>), oxytocin receptor antagonists (ORAs) (<LINK REF="REF-Flenady-2014a" TYPE="REFERENCE">Flenady 2014a</LINK>), betamimetics (<LINK REF="REF-Neilson-2014" TYPE="REFERENCE">Neilson 2014</LINK>), MgSO<SUB>4</SUB> (<LINK REF="REF-Crowther-2002" TYPE="REFERENCE">Crowther 2002</LINK>), calcium channel blockers (CCBs) (<LINK REF="REF-Flenady-2014b" TYPE="REFERENCE">Flenady 2014b</LINK>) and progesterone (<LINK REF="REF-Su-2010" TYPE="REFERENCE">Su 2010</LINK>). A review on combinations of different tocolytics for women in preterm labour is the subject of a recent review (<LINK REF="REF-Vogel-2014" TYPE="REFERENCE">Vogel 2014</LINK>).</P>
<P>Cyclo-oxygenase (COX) inhibitors have the advantage of being easily administered (orally or rectally) and have a better maternal side-effect profile than betamimetics (<LINK REF="REF-Babay-1998" TYPE="REFERENCE">Babay 1998</LINK>), however there remains a concern about adverse fetal and neonatal effects particularly at higher gestations (<LINK REF="REF-Koren-2006" TYPE="REFERENCE">Koren 2006</LINK>).</P>
<P>Maintenance tocolytic therapy, used to prevent recurrence of preterm labour after an initial course of successful treatment, has not been shown to improve perinatal outcomes or effectively prolong pregnancy and is not widely used (<LINK REF="REF-Sanchez_x002d_Ramos-1999" TYPE="REFERENCE">Sanchez-Ramos 1999</LINK>). The role of maintenance therapy for women following threatened preterm labour is not addressed in this review.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-04-13 18:06:34 +0100" MODIFIED_BY="Heather Maxwell">
<P>Prostaglandins are hormones that have a multitude of functions. Prostaglandins affect uterine muscle contraction by causing an increase in free intracellular calcium levels and amplifying activation of myosin light chain kinase (<LINK REF="REF-Murray-2006" TYPE="REFERENCE">Murray 2006</LINK>). Prostaglandins have an important role in the onset and maintenance of labour (<LINK REF="REF-Keirse-1992" TYPE="REFERENCE">Keirse 1992</LINK>). COX enzymes are fundamental to the production of prostaglandins and inhibition of COX activity, resulting in reduced production of prostaglandins, reduce uterine contractions (<LINK REF="REF-Doret-2002" TYPE="REFERENCE">Doret 2002</LINK>; <LINK REF="REF-Van-den-Veyver-1993" TYPE="REFERENCE">Van den Veyver 1993</LINK>). Indomethacin, the prostaglandin inhibitor most frequently used for tocolysis, achieves its effect by reversibly binding to COX.</P>
<P>The recognition of distinct forms of COX, namely COX-1 and COX-2, led to the development of COX-2 specific inhibitors. The expression of COX-2 has been shown to increase significantly prior to the onset of labour, while the expression of COX-1 remains unchanged (<LINK REF="REF-Slater-1999" TYPE="REFERENCE">Slater 1999</LINK>), indicating a role of COX-2 in labour induction. It is possible that selective inhibition of COX-2 could enable more effective tocolysis with reduced adverse events.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-04-13 18:07:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>The ideal tocolytic agent is one which is effective in prolonging pregnancy, easy to administer with minimal side effects for the woman or the baby (<LINK REF="REF-Crowther-2002" TYPE="REFERENCE">Crowther 2002</LINK>; <LINK REF="REF-Neilson-2014" TYPE="REFERENCE">Neilson 2014</LINK>).The betamimetics, arguably the most commonly used tocolytics (ritodrine, salbutamol and terbutaline), have been shown to be effective in delaying delivery by seven days and longer, although no impact has yet been shown on perinatal mortality (<LINK REF="REF-Neilson-2014" TYPE="REFERENCE">Neilson 2014</LINK>). Furthermore, betamimetics have a high frequency of unpleasant, sometimes severe maternal side effects including tachycardia, hypotension, tremor and a range of biochemical disturbances, and they have been associated with life-threatening cardiovascular and respiratory events and deaths (<LINK REF="REF-FDA-2011" TYPE="REFERENCE">FDA 2011</LINK>).</P>
<P>Compared with other tocolytic agents (mostly betamimetics), CCBs have been shown to prolong pregnancy and improve short-term neonatal outcomes, with fewer maternal adverse effects (<LINK REF="REF-Flenady-2014b" TYPE="REFERENCE">Flenady 2014b</LINK>). However, a fifth of women still delivered within 48 hours of CCB treatment so there is still a need for other safe, effective tocolytic agents, particularly at very early gestations.</P>
<P>Another class of tocolytics, ORAs, have been developed specifically as a tocolytic agent, with atosiban being the most researched and used ORA. ORAs are associated with fewer maternal side effects, however no clear benefit has been shown for ORAs as tocolytic agents (<LINK REF="REF-Flenady-2014a" TYPE="REFERENCE">Flenady 2014a</LINK>). Concerns regarding the increase in infant mortality with the use of MgSO<SUB>4</SUB> for treatment of preterm birth rightly limit its utility as a first-line tocolytic (<LINK REF="REF-Crowther-2002" TYPE="REFERENCE">Crowther 2002</LINK>).</P>
<P>In a recent network meta-analysis of tocolytic agents (<LINK REF="REF-Haas-2012" TYPE="REFERENCE">Haas 2012</LINK>), prostaglandin inhibitors were shown to be more efficacious in delaying delivery by 48 hours when compared with placebo and had a 96% probability of being ranked in the top three most efficacious tocolytics. However, COX inhibitors freely cross the placenta and can interfere with prostaglandin homeostasis in the fetus (<LINK REF="REF-Moise-1990" TYPE="REFERENCE">Moise 1990</LINK>) and concerns remain regarding the potentially deleterious effects of prolonged exposure on the fetal cardiovasculature, gut and kidney (<LINK REF="REF-Perron-2013" TYPE="REFERENCE">Perron 2013</LINK>; <LINK REF="REF-Walker-2011" TYPE="REFERENCE">Walker 2011</LINK>). Reports from case series have attributed a range of adverse effects in the fetus and neonate to in utero indomethacin exposure (the most common COX inhibitor) during tocolysis (<LINK REF="REF-Eronen-1994" TYPE="REFERENCE">Eronen 1994</LINK>; <LINK REF="REF-Norton-1993" TYPE="REFERENCE">Norton 1993</LINK>; <LINK REF="REF-Souter-1998" TYPE="REFERENCE">Souter 1998</LINK>) including oligohydramnios, renal failure, premature closure of the ductus arteriosus with consequent pulmonary hypertension, persistent patent ductus arteriosus, necrotising enterocolitis, and intraventricular haemorrhage.</P>
<P>It is important to undertake a systematic review of all randomised controlled trials of COX inhibitors used in the management of women in preterm labour to determine the relative risks and benefits of this intervention.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-09-05 03:05:12 +0100" MODIFIED_BY="Hanna E Reinebrant">
<OL>
<LI>To assess the effects on maternal, fetal and neonatal outcomes of COX inhibitors administered as a tocolytic agent to women in preterm labour when compared with either placebo or no intervention.</LI>
<LI>To assess the effects on maternal, fetal and neonatal outcomes of COX inhibitors administered as a tocolytic agent to women in preterm labour when compared with other tocolytic agents by type of other tocolytic as follows: betamimetics, MgSO<SUB>4</SUB>, CCBs and ORAs.</LI>
<LI>To assess the effects on maternal, fetal and neonatal outcomes of non-selective COX inhibitors administered as a tocolytic agent to women in preterm labour when compared with COX-2 selective inhibitors.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2015-04-27 11:13:23 +0100" MODIFIED_BY="Leanne V Jones">
<SELECTION_CRITERIA MODIFIED="2015-04-13 18:08:03 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2015-04-13 18:07:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>All published and unpublished randomised and cluster-randomised trials in which COX inhibitors were used for tocolysis in the management of preterm labour were assessed for eligibility. We excluded studies using quasi-random allocation. Studies using cross-over methodology were not eligible for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-05-18 05:25:36 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Women assessed as being in preterm labour (between 20 and 36 completed weeks of gestation), and suitable for tocolysis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-10-23 03:19:28 +0100" MODIFIED_BY="Hanna E Reinebrant">
<OL>
<LI>COX inhibitors administered by any route compared with placebo.</LI>
<LI>COX inhibitors administered by any route compared with other classes of tocolytic agents by type of other tocolytic.</LI>
<LI>Selective COX-2 inhibitors administered by any route compared with non-selective COX inhibitors administered by any route.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-04-13 18:08:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>In this review we aimed to assess clinically relevant maternal, perinatal and infant short- and long-term outcomes after use of COX inhibitors for threatened preterm labour, as well as tocolytic efficacy of treatment.</P>
<P>Clinically relevant outcomes for trials of tocolysis for inhibiting preterm labour have been prespecified following consultation with the editors and authors of the individual reviews. Consensus was reached on a set of &#8216;core&#8217; outcomes, which are highlighted below. These will be included in all tocolysis reviews. In addition to these core outcomes, individual teams may include other outcomes as necessary.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-04-13 18:08:03 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>
<B>Birth less than 48 hours after trial entry</B>
</LI>
<LI>Extremely preterm birth (before completion of 28 weeks of gestation)</LI>
<LI>
<B>Very preterm birth</B> (before completion of 34 weeks of gestation)</LI>
<LI>
<B>Perinatal mortality (</B>fetal death and neonatal death up to 28 days)</LI>
<LI>
<B>Serious infant outcome</B> - death or major sensorineural disability at two years of age (defined as any one or more of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (defined as developmental quotient or intelligence quotient less than two standard deviations below the mean))</LI>
<LI>
<B>Serious maternal outcome</B> (defined as death, cardiac arrest, respiratory arrest, admission to intensive care unit)</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-01-08 11:20:48 +0000" MODIFIED_BY="Leanne V Jones">
<SUBSECTION>
<HEADING LEVEL="5">Maternal</HEADING>
<OL>
<LI>
<B>Maternal adverse effects</B>
</LI>
<LI>Maternal adverse effects requiring cessation of treatment</LI>
<LI>Antepartum haemorrhage</LI>
<LI>Postpartum haemorrhage</LI>
<LI>Need for blood transfusion</LI>
<LI>Caesarean section</LI>
<LI>Length of postnatal hospital stay</LI>
<LI>Length of antenatal hospital stay</LI>
<LI>Satisfaction with the therapy</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Infant</HEADING>
<OL>
<LI>Complete course of antenatal steroids</LI>
<LI>Pregnancy prolongation (interval between randomisation and birth)</LI>
<LI>Birth less than seven days after trial entry</LI>
<LI>Preterm birth (before completion of 37 weeks of gestation)</LI>
<LI>Gestational age at birth</LI>
<LI>Birthweight</LI>
<LI>Birthweight less than the third centile for gestational age</LI>
<LI>Birthweight less than 2500 g</LI>
<LI>Apgar score less than seven at five minutes</LI>
<LI>Persistent pulmonary hypertension</LI>
<LI>Neonatal renal failure</LI>
<LI>Respiratory distress syndrome</LI>
<LI>Use of mechanical ventilation</LI>
<LI>Duration of mechanical ventilation</LI>
<LI>Intraventricular haemorrhage</LI>
<LI>Intraventricular haemorrhage - Grades III or IV</LI>
<LI>Periventricular leukomalacia</LI>
<LI>Retinopathy of prematurity</LI>
<LI>Retinopathy of prematurity - Grades III or IV</LI>
<LI>Chronic lung disease</LI>
<LI>Necrotising enterocolitis</LI>
<LI>Neonatal sepsis</LI>
<LI>Admission to neonatal intensive care unit</LI>
<LI>Duration of neonatal intensive care unit stay</LI>
<LI>Oligohydramnios</LI>
<LI>Premature closure of the ductus arteriosus</LI>
<LI>Patent ductus arteriosus</LI>
</OL>
<P>In this update, primary and secondary outcomes measures were revised to enhance consistency across Cochrane tocolytic reviews and to better reflect important outcome measures.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-04-01 13:28:59 +0100" MODIFIED_BY="[Empty name]">
<P>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-04-01 13:27:39 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register by contacting the Trials Search Co-ordinator (24 August 2014).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains studies identified from:</P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE (Ovid);</LI>
<LI>weekly searches of Embase (Ovid);</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Studies identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-04-01 13:28:59 +0100" MODIFIED_BY="[Empty name]">
<P>In addition, the review authors searched reference lists of retrieved studies and sought ongoing and unpublished studies by contacting experts in the field.</P>
<P>We did not apply any language or date restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-04-27 11:13:23 +0100" MODIFIED_BY="Leanne V Jones">
<P>For the methods used when assessing the studies identified in the previous version of this review, <I>see</I> <LINK REF="REF-King-2005" TYPE="REFERENCE">King 2005</LINK>.</P>
<P>For this update, we applied the following methods to all previously included and new studies.</P>
<P>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
<STUDY_SELECTION MODIFIED="2015-04-13 18:10:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>Two review authors (VF, JS) independently assessed for inclusion all the potential studies identified as a result of the search strategy. All disagreements in assessment of studies were resolved through discussion and if required, a third author (HR) was consulted.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-04-13 18:11:27 +0100" MODIFIED_BY="Heather Maxwell">
<P>A collection form was designed to extract data. For eligible studies, at least two review authors (HR, CR, RS, SK) extracted the data using the agreed form. Data were entered into Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) and checked for accuracy with 100% agreement between the authors. We resolved any disagreements through discussion and/or by consulting a third assessor.</P>
<P>When information regarding any of the above was unclear, we contacted authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-04-13 18:12:25 +0100" MODIFIED_BY="Heather Maxwell">
<P>At least two review authors (HR, CP, CR, RS, VF) independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). All disagreement were resolved by discussion or by involving a third assessor.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received.</P>
<P>We assessed the methods used to blind outcome assessment as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>We described for each included study the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the study authors, we re-included missing data in the analyses.</P>
<P>We assessed methods as:</P>
<UL>
<LI>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomisation);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias)</HEADING>
<P>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>We described for each included study any important concerns we have about other possible sources of bias.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings. We explored the impact of the level of bias through undertaking sensitivity analyses - <I>see </I>
<LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-04-13 18:12:42 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we presented results as summary risk ratio (RR) with 95% confidence intervals (CI). Calculations for number needed to treat for benefit (NNTB) and number needed to treat for harm (NNTH) were performed and included where applicable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we used the mean difference (MD) if outcomes were comparable between studies. We planned to use the standardised mean difference (SMD) to combine studies that measured comparable outcomes, but used different methods.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-04-13 18:12:56 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="4">Cross-over studies</HEADING>
<P>Cross-over studies were not eligible for inclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>We did not identify any cluster-randomised trials for inclusion in this review, but we may include studies of this type in future updates.</P>
<P>If cluster-randomised trials are included in future reviews, we plan to include these in the analyses along with individually-randomised trials. Their sample sizes will be adjusted using the methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) using an estimate of the intra cluster correlation co-efficient (ICC) derived from the trial (if possible), or from another source. If ICCs from other sources are used, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and individually-randomised trials, we plan to synthesise the relevant information. We consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation units.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Multi-arm studies</HEADING>
<P>To avoid double-counting we planned to divide out data from the shared group approximately evenly among the comparisons undertaken (described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)).</P>
<P>One study (<LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>) included three treatment groups: COX inhibitor, CCB and MgSO<SUB>4</SUB>. For the analyses undertaken in this review, we split the number of events and number of included infants/women in the COX inhibitor group between the comparison with CCB and MgSO<SUB>4</SUB>.</P>
<P>One three-armed study (<LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>) used two different non-selective COX inhibitors, and one COX-2 selective inhibitor. For this review, we used combined numbers of women/infants and events in the non-selective COX inhibitor groups in the comparisons with the COX-2 selective inhibitor.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Multiple pregnancy</HEADING>
<P>The analysis in this review involves multiple pregnancies, therefore we intended to adjust analyses for clustering to take into account the non-independence of babies from the same pregnancy (<LINK REF="REF-Gates-2004" TYPE="REFERENCE">Gates 2004</LINK>). Treating babies from multiple pregnancies as if they are independent, when they are more likely to have similar outcomes than babies from different pregnancies, will overestimate the sample size and give CIs that are too narrow. Each woman can be considered a cluster in multiple pregnancy, with the number of individuals in the cluster being equal to the number of fetuses in her pregnancy. Analysis using cluster trial methods allows calculation of risk ratio and adjustment of CIs. Usually this will mean that the CIs get wider. Although this may make little difference to the conclusion of a study, it avoids misleading results in those studies where the difference may be substantial. We planned to adjust for clustering in the analyses, wherever possible, and to use the inverse variance method for adjusted analyses, as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and in <LINK REF="REF-Yelland-2011" TYPE="REFERENCE">Yelland 2011</LINK>.</P>
<P>Eight studies reported infant outcomes from twin pregnancies (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>). In three studies the inclusion of multiple pregnancies were unclear, however, no infant outcomes were reported (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>). Due to the small number of included infants across the comparisons in this review, we have not adjusted for multiple pregnancies. The distribution of twin pregnancies was relatively equally distributed across the trial groups in these studies.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-10-23 02:40:13 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>For included studies we noted levels of attrition. We contacted authors for additional data. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each study was the number randomised minus any participants whose outcomes were known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-04-13 18:13:20 +0100" MODIFIED_BY="Heather Maxwell">
<P>We assessed statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if an I² was greater than 30% and either theTau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. 
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-04-13 18:13:26 +0100" MODIFIED_BY="Heather Maxwell">
<P>Had there been 10 or more studies in the meta-analysis for any particular outcome, we planned to investigate reporting biases (such as publication bias) using funnel plots. We planned to assess possible asymmetry visually. If asymmetry was suggested by a visual assessment, we planned to perform exploratory analyses to investigate it. In this review update there were insufficient data to allow for this analysis.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-04-13 18:13:35 +0100" MODIFIED_BY="Heather Maxwell">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where studies were examining the same intervention, and the studies&#8217; populations and methods were judged sufficiently similar. If the clinical heterogeneity was sufficient to expect that the underlying treatment effects differed between studies, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary, if an average treatment effect across studies could be considered clinically meaningful. The random-effects summary was treated as the average of the range of possible treatment effects and we discussed the clinical implications of treatment effects differing between studies. If the average treatment effect was not clinically meaningful, we did not combine studies.</P>
<P>If random-effects analyses were used, the results are presented as the average treatment effect with 95% CIs, and the estimates of Tau² and I².</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-04-27 11:13:23 +0100" MODIFIED_BY="Leanne V Jones">
<P>If substantial heterogeneity had been identified, we planned to investigate it using subgroup analyses and sensitivity analyses. We planned to consider whether an overall summary was meaningful, and if so, use random-effects analysis to produce it.</P>
<P>We planned to carry out the following subgroup analyses, as follows:</P>
<UL>
<LI>women receiving treatment commenced before 28 weeks' gestation versus 28 weeks and above;</LI>
<LI>women with a multiple pregnancy versus women with a singleton pregnancy;</LI>
<LI>women with ruptured membranes versus women with intact membranes;</LI>
<LI>high-quality versus low-quality studies (high-quality studies are defined as studies that employed an adequate method for blinding of randomisation and intervention - <I>see </I>
<LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK> for further details).</LI>
</UL>
<P>We planned to use the following outcomes for the subgroup analyses:</P>
<UL>
<LI>birth less than 48 hours after trial entry;</LI>
<LI>extremely preterm birth (before completion of 28 weeks of gestation);</LI>
<LI>very preterm birth (before completion of 34 weeks of gestation);</LI>
<LI>preterm birth (before completion of 37 weeks of gestation);</LI>
<LI>perinatal mortality;</LI>
<LI>respiratory distress syndrome;</LI>
<LI>serious infant outcome (defined as death or chronic lung disease (need for supplemental oxygen at 28 days of life or later), grade three or four intraventricular haemorrhage or periventricular leukomalacia, major sensorineural disability (defined as any of legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, or developmental delay/intellectual impairment [defined as developmental quotient (DQ) or intelligence quotient (IQ) less than two standard deviations below mean]));</LI>
<LI>serious maternal outcome (defined as death, cardiac arrest, respiratory arrest, admission to intensive care unit);</LI>
<LI>maternal adverse effects requiring cessation of treatment.</LI>
</UL>
<P>We planned to assess subgroup differences by interaction tests available within RevMan (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) and to report the results of subgroup analyses quoting the ChiI² statistic and P value, and the interaction test I² value.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-10-23 04:50:31 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>We planned to carry out sensitivity analyses to explore the effect of study quality assessed by concealment of allocation, high attrition rates (greater than 20%), or both, with poor-quality studies (including those assessed as high or unknown risk of bias) being excluded from the analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-04-13 18:19:22 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY_DESCRIPTION MODIFIED="2015-04-13 18:16:54 +0100" MODIFIED_BY="Heather Maxwell">
<SEARCH_RESULTS MODIFIED="2015-04-13 18:14:06 +0100" MODIFIED_BY="Heather Maxwell">
<P>In this review, 42 studies were identified as potentially eligible for inclusion. Of these, 20 studies were excluded (<LINK REF="STD-Abramov-2000" TYPE="STUDY">Abramov 2000</LINK>; <LINK REF="STD-Bartfield-1998" TYPE="STUDY">Bartfield 1998</LINK>; <LINK REF="STD-Bivins-1993" TYPE="STUDY">Bivins 1993</LINK>; <LINK REF="STD-Caballero-1979" TYPE="STUDY">Caballero 1979</LINK>; <LINK REF="STD-Carlan--1992" TYPE="STUDY">Carlan 1992</LINK>; <LINK REF="STD-Carlan-1995" TYPE="STUDY">Carlan 1995</LINK>; <LINK REF="STD-Ehsanipoor-2011" TYPE="STUDY">Ehsanipoor 2011</LINK>; <LINK REF="STD-Gamissans-1982" TYPE="STUDY">Gamissans 1982</LINK>; <LINK REF="STD-Gamissans-1984" TYPE="STUDY">Gamissans 1984</LINK>; <LINK REF="STD-Groom-2005" TYPE="STUDY">Groom 2005</LINK>; <LINK REF="STD-Hallak--1992" TYPE="STUDY">Hallak 1992</LINK>; <LINK REF="STD-Humphrey-2001" TYPE="STUDY">Humphrey 2001</LINK>; <LINK REF="STD-Jain-2006" TYPE="STUDY">Jain 2006</LINK>; <LINK REF="STD-Katz-1983" TYPE="STUDY">Katz 1983</LINK>; <LINK REF="STD-Mital-1992" TYPE="STUDY">Mital 1992</LINK>; <LINK REF="STD-Newton-1991" TYPE="STUDY">Newton 1991</LINK>; <LINK REF="STD-Rasanen-1995" TYPE="STUDY">Rasanen 1995</LINK>; <LINK REF="STD-Rios_x002d_Anez-2001" TYPE="STUDY">Rios-Anez 2001</LINK>; <LINK REF="STD-Spearing-1979" TYPE="STUDY">Spearing 1979</LINK>; <LINK REF="STD-Zuckerman-1984b" TYPE="STUDY">Zuckerman 1984b</LINK>). For further information please see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. In addition, two studies are awaiting classification, pending translation of published paper (<LINK REF="STD-Mesdaghinia-2012" TYPE="STUDY">Mesdaghinia 2012</LINK>) and additional information from authors (<LINK REF="STD-Castillo-1988" TYPE="STUDY">Castillo 1988</LINK>), please <I>see</I> <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> for further information.</P>
<P>Therefore, this review update includes a total of 20 studies involving 1509 women testing the effects of COX inhibitors for tocolysis for women with threatened preterm labour. Two included studies (57 women) did not contribute data for any outcomes reported in this review update (<LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-04-13 18:16:20 +0100" MODIFIED_BY="Heather Maxwell">
<P>A total of 1509 women participated in the 20 included studies (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>; <LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>).</P>
<P>Three of the included studies (involving 102 women) compared COX inhibitors versus placebo (<LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>), seven studies (involving 792 women) compared COX inhibitors versus magnesium sulphate (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>), seven studies (involving 331 women) compared COX inhibitors versus betamimetics (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>), two studies (involving 230 women) compared COX inhibitors versus CCBs (<LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>) and two studies (involving 54 women) compared selective COX-2 inhibitors versus non-selective COX inhibitors (<LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>The participants included in these studies were reasonably homogeneous. In 14 studies the gestational age at inclusion ranged from a minimum of 20 to 25 weeks to a maximum of 32 to 35 weeks (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>; <LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>). In six studies (<LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>), the gestation at inclusion ranged from less than 30 to less than 34 with no lower limit being specified. Preterm labour was reasonably consistently defined across the studies, most excluding those women with a cervical dilatation of greater than 4 cm. Twelve studies reported the exclusion of women with preterm premature rupture of membranes; and one study (<LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>) did not report whether this was an exclusion criterion. The standard contraindications for tocolysis were reported as exclusion criteria in the majority of included studies, i.e. fetal distress, chorioamnionitis, severe pre-eclampsia/eclampsia, abruptio placentae or contraindications to non-steroidal anti-inflammatory agents.</P>
<P>Eight studies reported infant outcomes from twin pregnancies (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>). Two of these studies (70 infants) compared COX inhibitors versus placebo (<LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>), two studies (142 infants) compared COX inhibitors versus betamimetics (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>), one study (170 infants) compared COX inhibitor versus CCB (<LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>) and four studies (490 infants) compared COX inhibitors versus MgSO<SUB>4</SUB> (<LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>). In three studies the inclusion of multiple pregnancies was unclear, however, no infant outcomes were reported (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>). One of these compared COX inhibitors versus MgSO<SUB>4</SUB> (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>) and excluded high-order multiples, but it is unclear if any twin pregnancies were included as the numbers of infants in the study were not reported. Another study comparing COX inhibitors versus MgSO<SUB>4</SUB> (<LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>) included singleton and twin pregnancies, however numbers of infants in the study were also not reported. In one study comparing COX inhibitors versus betamimetics (<LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>) it is unclear whether any multiple pregnancies were included as numbers of infants were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Tocolysis</HEADING>
<P>Of the 20 studies included, 15 used the COX inhibitor indomethacin. Indomethacin dosing regimens were similar across the studies with loading doses of 50 to 100 mg (mostly given rectally) followed by 25 to 50 mg orally every four to six hours (every eight hours for <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>) for 24 to 48 hours (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>). Three studies used a similar dosing regimen, but repeated the bolus dose if contractions persisted (<LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>). One study administered indomethacin 100 mg rectally every 12 hours to 48 hours (<LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>) and one study administered one dose of indomethacin 100 mg rectally and repeated after one hour if contractions persisted (<LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>). One study administered 25 mg every six hours up to a maximum of four doses (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>) and one study only reported that indomethacin was administered orally for 48 hours (<LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>).</P>
<P>Other COX inhibitors used for comparisons in the studies included in this review were: nimesulide (<LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>; <LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>), sulindac (<LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>), ketorolac (<LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>), rofecoxib (<LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>) and celecoxib (<LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>). Fifteen studies compared COX inhibitors with other tocolytic agents. Seven studies compared with betamimetic agents (three ritodrine (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>), two terbutaline (<LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>), one nylidrin (<LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>) and one isoxuprine (<LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>)), seven with MgSO<SUB>4</SUB> (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>) and two with CCBs (nifedipine only; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>). Two studies (<LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>) compared non-selective with selective COX inhibitors. One study (<LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>) compared indomethacin with the COX-2 inhibitor celecoxib and the other compared sulindac and indomethacin with nimesulide (<LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>). Four studies (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>) reported the use of maintenance tocolysis. Three of the studies reported use of maintenance tocolysis up to 35 to 37 completed weeks of gestation (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>); one study (<LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>) did not report an end-point for maintenance tocolysis. Two studies reported continuation of tocolysis beyond the treatment protocol if the patient required (<LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>). Nine studies (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>) reported using alternative tocolytics after failure of the study treatment (rescue tocolysis), although details on the tocolytics used were largely not reported. It was not possible to ascertain the proportion of women given rescue tocolysis from the various publications. Of the studies included, the majority (16) were from high-income countries.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antenatal corticosteroids</HEADING>
<P>Twelve out of 20 studies reported the administration of antenatal corticosteroids for all women enrolled (<LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>). However, the majority did not state the proportion of women who actually received corticosteroids. In the remaining studies antenatal corticosteroid use was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>No outcome data were available in any of the included studies for two of the six prespecified primary outcome measures for this review: death or major sensorineural disability at two years of age and extremely preterm birth (before completion of 28 weeks of gestation). The outcome neonatal mortality was reported in 15 studies (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>). Ten studies (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>) reported data for the prespecified primary outcome measure of birth less than 48 hours after trial entry. There was limited reporting for the remaining primary outcome of serious maternal outcome (defined as death, cardiac arrest, respiratory arrest, admission to intensive care unit), with only one study reporting on maternal death (<LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>). Although six studies (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>) reported maternal adverse drug reactions requiring cessation of treatment, other potential adverse effects such as antepartum and postpartum haemorrhage were reported in only two studies (<LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>). The majority of studies assessed either the efficacy of tocolysis of the COX inhibitor and/or the fetal/neonatal safety aspects of the agent.</P>
<P>Reporting of other prespecified fetal and neonatal outcomes is as follows: respiratory distress syndrome (11 studies), persistent pulmonary hypertension of the newborn (eight studies), intraventricular haemorrhage (10 studies), premature closure of the ductus arteriosis (10 studies), oligohydramnios (five studies) and neonatal renal failure (one study). Clear definitions of outcome measures were often lacking in the study reports.</P>
<P>Please <I>see </I>
<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for further details.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-04-13 18:16:54 +0100" MODIFIED_BY="Heather Maxwell">
<P>Twenty studies were excluded from this review.</P>
<P>One study was excluded on the basis of quasi-random allocation (<LINK REF="STD-Spearing-1979" TYPE="STUDY">Spearing 1979</LINK>), one study compared different administration routes (<LINK REF="STD-Abramov-2000" TYPE="STUDY">Abramov 2000</LINK>) and one publication was a book chapter that summarised results from other studies (<LINK REF="STD-Gamissans-1984" TYPE="STUDY">Gamissans 1984</LINK>). The remaining 17 studies did not fulfil inclusion criteria as follows: comparison between two types of non-selective COX inhibitors (<LINK REF="STD-Rasanen-1995" TYPE="STUDY">Rasanen 1995</LINK>); did not include a comparison group (<LINK REF="STD-Zuckerman-1984b" TYPE="STUDY">Zuckerman 1984b</LINK>); not described as randomised controlled trials (<LINK REF="STD-Caballero-1979" TYPE="STUDY">Caballero 1979</LINK>; <LINK REF="STD-Jain-2006" TYPE="STUDY">Jain 2006</LINK>); studies of combination therapy (<LINK REF="STD-Gamissans-1982" TYPE="STUDY">Gamissans 1982</LINK>; <LINK REF="STD-Katz-1983" TYPE="STUDY">Katz 1983</LINK>; <LINK REF="STD-Newton-1991" TYPE="STUDY">Newton 1991</LINK>; <LINK REF="STD-Rios_x002d_Anez-2001" TYPE="STUDY">Rios-Anez 2001</LINK>); studies of maintenance tocolysis (<LINK REF="STD-Bivins-1993" TYPE="STUDY">Bivins 1993</LINK>; <LINK REF="STD-Carlan-1995" TYPE="STUDY">Carlan 1995</LINK>; <LINK REF="STD-Humphrey-2001" TYPE="STUDY">Humphrey 2001</LINK>); assessment of treatment following successful (<LINK REF="STD-Bartfield-1998" TYPE="STUDY">Bartfield 1998</LINK>) or failed (<LINK REF="STD-Carlan--1992" TYPE="STUDY">Carlan 1992</LINK>) tocolytic treatment; not described as tocolytic studies (<LINK REF="STD-Groom-2005" TYPE="STUDY">Groom 2005</LINK>; <LINK REF="STD-Hallak--1992" TYPE="STUDY">Hallak 1992</LINK>; <LINK REF="STD-Mital-1992" TYPE="STUDY">Mital 1992</LINK>) and excluded women in preterm labour (<LINK REF="STD-Ehsanipoor-2011" TYPE="STUDY">Ehsanipoor 2011</LINK>).</P>
<P>Please <I>see</I> <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for further details.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-04-13 18:17:25 +0100" MODIFIED_BY="Heather Maxwell">
<P>Overall, the quality of the included studies was moderate to low. Please <I>see</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for further details and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for a summary of 'Risk of bias' assessment.</P>
<ALLOCATION MODIFIED="2015-01-08 11:53:40 +0000" MODIFIED_BY="Leanne V Jones">
<P>In 11 of the 20 studies the random sequence generation was considered adequate and as low risk of selection bias (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>), and one study was considered high risk of bias (<LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997)</LINK>. In the remaining eight studies the randomisation sequence generation was unclear (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004;</LINK> <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>).</P>
<P>Concealment of allocation was considered adequate (low risk bias) in seven studies (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Borna-2007">Borna 2007</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Kramer-1999">Kramer 1999</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-McWhorter-2004">McWhorter 2004</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Parilla-1997">Parilla 1997</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Sawdy-2003">Sawdy 2003</A>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Stika-2002">Stika 2002</A>) and deemed as high risk of bias in one study (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Odeh-1997">Odeh 1997</A>); while the allocation concealment processes were unclear in the remaining 12 studies (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Asgharnia-2002">Asgharnia 2002</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Besinger-1991">Besinger 1991</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Kashanian-2011">Kashanian 2011</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Klauser-2012">Klauser 2012</A>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Morales-1989">Morales 1989</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Morales-1993">Morales 1993</A>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Niebyl-1980">Niebyl 1980</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Panter-1999">Panter 1999</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1410281003110324556934516622093&amp;format=REVMAN#STD-Purwaka-2004">Purwaka 2004</A>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-04-13 18:17:02 +0100" MODIFIED_BY="Heather Maxwell">
<P>Nine studies described blinding of participants and personnel and were considered low risk of performance bias (<LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>) and nine studies were deemed high risk (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>). The processes for blinding of participants and personnel were unclear in the remaining two studies (<LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997)</LINK>.</P>
<P>The risk of detection bias was considered low in eight of the included studies (<LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>), high in two studies (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>) and unclear in 10 studies (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-04-13 18:17:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>The majority of included studies (14 of the 20 included studies) had minimal or no attrition and were assessed as having low risk of bias. One study had high risk of attrition (<LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>): of 45 women randomised, 22 were included in analyses. For the remaining five studies it was unclear whether outcome data were complete (<LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-04-13 18:17:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>In 10 studies, we found no obvious evidence of reporting bias (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>) and judged these studies to be at low risk of bias. Two studies were deemed to be at high risk of reporting bias. In one study (<LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>), the objective of the study was to establish fetal side effects of two different drugs after acute maternal exposure for tocolysis; however very limited data on side effects were reported from this study. Instead the authors state: "There were no reports of adverse neonatal complications related to the study drugs". The aim of the other study (<LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>) was to evaluate safety and efficacy of tocolysis; however limited data were available in the report for pregnancy prolongation and maternal, fetal and neonatal side effects. In the remaining eight studies (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>), it was unclear whether selective reporting bias was present.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-04-13 18:17:25 +0100" MODIFIED_BY="Heather Maxwell">
<P>Eighteen of the included 20 studies were assessed as being at low risk of bias for other potential sources of bias based on baseline characteristics being similar between groups and no other bias was apparent (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>; <LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>). In the remaining two studies (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>), the risk of other sources of bias was unclear.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-04-13 18:19:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>This review includes outcomes data from 20 studies with a total of 1509 women. Due to small numbers, all estimates of effect are therefore imprecise and need to be interpreted with caution. The following comparisons were undertaken:</P>
<UL>
<LI>any COX inhibitor versus placebo;</LI>
<LI>COX inhibitor versus other tocolytic agents, i.e. betamimetics, MgSO<SUB>4</SUB>and CCBs;</LI>
<LI>any non-selective COX inhibitor versus any COX-2 inhibitor.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="3">Any COX inhibitor versus placebo</HEADING>
<P>Three small studies (102 women), two of which were conducted in the 1980s, compared COX inhibition (indomethacin only) with placebo (<LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>
<B>Birth less than 48 hours after trial entry </B>(<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)</P>
<P>No difference was shown in birth less than 48 hours after trial entry (average risk ratio (RR) 0.20, 95% confidence interval (CI) 0.03 to 1.28, random-effects, two studies with 70 women). Statistical heterogeneity was evident (Tau² = 1.18; Chi² = 2.81, df = 1 (P = 0.09); I² = 64%). However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies, we considered an overall summary was meaningful using a random-effects analysis.</P>
<P>
<B>Neonatal mortality </B>(<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2)</LINK>
</P>
<P>No differences were shown in neonatal mortality (RR 0.80, 95% CI 0.25 to 2.58; three studies with 106 infants). No data were available on stillbirth or perinatal mortality in any of the included studies.</P>
<P>No data were available for the other primary outcomes: extremely preterm birth (before completion of 28 weeks of gestation), very preterm birth (before completion of 34 weeks of gestation), death or major sensorineural disability at two years of age or serious maternal outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For the infant</HEADING>
<P>
<B>Preterm birth (before completion of 37 weeks of gestation) </B>(<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>)</P>
<P>When compared with placebo, COX inhibition (indomethacin only) resulted in a statistically significant reduction in the number of preterm births (before completion of 37 weeks of gestation) (RR 0.21, 95% CI 0.07 to 0.62; one study with 36 women) (number needed to treat for benefit (NNTB) 2, 95% CI 2 to 4).</P>
<P>
<B>Gestational age at birth </B>(<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) <B>and Birthweight </B>(<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>)</P>
<P>Two studies showed an increase in birthweight in the COX inhibitor group versus placebo (MD 716.34 g, 95% CI 425.52 to 1007.16; 67 women) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), but no difference in gestational age at birth (mean difference (MD) 3.59 weeks; 95% CI 0.65 to 6.52; 66 women) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>Statistical heterogeneity was evident for the outcome of gestational age at birth (Tau² = 1.44; Chi² = 1.47, df = 1 (P = 0.22); I² = 32%). However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies, we considered an overall summary was meaningful using a random-effects analysis.</P>
<P>No differences were shown in the following neonatal outcome measures.</P>
<UL>
<LI>Birth less than seven days after trial entry: average RR 0.41, 95% CI 0.10 to 1.66; two studies with 70 women. Statistical heterogeneity was evident (Tau² = 0.83; Chi² = 5.36, df = 1 (P = 0.02); I² = 81%) as in other comparisons combining these two studies. However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies, we considered an overall summary was meaningful using a random-effects analysis (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</LI>
<LI>Apgar score less than seven at five minutes: RR 0.53, 95% CI 0.05 to 5.34; one study with 39 infants (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</LI>
<LI>Admission to neonatal intensive care unit: RR 0.80, 95% CI 0.56 to 1.15; one study with 39 infants (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</LI>
<LI>Respiratory distress syndrome: RR 1.00, 95% CI 0.40 to 2.49; three studies with 106 infants (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</LI>
<LI>Chronic lung disease: average RR 0.96, 95% CI 0.07 to 12.37; two studies with 70 infants, random-effects. Statistical heterogeneity was evident (Tau² = 2.17; Chi² = 2.51, df = 1 (P = 0.11); I² = 60%). However, upon exploration of the possible reasons for the heterogeneity including examining clinical features of the studies, we considered an overall summary was meaningful using a random-effects analysis. (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</LI>
<LI>Persistent pulmonary hypertension of the newborn: three studies with 106 infants reported no events of persistent pulmonary hypertension of the newborn during the trial (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</LI>
<LI>Intraventricular haemorrhage (Grades III or IV): RR 3.15, 95% CI 0.14 to 72.88; one study with 39 infants (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</LI>
<LI>Necrotising enterocolitis: RR 0.97, 95% CI 0.21 to 4.43; two studies with 70 infants (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</LI>
<LI>Neonatal sepsis: RR 0.31, 95% CI 0.01 to 7.15; two studies with 70 infants (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</LI>
<LI>Premature closure of the ductus arteriosus: three studies with 106 infants; no events were reported. (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</LI>
<LI>Patent ductus arteriosus: RR 1.40, 95% CI 0.36 to 5.46; one study with 39 infants (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For the woman</HEADING>
<P>No differences were shown in the maternal outcomes measures as follows.</P>
<UL>
<LI>Maternal adverse drug reaction: RR 1.58, 95% CI 0.66 to 3.78; three studies with 101 women (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</LI>
<LI>Postpartum haemorrhage: one study with 34 women (<LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>) showed a trend towards increased proportion of postpartum haemorrhage for women treated with COX inhibitors compared with placebo (RR 3.94, 95% CI 0.95 to 16.29) (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</LI>
<LI>Chorioamnionitis or endometritis: RR 1.94, 95% CI 0.44 to 8.60; two studies with 64 women (<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>).</LI>
<LI>Caesarean section: RR 1.00, 95% CI 0.07 to 14.79; one study with 36 women (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Any COX inhibitor versus any other tocolytic by class of other tocolytic</HEADING>
<P>This comparison includes seven studies with 331 women comparing COX inhibitors with betamimetics (<LINK REF="STD-Besinger-1991" TYPE="STUDY">Besinger 1991</LINK>; <LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>; <LINK REF="STD-Kurki-1991" TYPE="STUDY">Kurki 1991</LINK>; <LINK REF="STD-Morales-1989" TYPE="STUDY">Morales 1989</LINK>; <LINK REF="STD-Nevils-1994" TYPE="STUDY">Nevils 1994</LINK>; <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>; <LINK REF="STD-Purwaka-2004" TYPE="STUDY">Purwaka 2004</LINK>); seven studies with 792 women comparing COX inhibitors with MgSO<SUB>4</SUB> (<LINK REF="STD-Asgharnia-2002" TYPE="STUDY">Asgharnia 2002</LINK>; <LINK REF="STD-Borna-2007" TYPE="STUDY">Borna 2007</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>; <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK>; <LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>; <LINK REF="STD-Parilla-1997" TYPE="STUDY">Parilla 1997</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>) and two studies with 230 women (<LINK REF="STD-Kashanian-2011" TYPE="STUDY">Kashanian 2011</LINK>; <LINK REF="STD-Klauser-2012" TYPE="STUDY">Klauser 2012</LINK>) comparing COX inhibitors with CCBs.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>
<B>Birth less than 48 hours after trial entry</B> (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>a reduction in birth less than 48 hours after trial entry was shown with the use of COX inhibitors when compared with betamimetics: RR 0.27, 95% CI 0.08 to 0.96; NNTB 7, 95% CI 6 to 120; two studies with 100 women.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>no difference was shown in birth within 48 hours of trial entry with the use of COX inhibitors when compared with MgSO<SUB>4</SUB>: RR 0.87; 95% CI 0.59 to 1.29; four studies with 547 women.</P>
<P>
<I>COX inhibitors versus CCBs: </I>there was no difference between COX inhibitors versus any CCB for the outcome birth within 48 hours of trial entry: RR 1.08; 95% CI 0.58 to 2.01; two studies with 230 women.</P>
<P>
<B>Neonatal mortality</B> (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2)</LINK>
</P>
<P>No statistically significant differences were shown in neonatal mortality comparing COX inhibitors with other tocolytic as follows.</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 0.99, 95% CI 0.27 to 3.57; four studies with 237 infants.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> RR 1.59, 95% CI 0.59 to 4.29; five studies with 570 infants</P>
<P>
<I>COX inhibitors versus CCBs: </I>RR 2.81, 95% CI 0.82 to 9.62; two studies with 249 infants.</P>
<P>No data were available for stillbirth or perinatal mortality or the other primary outcomes of death, major sensorineural disability at two years of age or serious maternal outcome.</P>
<P>
<B>Very preterm birth (before completion of 34 weeks of gestation)</B> (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics:</I> no outcome data were reported.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> no difference was shown in very preterm birth: RR 0.84, 95% CI 0.64 to 1.11; one study with 128 women.</P>
<P>
<I>COX inhibitors versus CCBs:</I> no difference was shown in preterm birth: RR 0.92, 95% CI 0.70 to 1.21; one study with 148 women.</P>
<P>
<B>Maternal death</B> (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>no outcome data were reported.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>one study with 128 women reported no events in the COX inhibitor group or in the MgSO<SUB>4</SUB> group for this outcome.</P>
<P>
<I>COX inhibitors versus CCBs: </I>one study with 148 women reported no events in the COX inhibitor group or in the CCB group for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For the infant</HEADING>
<P>
<B>Preterm birth (before completion of 37 weeks of gestation)</B> (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>)</P>
<P>Statistical heterogeneity was evident for this outcome in the comparison of COX inhibitors versus MgSO<SUB>4</SUB> (Tau² = 0.08; Chi² = 1.45, df = 1 (P = 0.23); I² = 31%). However, upon exploration of the possible reasons for the heterogeneity including examining clinical features of the studies, we considered an overall summary was meaningful using a random-effects analysis.</P>
<P>
<I>COX inhibitors versus betamimetics: </I>a reduction in preterm birth was shown with the use of COX inhibitors when compared with betamimetics: average RR 0.53, 95% CI 0.28 to 0.99; NNTB 6, 95% CI 4 to 236; two studies with 80 women.<BR/>
</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>no difference was shown in preterm birth comparing COX inhibitors with MgSO<SUB>4</SUB>: average RR 0.88, 95% CI 0.52 to 1.47; two studies with 216 women.</P>
<P>
<I>COX inhibitors versus CCBs: </I>no difference was shown in preterm birth comparing COX inhibitors with CCBs: average RR 1.08, 95% CI 0.94 to 1.25; one study with 148 women.</P>
<P>No statistically significant differences were shown for any other reported outcome measures of pregnancy prolongation or neonatal morbidity as follows.</P>
<P>
<B>Birth less than seven7 days after trial entry </B>(<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 0.88, 95% CI 0.52 to 1.46; two studies with 146 women.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>
</I>: no outcome data were reported.</P>
<P>
<I>COX inhibitors versus CCBs</I>: RR 0.26, 95% CI 0.03 to 2.19; one study with 79 women.</P>
<P>
<B>Pregnancy prolongation (days) </B>(<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>no outcome data were reported.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> MD 0.20 days, 95% CI -4.66 to 5.06; one study with 101 women.</P>
<P>
<I>COX inhibitors versus CCBs</I>: no outcome data were reported.</P>
<P>
<B>Gestational age </B>(<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>) and <B>Birthweight </B>(<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>gestational age (MD 1.55 weeks, 95% CI -0.41 to 3.50; two studies with 100 women); birthweight (MD 199.40 g; 95% CI -176.85 to 575.65; two studies with 105 infants).</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> gestational age (MD 0.21 weeks, 95% CI -0.39 to 0.80; five studies with 538 women); birthweight (MD -74.93, 95% CI -190.16 to 40.30; five studies with 578 infants).</P>
<P>
<I>COX inhibitors versus CCBs: </I>gestational age (MD -0.75 weeks, 95% CI -1.63 to 0.14; two studies with 230 women); birthweight (MD -34.00, 95% CI -256.20 to 188.20; one study with 170 infants).</P>
<P>
<B>Antenatal corticosteroids</B> (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics:</I> no outcome data were reported.</P>
<P>
<I>COX inhibitors versus magnesium sulphate: </I>no outcome data were reported.</P>
<P>
<I>COX inhibitors versus any calcium channel blocker: </I>RR 0.26, 95% CI 0.03 to 2.19; one study with 79 women.</P>
<P>
<B>Respirory distress syndrome</B> (<LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 1.50, 95% CI 0.27 to 8.34; two studies with 80 infants. One of these studies (<LINK REF="STD-Kramer-1999" TYPE="STUDY">Kramer 1999</LINK>) reported no events for this outcome in the COX inhibitor group or in the betamimetics group.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>RR 1.01, 95% CI 0.73 to 1.40; five studies with 570 infants. One of these studies (<LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>) reported no events for this outcome in the COX inhibitor group or in the MgSO<SUB>4</SUB> group.</P>
<P>
<I>COX inhibitors versus CCBs:</I> RR 1.44, 95% CI 0.93 to 2.22; one study with 170 infants.</P>
<P>
<B>Apgar score less than seven at five minutes</B> (<LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 3.00, 95% CI 0.13 to 70.83, one study with 60 infants.</P>
<P>
<I>COX inhibitors versus magnesium sulphate:</I> RR 0.43, 95% CI 0.16 to 1.15; one study with 194 infants.</P>
<P>
<I>COX inhibitors versus any calcium channel blocker:</I> no outcome data were reported.</P>
<P>
<B>Admission to neonatal intensive care unit</B> (<LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>no outcome data were reported.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>RR 0.83, 95% CI 0.48 to 1.43; one study with 194 infants.</P>
<P>
<I>COX inhibitors versus CCBs:</I> no outcome data were reported.</P>
<P>
<B>Duration of neonatal intensive care unit stay</B> (<LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>no outcome data were reported.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> MD -2.62 days, 95% CI -7.51 to 2.28; two studies with 341 infants.</P>
<P>
<I>COX inhibitors versus CCBs:</I> MD -3.60 days, 95% CI -14.97 to 7.77; one study with 170 infants.</P>
<P>
<B>Use of mechanical ventilation</B> (<LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 1.50, 95% CI 0.47 to 4.78; one study with 60 infants.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>no outcome data were reported.</P>
<P>
<I>COX inhibitors versus CCBs: </I>no outcome data were reported.</P>
<P>
<B>Duration of mechanical ventilation </B>(<LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>no outcome data were reported.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> MD -3.70 days, 95% CI -10.02 to 2.62; one study with 147 infants.</P>
<P>
<I>COX inhibitors versus CCBs: </I>MD 2.00 days, 95% CI -2.58 to 6.58; one study with 170 infants.</P>
<P>
<B>Persistent pulmonary hypertension of the newborn </B>(<LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 5.65, 95% CI 0.31 to 103.46; three studies with 177 infants.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>RR 1.78, 95% CI 0.23 to 13.44; two studies with 311 infants.</P>
<P>
<I>COX inhibitors versus CCBs:</I> no outcome data were reported.</P>
<P>
<B>Intraventricular haemorrhage all grades </B>(<LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 5.34, 95% CI 0.66 to 43.10; three studies with 125 infants.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>RR 1.00, 95% CI 0.60 to 1.66; five studies with 570 infants.</P>
<P>
<I>COX inhibitors versus CCBs:</I> RR 1.63, 95% CI 0.66 to 4.05; one study with 170 infants.</P>
<P>
<B>Intraventricular haemorrhage Grades III or IV </B>(<LINK REF="CMP-002.19" TYPE="ANALYSIS">Analysis 2.19</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>one small study including 20 infants reported no events in the COX inhibitor group or in the betamimetics group for this outcome.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> RR 0.61, 95% CI 0.08 to 4.40; three studies with 229 infants.</P>
<P>
<I>COX inhibitors versus CCBs: </I>no outcome data were reported.</P>
<P>
<B>Other major cerebral abnormality</B> (<LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>no outcome data were reported.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> RR 5.43, 95% CI 0.23 to 131.06; one study with 147 infants.</P>
<P>
<I>COX inhibitors versus CCBs: </I>RR 6.92, 95% CI 0.29 to 167.15; one study with 170 infants.</P>
<P>
<B>Retinopathy of prematurity Grades III or IV</B> (<LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>one small study including 20 infants reported no events in the COX inhibitor group or in the betamimetics group for this outcome.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>no outcome data were reported.</P>
<P>
<I>COX inhibitors versus CCBs: </I>no outcome data were reported.</P>
<P>
<B>Necrotising enterocolitis</B> (<LINK REF="CMP-002.22" TYPE="ANALYSIS">Analysis 2.22</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 3.00, 95% CI 0.13 to 70.83; two studies with 80 infants.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>RR 1.49, 95% CI 0.46 to 4.84; three studies with 365 infants.</P>
<P>
<I>COX inhibitors versus CCBs:</I> RR 1.75, 95% CI 0.41 to 7.54; one study with 170 infants.</P>
<P>
<B>Neonatal sepsis </B>(<LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 1.00, 95% CI 0.07 to 15.26; two studies with 80 infants.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> RR 1.10, 95% CI 0.42 to 2.85; one study with 147 infants.</P>
<P>
<I>COX inhibitors versus CCBs: </I>RR 1.63, 95% CI 0.66 to 4.05; one study with 170 infants.</P>
<P>
<B>Oligohydramnios</B> (<LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 2.50, 95% CI 0.75 to 8.33; two studies with 138 infants.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>RR 5.30, 95% CI 0.26 to 107.70; two studies with 189 infants.</P>
<P>
<I>COX inhibitors versus CCBs: </I>no outcome data were reported.</P>
<P>
<B>Premature closure of the ductus arteriosus </B>(<LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>three studies including 154 infants reported no events for this outcome.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>RR 3.05, 95% CI 0.13 to 73.39; two studies with 205 infants. Only one event was reported in the COX inhibitor group in one of the studies (<LINK REF="STD-Morales-1993" TYPE="STUDY">Morales 1993</LINK>) for this outcome.</P>
<P>
<I>COX inhibitors versus CCBs:</I> no outcome data were reported.</P>
<P>
<B>Patent ductus arteriosus </B>(<LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>RR 1.66, 95% CI 0.36 to 7.66; three studies with 125 infants.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> RR 0.65, 95% CI 0.28 to 1.49; two studies with 235 infants.</P>
<P>
<I>COX inhibitors versus CCBs:</I> RR 1.27, 95% CI 0.50 to 3.26; one study with 170 infants.</P>
<P>
<B>Neonatal renal failure </B>(<LINK REF="CMP-002.27" TYPE="ANALYSIS">Analysis 2.27</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>one small study, including 20 infants, reported no events in the COX inhibitor group or in the betamimetics group for this outcome.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> no outcome data were reported.</P>
<P>
<I>COX inhibitors versus CCBs:</I> no outcome data were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For the woman</HEADING>
<P>
<B>Maternal adverse effects</B> (<LINK REF="CMP-002.28" TYPE="ANALYSIS">Analysis 2.28</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>a reduction in maternal adverse effects was shown with the use of COX inhibitors when compared with betamimetics: RR 0.19, 95% CI 0.11 to 0.31, NNTB 3, 95% CI 2 to 3; five studies with 248 women.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>a reduction in maternal adverse effects was shown with the use of COX inhibitors when compared with MgSO<SUB>4</SUB>: RR 0.39, 95% CI 0.25 to 0.62; NNTB 11, 95% CI 9 to 17; five studies with 635 women.</P>
<P>
<I>COX inhibitors versus CCBs: </I>no statistically significant differences was shown in maternal adverse effects with the use of COX inhibitors when compared with CCBs: RR 0.67, 95% CI 0.36 to 1.23; two studies with 227 women.</P>
<P>
<B>Maternal adverse drug reaction requiring cessation of treatment </B>(<LINK REF="CMP-002.29" TYPE="ANALYSIS">Analysis 2.29</LINK>)</P>
<P>Statistical heterogeneity was evident for this outcome in the comparison of COX inhibitors versus MgSO<SUB>4</SUB> (Tau² = 12.58; Chi² = 6.81, df = 1 (P = 0.009); I² = 85%). However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies, we considered an overall summary was meaningful using a random-effects analysis.</P>
<P>
<I>COX inhibitors versus betamimetics</I>: three studies including 166 women showed a reduction in maternal adverse drug reaction requiring cessation of treatment with the use of COX inhibitors when compared with betamimetics (average RR 0.09, 95% CI 0.02 to 0.49; NNTB 5, CI 95% 5 to 9).</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>there was no difference comparing COX inhibitors versus MgSO<SUB>4</SUB>: average RR 0.91, 95% CI 0.00 to 186.10; three studies with 317 women.</P>
<P>
<I>COX inhibitors versus CCBs: </I>no difference was shown in maternal adverse effects comparing COX inhibitors with CCBs: average RR 1.18, 95% CI 0.31 to 4.51; one study with 148 women.</P>
<P>No statistically significant differences were shown for any of the following secondary maternal outcome.</P>
<P>
<B>Chorioamnionitis or endometritis </B>(<LINK REF="CMP-002.30" TYPE="ANALYSIS">Analysis 2.30</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics: </I>no outcome data were reported.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>: </I>one study with 88 women reported no events in the COX inhibitor group or in the MgSO<SUB>4</SUB> group for this outcome.</P>
<P>
<I>COX inhibitors versus CCBs:</I> no outcome data were reported.</P>
<P>
<B>Caesarean section </B>(<LINK REF="CMP-002.31" TYPE="ANALYSIS">Analysis 2.31</LINK>)</P>
<P>
<I>COX inhibitors versus betamimetics:</I> no outcome data were reported.</P>
<P>
<I>COX inhibitors versus MgSO<SUB>4</SUB>:</I> RR 1.23, 95% CI 0.70 to 2.13; one study with 194 women.</P>
<P>
<I>COX inhibitors versus CCBs: </I>no outcome data were reported.</P>
<P>Due to insufficient data, the planned subgroup analyses (treatment commenced before 28 weeks' gestation; and studies enrolling women with a multiple pregnancy) could not be performed.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Any non-selective COX inhibitor versus any COX-2 inhibitor</HEADING>
<P>A comparison of any non-selective COX inhibitor (indomethacin and sulindac) versus any COX-2 inhibitor (celecoxib and nimesulide) including two studies with 54 women (<LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>) showed no differences in any reported maternal or neonatal outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>
<B>Birth less than 48 hours after trial entry</B> (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
<P>One study (24 women) (<LINK REF="STD-Stika-2002" TYPE="STUDY">Stika 2002</LINK>) reported no births less than 48 hours after trial entry in either group.</P>
<P>
<B>Neonatal mortality </B>(<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>)</P>
<P>Both included studies reported no events for this outcome in the non-selective COX inhibitor group or COX-2 inhibitor group.</P>
<P>No data were available for the other primary outcome measures of extremely preterm birth (before completion of 28 weeks of gestation), very preterm birth (before completion of 34 weeks of gestation), death or major sensorineural disability at two years of age or serious maternal outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For the infant/child</HEADING>
<P>No differences were shown in the following neonatal outcome measures.</P>
<UL>
<LI>Preterm birth (before completion of 37 weeks of gestation): RR 1.00, 95% CI 0.31 to 3.19; two studies with 54 women (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</LI>
<LI>Birth less than seven days after trial entry: RR 3.00, 95% CI 0.13 to 67.06; one study with 24 women (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</LI>
<LI>Gestational age at birth: MD 0.00 weeks, 95% CI -2.81 to 2.81; one study with 24 women (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</LI>
<LI>Birthweight: MD 27.00 g, 95% CI -549.58 to 603.58; one study with 24 infants (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</LI>
<LI>Respiratory distress syndrome: RR 1.00, 95% CI 0.07 to 14.21; one study with 24 infants (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</LI>
<LI>Intraventricular haemorrhage Grades III or IV: no events reported in one study with 24 infants (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>).</LI>
<LI>Intraventricular haemorrhage - all grades: RR 0.50, 95% CI 0.05 to 4.81; one study with 24 infants (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>).</LI>
<LI>Necrotising enterocolitis: no events reported in one study with 24 infants (<LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>).</LI>
<LI>Apgar score less than seven at five minutes: RR 3.00, 95% CI 0.13 to 67.06; one study with 24 infants (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>).</LI>
<LI>Admission to neonatal intensive care unit: RR 1.00, 95% CI 0.34 to 2.91; two studies with 54 infants (<LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>).</LI>
<LI>Use of mechanical ventilation: RR 1.00, 95% CI 0.07 to 14.21; one study with 24 infants (<LINK REF="CMP-003.13" TYPE="ANALYSIS">Analysis 3.13</LINK>).</LI>
<LI>Neonatal sepsis: RR 0.33, 95% CI 0.01 to 7.45; one study with 24 infants (<LINK REF="CMP-003.14" TYPE="ANALYSIS">Analysis 3.14</LINK>).</LI>
<LI>Premature closure of the ductus arteriosus: no events reported in two studies with 54 infants (<LINK REF="CMP-003.15" TYPE="ANALYSIS">Analysis 3.15</LINK>).</LI>
<LI>Oligohydramnios: RR 4.00, 95% CI 0.52 to 30.76; one study with 24 infants (<LINK REF="CMP-003.16" TYPE="ANALYSIS">Analysis 3.16</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For the woman</HEADING>
<P>No differences were shown in the maternal outcomes measures as follows.</P>
<UL>
<LI>Maternal adverse effects: two studies with 54 women reported no maternal adverse effects (<LINK REF="CMP-003.17" TYPE="ANALYSIS">Analysis 3.17</LINK>).</LI>
<LI>Antepartum haemorrhage: RR 0.33, 95% CI 0.01 to 7.45; one study with 24 women (<LINK REF="CMP-003.18" TYPE="ANALYSIS">Analysis 3.18</LINK>).</LI>
<LI>Chorioamnionitis or endometritis: RR 2.00, 95% CI 0.21 to 19.23; one study with 24 women (<LINK REF="CMP-003.19" TYPE="ANALYSIS">Analysis 3.19</LINK>).</LI>
<LI>Caesarean section: RR 0.67, 95% CI 0.13 to 3.30; one study with 24 women (<LINK REF="CMP-003.20" TYPE="ANALYSIS">Analysis 3.20</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-05-20 14:48:57 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-04-13 18:20:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>With the addition of seven studies with a total of 684 women, this review now includes outcome data from 20 studies including 1509 women. The non-selective cyclo-oxygenase (COX) inhibitor indomethacin was used in 15 studies. Three small studies (106 women), two of which were conducted in the 1980s, compared COX inhibition (indomethacin only) with placebo. A trend towards fewer births less than 48 hours after trial entry, which was not statistically significant was shown when combining the results of two small studies; however a reduction in preterm birth (before completion of 37 weeks of gestation) and less than 48 hours after trial entry was shown in one of these studies (36 women). Some benefit was also shown in gestational age (four weeks on average) and birthweight (716 g on average) (two studies with 67 women). However, despite this modest improvement in prolongation of pregnancy no difference was shown in important neonatal outcomes. No benefit was shown in measures of neonatal morbidity or neonatal mortality in any of the comparisons in this review. Further, no data were available on longer-term infant outcomes and potential adverse effects of COX inhibition on the fetus, newborn or mother could not be adequately assessed due to insufficient data.</P>
<P>Compared to betamimetics, COX inhibitors resulted in a reduction in birth less than 48 hours after trial entry combing the results of two small studies yielding a NNTB of 7 on average, however confidence intervals (CIs) were wide (95% CI 6 to 120) (100 women) and preterm birth (before 37 weeks of gestation) (80 women); NNTB of 6, again with wide CIs (95% CI 4 to 236). No differences were shown when comparing COX inhibitors with magnesium sulphate (MgSO<SUB>4</SUB>) (four studies with 508 women), or calcium channel blockers (CCBs) (one study with 79 women) in terms of prolongation of pregnancy or fetal/neonatal outcomes. No data were available to assess COX inhibitors compared with oxytocin receptor antagonists (ORAs). No conclusions could be drawn on the relative benefits of non-selective COX inhibitors over COX-2 inhibitors (two studies with 54 women). COX inhibition was associated with fewer maternal adverse affects than betamimetics and MgSO<SUB>4</SUB> but not when compared with CCBs.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-05-20 14:48:57 +0100" MODIFIED_BY="[Empty name]">
<P>Because these conclusions are based on small numbers, they must be interpreted with caution. Despite some positive findings of prolongation of pregnancy, COX inhibitors were not associated with improvements in neonatal mortality or any markers of neonatal morbidity. There are only three studies (<LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Panter-1999" TYPE="STUDY">Panter 1999</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>) comparing COX inhibition with placebo, with a total of 102 participants. Two of these studies (<LINK REF="STD-Niebyl-1980" TYPE="STUDY">Niebyl 1980</LINK>; <LINK REF="STD-Zuckerman-1984a" TYPE="STUDY">Zuckerman 1984a</LINK>) included participants up to 35 weeks' gestation, when the incidence of neonatal adverse events is low. The small number of adverse events reported allows no meaningful conclusion to be drawn. Inclusion criteria of very low gestational age (&#8804; 24 weeks) in studies (20 weeks in one study) again raises concerns about the validity of extrapolating results of tocolytic efficacy and other outcomes as the pathophysiology of parturition at these extreme gestations may be very different compared to later in pregnancy (e.g. cervical incompetence). There was a paucity of more recent studies included in this review (the oldest study being almost 34 years old), which may diminish applicability to current clinical practice for women in preterm labour.</P>
<P>In 12 of the 20 included studies, administration of antenatal corticosteroids to all women enrolled was stated in the methodology; however the majority did not report the proportion of women who completed the course of antenatal steroids.</P>
<P>Eleven studies included multiple pregnancy, which may have different preterm labour aetiologies and therefore extrapolation of the efficacy of COX inhibitors in this group of women has to be guarded. Notwithstanding these caveats, what is quite apparent from this review is the reassuring data on maternal safety and low incidence of side effects with the use of COX inhibitors for the inhibition of preterm labour.</P>
<P>A major clinical issue regarding the use of COX inhibitors has been concerned about possible effects on the fetal ductus arteriosus; in particular, antenatal premature constriction and closure leading to postnatal persistent patent ductus. In this review, premature closure of the ductus arteriosus was reported in 10 studies with 287 infants exposed to short-term tocolysis (up to 48 hours) with COX inhibitors (mainly indomethacin); only one event of premature closure of the ductus arteriosus was reported. Further, in six studies with 232 infants exposed to short-term tocolysis with COX inhibitors there were 20 events of patent ductus arteriosus; no significant increase in the incidence of patent ductus arteriosus postnatally for infants exposed to COX inhibitors was noted. These data suggest that, for short-term COX inhibition, the concern about ductal effects of COX inhibitors may have been overstated. In addition, the data also suggest that with short-term use of COX inhibitors, maternal side effects and symptoms appear to be minimal. Given the benefits shown in this review (pregnancy prolongation and less maternal adverse effects than betamimetics), the role of COX inhibitors for women in preterm labour warrants further attention in the form of further high-quality studies.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-04-13 18:21:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>The overall quality of the included studies was considered moderate to low. Only half (11) of the included studies reported adequate random sequence generation. One study (<LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>) was considered high risk and in the remaining studies, the randomisation sequence generation was unclear. Similarly, concealment of allocation was considered low risk of bias in less than half (seven of the 20 studies). One study (<LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK>) was considered high risk of bias for allocation concealment while 12 studies were unclear. Importantly, <LINK REF="STD-Odeh-1997" TYPE="STUDY">Odeh 1997</LINK> did not contribute data to the outcomes assessed in this review. Nine studies employed blinding of participants and personnel and nine studies did not. Eight studies had adequate blinding of outcome assessment while two studies were considered high risk. The majority (14) of included studies had minimal or no attrition and were assessed as having low risk of bias; only one study was considered to have high risk of attrition bias. In 10 studies, we found no obvious evidence of reporting bias and judged these studies to be at low risk of bias. Two studies (<LINK REF="STD-Sawdy-2003" TYPE="STUDY">Sawdy 2003</LINK>; <LINK REF="STD-Schorr-1998" TYPE="STUDY">Schorr 1998</LINK>) were deemed to be at high risk of reporting bias with minimal data reported as expected. The majority of studies were assessed as being at low risk of bias for other potential sources of bias.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-04-13 18:21:21 +0100" MODIFIED_BY="Heather Maxwell">
<P>We are aware that the review process itself is subject to bias, and we took steps to minimise bias. At least two review authors carried out data extraction and independently assessed risk of bias; however, a different review team may not have made identical decisions.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-04-13 18:21:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>Our finding of a reduction in births less than 48 hours after trial entry randomisation and less preterm births with the use of COX inhibitors (mainly indomethacin) is consistent with a network meta-analysis (<LINK REF="REF-Haas-2012" TYPE="REFERENCE">Haas 2012)</LINK> showing COX inhibitors tended to have the best probability of delaying birth for 48 hours or more. Further, this review reported that nifedipine (the most commonly used CCB) may be superior in preventing neonatal complications, which is consistent with the recently updated Cochrane review on CCBs (<LINK REF="REF-Flenady-2014b" TYPE="REFERENCE">Flenady 2014b</LINK>), when compared to other tocolytics. Similar to our review, this review found limited study outcome data comparing COX inhibitors with CCBs although these tocolytics appear to have a similarly lower adverse effect profile for women. However, the effect on neonatal mortality or morbidity is not clear when comparing CCBs and COX inhibitors. We were not able to identify any studies comparing ORAs with COX inhibitors. The most commonly used COX inhibitor for tocolysis is indomethacin, which has the advantage of ease of administration and less cost compared with some other tocolytic agents, e.g. ORA. Consistent with our conclusions, Haas et al (<LINK REF="REF-Haas-2012" TYPE="REFERENCE">Haas 2012</LINK>) supported further well-designed, randomised, placebo-controlled studies to evaluate COX inhibitors in prolonging pregnancy for women in preterm labour.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-10-23 06:06:13 +0100" MODIFIED_BY="Hanna E Reinebrant">
<IMPLICATIONS_PRACTICE MODIFIED="2014-08-30 04:06:45 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>There is insufficient information on which to base decisions about the value of COX inhibition for women in preterm labour.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-10-23 06:06:13 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>On the basis of the results of this review, further well-designed placebo controlled studies are justified to assess the potential benefits and safety of COX inhibition for women in preterm labour, particularly addressing longer-term outcomes for infants.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-05-21 12:13:11 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Steve Carlan for assistance in providing unpublished information from the <LINK REF="STD-McWhorter-2004" TYPE="STUDY">McWhorter 2004</LINK> study. We would also like to thank Steve Thornton, James King and Steve Colewho who were authors on previous versions of this review. We would also like to thank Katie Welsh for assistance with reference management</P>
<P>As part of the pre-publication editorial process, this review has been commented on by three peers (2005 version) (an editor and two referees who are external to the editorial team), one or more members of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.</P>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-04-27 11:05:05 +0100" MODIFIED_BY="Leanne V Jones">
<P>All authors declared no conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-04-27 11:21:25 +0100" MODIFIED_BY="Leanne V Jones">
<P>For this update (2014) João Paulo Souza and Vicki Flenady screened studies for inclusion. Hanna Reinebrant, Rafaela Neman dos Santos and Carla Romero performed data extraction and assessment of quality of the new studies for inclusion; Cynthia Pileggi-Castro, Hanna Reinebrant and Vicki Flenady also assessed study quality and Hanna Reinebrant and Vicki Flenady completed all 'Risk of bias' tables, revised the analyses and results section based on recent guidelines from the Pregnancy and Childbirth Group. Sailesh Kumar revised the characteristics of the studies tables and accompanying text. All review authors reviewed the final version of the review and approved the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-01-08 13:30:37 +0000" MODIFIED_BY="Leanne V Jones">
<P>In this update, primary and secondary outcomes measures were revised to enhance consistency across Cochrane tocolytic reviews and to better reflect important outcome measures.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-04-13 11:58:21 +0100" MODIFIED_BY="Heather Maxwell">
<STUDIES MODIFIED="2015-04-13 11:50:16 +0100" MODIFIED_BY="Heather Maxwell">
<INCLUDED_STUDIES MODIFIED="2015-04-13 11:43:59 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Asgharnia-2002" MODIFIED="2014-02-24 17:13:15 +0000" MODIFIED_BY="[Empty name]" NAME="Asgharnia 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-01-24 10:33:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asgharnia M, Sobhani A, Omidvar-Jalali Z</AU>
<TI>Comparison of Mg-Sulfate and indomethacin in management of women with preterm labor</TI>
<SO>Journal of Gorgan University of Medical Sciences</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>2</NO>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Besinger-1991" MODIFIED="2014-08-31 23:54:57 +0100" MODIFIED_BY="Hanna E Reinebrant" NAME="Besinger 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-08-31 23:54:57 +0100" MODIFIED_BY="Hanna E Reinebrant" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Besinger RE, Niebyl JR, Keyes WG, Johnson TR</AU>
<TI>Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>164</VL>
<NO>4</NO>
<PG>981-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borna-2007" MODIFIED="2014-04-23 05:10:24 +0100" MODIFIED_BY="[Empty name]" NAME="Borna 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-04-23 05:10:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borna S, Saeidi FM</AU>
<TI>Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>5</NO>
<PG>631-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kashanian-2011" MODIFIED="2013-12-05 18:51:24 +0000" MODIFIED_BY="[Empty name]" NAME="Kashanian 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-12-05 18:51:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kashanian M, Bahasadri S, Zolali B</AU>
<TI>Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2011</YR>
<VL>113</VL>
<NO>3</NO>
<PG>192-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klauser-2012" MODIFIED="2015-04-13 11:28:48 +0100" MODIFIED_BY="Heather Maxwell" NAME="Klauser 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-04-13 11:28:48 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klauser CK, Briery CM, Keiser SD, Martin RW, Kosek MA, Morrison JC</AU>
<TI>Effect of antenatal tocolysis on neonatal outcomes</TI>
<SO>Journal of Maternal-Fetal and Neonatal Medicine</SO>
<YR>2012</YR>
<VL>25</VL>
<NO>12</NO>
<PG>2778-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:52:01 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klauser CK, Briery CM, Martin RW, Langston L, Magann EF, Morrison JC</AU>
<TI>A comparison of three tocolytics for preterm labor: a randomized clinical trial</TI>
<SO>Journal of Maternal-Fetal &amp; Neonatal Medicine</SO>
<YR>2014</YR>
<VL>27</VL>
<NO>8</NO>
<PG>801-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramer-1999" MODIFIED="2014-10-28 08:24:14 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Kramer 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-10-28 08:24:14 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramer W, Saade G, Belfort M, Dorman K, Mayes MMK</AU>
<TI>Randomized double-blind study comparing sulindac to terbutaline: fetal cardiovascular effects</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>1 Pt 2</NO>
<PG>326</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kramer WB, Saade GR, Belfort M, Dorman K, Mayes M, Moise KJ</AU>
<TI>A randomized double-blind study comparing the fetal effects of sulindac to terbutaline during the management of preterm labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>180</VL>
<NO>2</NO>
<PG>396-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurki-1991" MODIFIED="2014-10-28 08:53:40 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Kurki 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eronen M, Pesonen E, Kurki T, Ylikorkala O, Hallman M</AU>
<TI>The effects of indomethacin and beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: A randomized double-blind study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>164</VL>
<PG>141-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eronen M</AU>
<TI>The hemodynamic effects of antenatal indomethacin in a beta-sympathomimetic agent on the fetus and the newborn: a randomized study</TI>
<SO>Pediatric Research</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>6</NO>
<PG>615-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eronen N, Pesonen E, Kurki T, Teramo K, Ylikorkala O, Hallman M</AU>
<TI>Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterm labor</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<PG>782-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kurki T, Eronen M, Lumme R, Ylikorkala O</AU>
<TI>A randomized double-dummy comparison between indomethacin and nylidrin in threatened preterm labor</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1991</YR>
<VL>78</VL>
<NO>6</NO>
<PG>1093-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurki T, Laatikainen T, Salminen-Lappalainen K, Ylikorkala O</AU>
<TI>Maternal plasma corticotrophin-releasing hormone - elevated in preterm labour but unaffected by indomethacin or nylidrin</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1991</YR>
<VL>98</VL>
<PG>685-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurki T, Schultz E, Linden IB, Ylikorkala O</AU>
<TI>Catechol-O-methyltransferase activity in red blood cells in threatened preterm labor: effect of indomethacin and nylidrin</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1991</YR>
<VL>70</VL>
<PG>187-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:53:28 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lumme R, Kurki T, Pyorala T, Ylikorkala O</AU>
<TI>Indomethacin is more effective than nylidrine in arresting preterm labor</TI>
<SO>Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30-May 3; The Hague, Netherlands</SO>
<YR>1991</YR>
<PG>202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salokorpi T, Eronen M, von Wendt L</AU>
<TI>Growth and development until 18 months of children exposed to tocolytics indomethacin or nylidrin</TI>
<SO>Neuropediatrics</SO>
<YR>1996</YR>
<VL>27</VL>
<PG>147-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McWhorter-2004" MODIFIED="2014-10-28 08:28:38 +0000" MODIFIED_BY="Lynn Hampaon" NAME="McWhorter 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McWhorter J, Carlan S, O'Leary T, Richici K, O'Brien W</AU>
<TI>Rofecoxib versus magnesium sulfate to arrest preterm labour: a randomised trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2004</YR>
<VL>103</VL>
<PG>923-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:28:38 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McWhorter J, Carlan SJ, O'Leary TD</AU>
<TI>Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double-blind trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2002</YR>
<VL>99</VL>
<NO>4 Suppl 1</NO>
<PG>2S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morales-1989" MODIFIED="2014-10-28 08:54:01 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Morales 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morales WJ, Smith SG, Angel JL, O'Brien WF, Knuppel RA</AU>
<TI>Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor: a randomized study</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1989</YR>
<VL>74</VL>
<NO>4</NO>
<PG>567-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:52:01 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Morales WJ, Smith SG, Angel JL, O'Brien WF</AU>
<TI>Efficacy and safety of indomethacin vs ritodrine in the management of preterm labor: a randomized study</TI>
<SO>Proceedings of 9th Annual Meeting of the Society of Perinatal Obstetricians; 1989 Feb 1-4; New Orleans, Louisiana, USA</SO>
<YR>1989</YR>
<PG>35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morales-1993" MODIFIED="2015-04-13 11:33:00 +0100" MODIFIED_BY="Heather Maxwell" NAME="Morales 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-04-13 11:33:00 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morales WJ, Madhav H</AU>
<TI>Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study</TI>
<SO>JAMA</SO>
<YR>1993</YR>
<VL>270</VL>
<PG>2676</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morales WJ, Madhav H</AU>
<TI>Efficacy and safety of indomethacin compared with magnesium sulfate in the management or preterm labor: a randomized study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>169</VL>
<NO>1</NO>
<PG>97-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:30:25 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morales WJ, Madhav H</AU>
<TI>Efficacy and safety of indomethacin vs. magnesium in the management of preterm labor: a randomized study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>164</VL>
<PG>280</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nevils-1994" MODIFIED="2015-04-13 11:37:25 +0100" MODIFIED_BY="Heather Maxwell" NAME="Nevils 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-04-13 11:37:25 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nevils B, Curet L, Izquierdo L, Chatterjee M, Gilson G, Maciulla J, et al</AU>
<TI>Indomethacin as a "rescue" tocolytic in pre-term labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>170</VL>
<PG>378</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niebyl-1980" MODIFIED="2015-04-13 11:38:08 +0100" MODIFIED_BY="Heather Maxwell" NAME="Niebyl 1980" YEAR="1980">
<REFERENCE MODIFIED="2015-04-13 11:37:46 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blake DA, Niebyl JR, White RD, Kumor KM, Dubin NH, Robinson JC, et al</AU>
<TI>Treatment of premature labor with indomethacin</TI>
<SO>Advances in prostaglandin, thromboxane and leukotriene research</SO>
<YR>1980</YR>
<VL>8</VL>
<PG>1465-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-04-13 11:38:08 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Niebyl JR, Blake DA, White RD, Kumor KM, Dubin NH, Robinson JC, et al</AU>
<TI>The inhibition of premature labor with indomethacin</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1980</YR>
<VL>136</VL>
<NO>8</NO>
<PG>1014-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Odeh-1997" MODIFIED="2014-02-24 17:13:01 +0000" MODIFIED_BY="[Empty name]" NAME="Odeh 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-01-14 12:31:57 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Odeh M, Kaiis M, Markowitz J, Oettinger M. Progesterone levels in preterm labor are not affected by ritodrin treatment. Gynecologic and Obstetric Investigation 1997;43(1):34-6&lt;/p&gt;" NOTES_MODIFIED="2014-01-14 12:31:57 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Odeh M, Kaiis M, Markowitz J, Oettinger M</AU>
<TI>Progesterone levels in preterm labor are not affected by ritodrin treatment</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1997</YR>
<VL>43</VL>
<NO>1</NO>
<PG>34-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panter-1999" MODIFIED="2014-10-28 08:31:39 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Panter 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-10-28 08:31:06 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavalle-Garrido T, Panter K, Smallhorn J, Seaward D, Farine D</AU>
<TI>A RCT of indomethacin for preterm labor: effects on fetal heart and ductus arteriosus</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1 Pt 2</NO>
<PG>S46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:31:39 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panter K, Hannah M, Farine D, Amankwah K, Jefferies A, Ohlsson A</AU>
<TI>The effect of indomethacin tocolysis of preterm labor on perinatal outcome: a RCT</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1 Pt 2</NO>
<PG>S46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Panter KR, Hannah ME, Amankwah KS, Ohlsson A, Jefferies AL, Farine D</AU>
<TI>The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1999</YR>
<VL>106</VL>
<NO>5</NO>
<PG>467-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parilla-1997" MODIFIED="2014-08-31 23:56:47 +0100" MODIFIED_BY="Hanna E Reinebrant" NAME="Parilla 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-08-31 23:56:47 +0100" MODIFIED_BY="Hanna E Reinebrant" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parilla BV, Tamura RK, Cohen LS, Clark E</AU>
<TI>Lack of effect of antenatal indomethacin on fetal cerebral blood flow</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>6</NO>
<PG>1166-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Purwaka-2004" MODIFIED="2014-10-28 08:32:36 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Purwaka 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-10-28 08:32:36 +0000" MODIFIED_BY="Lynn Hampaon" NOTES="&lt;p&gt;Purwaka BT, Abadi A, Prasetyadi FOH. Comparison of  efficacy between oral nimesulide and parenteral-oral isoxsuprine to delay threatened preterm labour [abstract]. Journal of Obstetrics and Gynaecology Research 2004;30(3):264&lt;/p&gt;" NOTES_MODIFIED="2014-10-28 08:32:36 +0000" NOTES_MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purwaka BT, Abadi A, Prasetyadi FOH</AU>
<TI>Comparison of efficacy between oral nimesulide and parenteral-oral isoxsuprine to delay threatened preterm labour</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>3</NO>
<PG>264</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawdy-2003" NAME="Sawdy 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Sawdy RJ, Lye S, Fisk NM, Bennett PR. A double-blind randomized study of fetal side effects during and after the short-term maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm labor. American Journal of Obstetrics and Gynecology 2003;188:1046-51&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sawdy RJ, Lye S, Fisk NM, Bennett PR</AU>
<TI>A double-blind randomized study of fetal side effects during and after the short-term maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>188</VL>
<PG>1046-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schorr-1998" MODIFIED="2015-04-13 11:43:40 +0100" MODIFIED_BY="Heather Maxwell" NAME="Schorr 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-04-13 11:43:19 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schorr SJ, Ascarelli MH, Rust OA, Ross EL, Calfee EL, Perry KG Jr., et al</AU>
<TI>A comparative study of ketorolac (Toradol) and magnesium sulfate for arrest of preterm labor</TI>
<SO>Southern Medical Journal</SO>
<YR>1998</YR>
<VL>91</VL>
<NO>11</NO>
<PG>1028-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-04-13 11:43:40 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schorr SJ, Ascarelli MH, Rust OA, Ross EL, Calfee EL, Perry KG Jr., et al</AU>
<TI>Ketorolac is a safe and effective drug for acute tocolysis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1</NO>
<PG>S7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stika-2002" MODIFIED="2015-04-13 11:43:59 +0100" MODIFIED_BY="Heather Maxwell" NAME="Stika 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-04-13 11:43:59 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stika CS, Gross GA, Leguizamon G, Gerber S, Levy R, Mathur A, et al</AU>
<TI>A prospective randomized safety trial of celecoxib for treatment of preterm labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>3</NO>
<PG>653-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zuckerman-1984a" MODIFIED="2014-04-24 01:58:57 +0100" MODIFIED_BY="Hanna E Reinebrant" NAME="Zuckerman 1984a" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuckerman H, Shalev E, Gilad G, Katzuni E</AU>
<TI>Further study of the inhibition of premature labor by indomethacin. Part II double-blind study</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>1984</YR>
<VL>12</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-04-13 11:50:16 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Abramov-2000" NAME="Abramov 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abramov Y, Nadjari M, Weinstein D, Ben-Shachar I, Plotkin V, Ezra Y</AU>
<TI>Indomethacin for preterm labor: a randomized comparision of vaginal and rectal-oral routes</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>4</NO>
<PG>482-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartfield-1998" MODIFIED="2014-10-28 08:33:16 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Bartfield 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-10-28 08:33:16 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bartfield M, Carlan SJ</AU>
<TI>The safety and efficacy of prolonged outpatient sulindac to prevent the recurrence of preterm labor: a prospective double-blind study</TI>
<SO>Primary Care Update for Ob/Gyns</SO>
<YR>1998</YR>
<VL>5</VL>
<NO>4</NO>
<PG>178</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bivins-1993" MODIFIED="2014-10-28 08:54:50 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Bivins 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-10-28 08:54:50 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bivins HA, Newman RB, Fyfe DA, Campbell BA, Stramm SL</AU>
<TI>Randomized comparative trial of indomethacin and terbutaline for the long term treatment of preterm labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<NO>1 Pt 2</NO>
<PG>375</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Bivins HA, Newman RB, Fyfe DA, Campbell BA, Stramm SL. Randomized trial of oral indomethacin and terbutaline sulfate for the long-term suppression of preterm labor . American Journal of Obstetrics and Gynecology 1993;169:1065-70&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bivins HA, Newman RB, Fyfe DA, Campbell BA, Stramm SL</AU>
<TI>Randomized trial of oral indomethacin and terbutaline sulfate for the long-term suppression of preterm labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>169</VL>
<PG>1065-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caballero-1979" MODIFIED="2015-04-13 11:46:14 +0100" MODIFIED_BY="Heather Maxwell" NAME="Caballero 1979" YEAR="1979">
<REFERENCE MODIFIED="2015-04-13 11:46:14 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Caballero A, Tejerina A, Dominguez A, Nava JM, Caballero AJ</AU>
<TI>Indomethacine alone or associated to ritodrine in the prevention of premature labour [abstract]</TI>
<SO>9th World Congress of Gynecology and Obstetrics; 1979 Oct 26-31;Tokyo, Japan</SO>
<YR>1979</YR>
<PG>300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlan--1992" MODIFIED="2014-10-28 08:33:37 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Carlan  1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carlan SJ, O'Brien WF, O'Leary TD, Mastrogiannis D</AU>
<TI>Randomized comparative trial of indomethacin and sulindac for the treatment of refactory preterm labor</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1992</YR>
<VL>79</VL>
<NO>2</NO>
<PG>223-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:33:37 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlan SJ, O'Brien WF, O'Leary TD, Mastrogiannis DS</AU>
<TI>A randomized comparative trial of indomethacin and sulindac for the treatment of refactory preterm labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>166</VL>
<PG>361</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlan-1995" MODIFIED="2015-04-13 11:47:20 +0100" MODIFIED_BY="Heather Maxwell" NAME="Carlan 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-10-28 08:33:47 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlan S, Jones M, Schorr S, McNeill T, Rawji H, Clark K</AU>
<TI>Oral sulindac to prevent recurrence of preterm labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>170</VL>
<PG>381</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carlan SJ, O'Brien WF, Jones MH, O'Leary TD, Roth L</AU>
<TI>Outpatient oral sulindac to prevent recurrence of preterm labor</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1995</YR>
<VL>85</VL>
<PG>769-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-04-13 11:47:20 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones M, Carlan S, Schorr S, McNeill T, Rawji H, Clark K, et al</AU>
<TI>Oral sulindac to prevent recurrence of preterm labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>172</VL>
<PG>416</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ehsanipoor-2011" MODIFIED="2015-04-13 11:49:31 +0100" MODIFIED_BY="Heather Maxwell" NAME="Ehsanipoor 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-04-13 11:49:31 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ehsanipoor RM, Shrivastava VK, Lee RM, Chan K, Galyean AM, Garite TJ, et al</AU>
<TI>A randomized, double-masked trial of prophylactic indomethacin tocolysis versus placebo in women with premature rupture of membranes</TI>
<SO>American Journal of Perinatology</SO>
<YR>2011</YR>
<VL>28</VL>
<NO>6</NO>
<PG>473-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:35:51 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shrivastava V, Ehsanipoor R, Lee RM, Chan K, Gaylean A, Garite T, et al</AU>
<TI>Randomized double-blinded trial of indomethacin tocolysis versus expectant management in patients with premature rupture of membranes at 24-32 weeks of gestation</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2008</YR>
<VL>199</VL>
<NO>6 Suppl 1</NO>
<PG>S59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gamissans-1982" MODIFIED="2015-04-13 11:50:16 +0100" MODIFIED_BY="Heather Maxwell" NAME="Gamissans 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gamissans O, Canas E, Cararach V, Ribas J, Puerto B, Edo A</AU>
<TI>A study of indomethacin combined with ritodrine in threatened preterm labor</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1978</YR>
<VL>8</VL>
<PG>123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:52:01 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gamissans O, Canas E, Cararach V, Ribas J, Puerto B, Edo A</AU>
<TI>A study of indomethacin combined with ritodrine in threatened preterm labor</TI>
<SO>Proceedings of 6th European Congress of Perinatal Medicine; 1978 Aug 29-Sept 1 Vienna, Austria</SO>
<YR>1978</YR>
<PG>Abstract no: 165</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-04-13 11:50:16 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Gamissans O, Cararach V, Serra J. The role of prostaglandin-inhibitors, beta-adrenergic drugs and glucocorticoids in the management of threatened preterm labor . In: Jung H, Lamberti G (editors). Beta-mimetic drugs in obstetrics and perinatology.  3rd Symposium on beta-mimetic drugs, Aachen, November 1980.  Stuttgard: Georg Thieme, 1982;71-84&lt;/p&gt;" NOTES_MODIFIED="2015-04-13 11:50:16 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Gamissans O, Cararach V, Serra J</AU>
<TI>The role of prostaglandin-inhibitors, beta-adrenergic drugs and glucocorticoids in the management of threatened preterm labor</TI>
<SO>Beta-Mimetic Drugs in Obstetrics and Perinatology</SO>
<YR>1982</YR>
<PG>71-84</PG>
<ED>Jung H, Lamberti G</ED>
<PB>Georg Thieme</PB>
<CY>Stuttgart</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gamissans-1984" MODIFIED="2014-10-28 08:36:54 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Gamissans 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-10-28 08:36:54 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Gamissans O, Balasch J</AU>
<TI>Prostaglandin synthetase inhibitors in the treatment of preterm labor</TI>
<SO>Preterm Birth: Causes, Prevention and Management</SO>
<YR>1984</YR>
<PG>223-48</PG>
<ED>Fuchs F, Stubblefield PG</ED>
<PB>Macmillan</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groom-2005" MODIFIED="2014-10-28 09:00:06 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Groom 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-10-28 09:00:06 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groom KM, Shennan AH, Jones BA, Seed P, Bennett PR</AU>
<TI>Tocox--a randomised, double-blind, placebo-controlled trial of rofecoxib (a cox-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2005</YR>
<VL>112</VL>
<PG>725-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hallak--1992" MODIFIED="2014-10-28 08:37:48 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Hallak  1992" YEAR="1992">
<REFERENCE MODIFIED="2014-10-28 08:37:39 +0000" MODIFIED_BY="Lynn Hampaon" NOTES="&lt;p&gt;Hallak M, Moise KJ, Lira N, Dorman K, O'Brian Smith E, Cotton DB. The effect of tocolytic agents (indomethacin and terbutaline) on fetal breathing (FBM) and body movements (FM):  a prospective, randomized, double blind, placebo-controlled clinical trial . American Journal of Obstetrics and Gynecology 1992;166:375&lt;/p&gt;" NOTES_MODIFIED="2014-10-28 08:37:39 +0000" NOTES_MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hallak M, Moise KJ, Lira N, Dorman K, O'Brian Smith E, Cotton DB</AU>
<TI>The effect of tocolytic agents (indomethacin and terbutaline) on fetal breathing (FBM) and body movements (FM): a prospective, randomized, double blind, placebo-controlled clinical trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>166</VL>
<NO>1 Pt 2</NO>
<PG>375</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Hallak M, Moise KJ, Lira N, Dorman KF, O'Brian Smith E, Cotton DB. The effect of tocolytic agents (indomethacin and terbutaline) on fetal breathing and body movements:  a prospective, randomized, double-blind, placebo-controlled clinical trial . American Journal of Obstetrics and Gynecology 1992;167:1059-63&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hallak M, Moise KJ, Lira N, Dorman KF, O'Brian Smith E, Cotton DB</AU>
<TI>The effect of tocolytic agents (indomethacin and terbutaline) on fetal breathing and body movements: a prospective, randomized, double-blind, placebo-controlled clinical trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>167</VL>
<NO>4</NO>
<PG>1059-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:37:48 +0000" MODIFIED_BY="Lynn Hampaon" NOTES="&lt;p&gt;Hallak M, Moise KJ, O'Brian Smith E, Cotton DB. The effects of indomethacin and terbutaline on human fetal umbilical artery velocimetry:  a randomized double-blind study . American Journal of Obstetrics and Gynecology 1993;168:348&lt;/p&gt;" NOTES_MODIFIED="2014-10-28 08:37:48 +0000" NOTES_MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hallak M, Moise KJ, O'Brian Smith E, Cotton DB</AU>
<TI>The effects of indomethacin and terbutaline on human fetal umbilical artery velocimetry: a randomized double-blind study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<NO>1 Pt 2</NO>
<PG>348</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Hallak M, Moise KJ, O'Brian Smith E, Cotton DB. The effects of indomethacin and terbutaline on human fetal umbilical artery velocimetry:  a randomized, double-blind study . American Journal of Obstetrics and Gynecology 1993;168:865-8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hallak M, Moise KJ, O'Brian Smith E, Cotton DB</AU>
<TI>The effects of indomethacin and terbutaline on human fetal umbilical artery velocimetry: a randomized, double-blind study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<NO>3</NO>
<PG>865-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Humphrey-2001" NAME="Humphrey 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Humphrey RG, Bartfield MC, Carlan SJ, O'Brien WF, O'Leary TD, Triana T</AU>
<TI>Sulindac to prevent recurrent preterm labor: a randomized controlled trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2001</YR>
<VL>98</VL>
<NO>4</NO>
<PG>555-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jain-2006" MODIFIED="2014-10-28 08:57:25 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Jain 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-10-28 08:52:01 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jain N, Gahlot D</AU>
<TI>A comparative study of isoxuprine versus ritodrine hydrochloride in the management of preterm labour [abstract]</TI>
<SO>49th All India Congress of Obstetrics and Gynaecology; 2006 January 6-9; Cochin, Kerala State, India</SO>
<YR>2006</YR>
<PG>148</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1983" NAME="Katz 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Katz Z, Lancet M, Yemini M, Mogilner BM, Feigl A, Ben-Hur H. Treatment of premature labor contractions with combined ritodrine and indomethacine . International Journal of Gynecology and Obstetrics 1983;21:337-42&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz Z, Lancet M, Yemini M, Mogilner BM, Feigl A, Ben-Hur H</AU>
<TI>Treatment of premature labor contractions with combined ritodrine and indomethacine</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1983</YR>
<VL>21</VL>
<PG>337-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mital-1992" MODIFIED="2014-10-28 08:57:37 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Mital 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-10-28 08:52:01 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Khuteta RP, Garg S, Bhargava A</AU>
<TI>Mefanimic acid in prevention of premature labour</TI>
<SO>12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil</SO>
<YR>1988</YR>
<PG>222</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Mital P, Garg S, Khuteta RP, Khuteta S, Mital P. Mefenamic acid in prevention of premature labour . Journal of the Royal Society of Health 1992;214-6&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mital P, Garg S, Khuteta RP, Khuteta S, Mital P</AU>
<TI>Mefenamic acid in prevention of premature labour</TI>
<SO>Journal of the Royal Society of Health</SO>
<YR>1992</YR>
<VL>112</VL>
<NO>5</NO>
<PG>214-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newton-1991" NAME="Newton 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Newton ER, Shields L, Ridgway LE, Berkus MD, Elliott BD. Combination antibiotics and indomethacin in idiopathic preterm labor:  a randomized double-blind clinical trial . American Journal of Obstetrics and Gynecology 1991;165:1753-9&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Newton ER, Shields L, Ridgway LE, Berkus MD, Elliott BD</AU>
<TI>Combination antibiotics and indomethacin in idiopathic preterm labor: a randomized double-blind clinical trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>165</VL>
<NO>6</NO>
<PG>1753-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Ridgway L, Wright J, Newton E. The effect of indomethacin on fetal heart biometry . American Journal of Obstetrics and Gynecology 1991;164:349&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ridgway L, Wright J, Newton E</AU>
<TI>The effect of indomethacin on fetal heart biometry</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>164</VL>
<PG>349</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasanen-1995" MODIFIED="2014-10-28 08:57:53 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Rasanen 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-10-28 08:52:01 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jouppila P, Rasanen J</AU>
<TI>Response of the fetal hemodynamics to different maternal prostaglandin synthetase inhibitors</TI>
<SO>Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland</SO>
<YR>1994</YR>
<PG>Abstract no: 269</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-04 03:29:26 +0100" MODIFIED_BY="Hanna E Reinebrant" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jouppila P, Rasanen J</AU>
<TI>Response to the fetal hemodynamics to different maternal prostaglandin synthetase inhibitors</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1994</YR>
<VL>46</VL>
<PG>48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rasanen J, Jouppila P</AU>
<TI>Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: a randomized study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<NO>1</NO>
<PG>20-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rios_x002d_Anez-2001" MODIFIED="2014-10-28 08:39:34 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Rios-Anez 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-10-28 08:39:34 +0000" MODIFIED_BY="Lynn Hampaon" NOTES="&lt;p&gt;Rios-Anez R, Santos-Luque M, Noguera M. Use of an antagonist of the prostaglandins associated to a b-sympathomimetic agent in the treatment of pre-term labour [abstract]. Journal of Perinatal Medicine 2001;29 Suppl 1(Pt 1):165&lt;/p&gt;" NOTES_MODIFIED="2014-10-28 08:39:34 +0000" NOTES_MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rios-Anez R, Santos-Luque M, Noguera M</AU>
<TI>Use of an antagonist of the prostaglandins associated to a b-sympathomimetic agent in the treatment of pre-term labour</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>2001</YR>
<VL>29 Suppl 1</VL>
<NO>Pt 1</NO>
<PG>165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spearing-1979" NAME="Spearing 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Spearing G. Alcohol, indomethacin and salbutamol.  A comparative trial of their use in preterm labour. Obstetrics &amp;amp; Gynecology 1979;53:171-4&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spearing G</AU>
<TI>Alcohol, indomethacin and salbutamol. A comparative trial of their use in preterm labour</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1979</YR>
<VL>53</VL>
<PG>171-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zuckerman-1984b" MODIFIED="2014-04-24 01:58:31 +0100" MODIFIED_BY="Hanna E Reinebrant" NAME="Zuckerman 1984b" YEAR="1984">
<REFERENCE MODIFIED="2014-04-24 01:58:28 +0100" MODIFIED_BY="Hanna E Reinebrant" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuckerman H, Shalev E, Gilad G, Katzuni E</AU>
<TI>Further study of the inhibition of premature labor by indomethacin Part I</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>1984</YR>
<VL>12</VL>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-10-28 08:58:51 +0000" MODIFIED_BY="Lynn Hampaon">
<STUDY DATA_SOURCE="PUB" ID="STD-Castillo-1988" MODIFIED="2014-10-28 08:58:14 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Castillo 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-10-28 08:52:01 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Castillo JM, Alonso J, Hernandez-Garcia JM, Sancho B, Martinez V</AU>
<TI>Study of biochemical and biophysical modifications produced on pregnant women treated in threatened of premature labor with ritodrine and indometacine</TI>
<SO>12th World Congress of Gynecology and Obstetrics; 1988 Oct 23-28; Rio de Janeiro, Brazil</SO>
<YR>1988</YR>
<PG>20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mesdaghinia-2012" MODIFIED="2014-10-28 08:58:51 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Mesdaghinia 2012" YEAR="2011">
<REFERENCE MODIFIED="2014-08-13 13:40:14 +0100" MODIFIED_BY="Hanna E Reinebrant" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mesdaghinia E, Mesdaghinia A, Hashemi T, Sooky Z, Mousavi GA</AU>
<TI>Comparing the effects fo indomethacin and magnesium-sufate in the treatment of preterm labor</TI>
<SO>Feyz, Journal of Kashan University of Medical Sciences</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>2</NO>
<PG>95-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-28 08:58:42 +0000" MODIFIED_BY="Lynn Hampaon" PRIMARY="NO" TYPE="OTHER">
<AU>Sooky Z</AU>
<TI>Comparison of delaying in premature labour by indomethacin and Mg sulphate in pregnant women referred to maternity hospital</TI>
<SO>IRCT Iranian Registry of Clinical Trials (www.irct.ir) (accessed 6 December 2010)</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-28 08:58:51 +0000" MODIFIED_BY="Lynn Hampaon">
<IDENTIFIER MODIFIED="2014-10-28 08:58:51 +0000" MODIFIED_BY="Lynn Hampaon" TYPE="OTHER" VALUE="IRCT138811223329N1"/>
</IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2014-04-24 01:51:10 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-04-13 11:58:21 +0100" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2015-04-01 13:34:11 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Babay-1998" MODIFIED="2015-04-01 13:32:07 +0100" MODIFIED_BY="[Empty name]" NAME="Babay 1998" TYPE="JOURNAL_ARTICLE">
<AU>Babay Z, Lange IR, Amin H</AU>
<TI>Neonatal and maternal complications after administration of indomethacin for preterm labour between 24 and 30 weeks gestation</TI>
<SO>Journal of the Society of Obstetricians and Gynaecologists of Canada</SO>
<YR>1998</YR>
<VL>20</VL>
<NO>5</NO>
<PG>505-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowther-2002" MODIFIED="2008-05-12 16:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Crowther 2002" TYPE="COCHRANE_REVIEW">
<AU>Crowther CA, Hiller JE, Doyle LW</AU>
<TI>Magnesium sulphate for preventing preterm birth in threatened preterm labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-05-12 16:00:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-05-12 16:00:32 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001060"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Doret-2002" MODIFIED="2015-04-01 13:32:16 +0100" MODIFIED_BY="[Empty name]" NAME="Doret 2002" TYPE="JOURNAL_ARTICLE">
<AU>Doret M, Mellier G, Benchaib M, Piacenza JM, Gharib C, Pasquier JC</AU>
<TI>In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2002</YR>
<VL>109</VL>
<PG>983-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doyle-2009" MODIFIED="2014-04-19 04:12:37 +0100" MODIFIED_BY="[Empty name]" NAME="Doyle 2009" TYPE="COCHRANE_REVIEW">
<AU>Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D</AU>
<TI>Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004661.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duckitt-2014" MODIFIED="2014-09-04 04:24:05 +0100" MODIFIED_BY="Hanna E Reinebrant" NAME="Duckitt 2014" TYPE="COCHRANE_REVIEW">
<AU>Duckitt K, Thornton S, O'Donovan OP, Dowswell T</AU>
<TI>Nitric oxide donors for treating preterm labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2014-08-13 12:22:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-13 12:22:12 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002860.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eronen-1994" NAME="Eronen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Eronen M, Pesonen E, Kurki T, Teramo K, Ylikorkola O, Hallman M</AU>
<TI>Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterm labor</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<NO>5</NO>
<PG>783-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2011" MODIFIED="2014-04-19 04:53:40 +0100" MODIFIED_BY="[Empty name]" NAME="FDA 2011" TYPE="OTHER">
<AU>U.S. Food and Drug Administration</AU>
<TI>Drug Safety Communication: New warnings against use of terbutaline to treat preterm labor</TI>
<SO>http://www.fda.gov/Drugs/DrugSafety/ucm243539.htm</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Flenady-2014a" MODIFIED="2014-09-01 00:04:43 +0100" MODIFIED_BY="[Empty name]" NAME="Flenady 2014a" TYPE="COCHRANE_REVIEW">
<AU>Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN</AU>
<TI>Oxytocin receptor antagonists for inhibiting preterm labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2014-08-13 12:38:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-13 12:38:16 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004452.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Flenady-2014b" MODIFIED="2014-11-07 14:09:07 +0000" MODIFIED_BY="[Empty name]" NAME="Flenady 2014b" TYPE="COCHRANE_REVIEW">
<AU>Flenady V, Wojcieszek AM, Papatsonis DNM, Stock OM, Murray L, Jardine LA, et al</AU>
<TI>Calcium channel blockers for inhibiting preterm labour and birth</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2014-08-13 12:27:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-13 12:27:20 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002255.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gates-2004" MODIFIED="2014-10-28 09:01:23 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Gates 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gates S, Brocklehurst P</AU>
<TI>How should randomised trials including multiple pregnancies be analysed?</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2004</YR>
<VL>111</VL>
<NO>3</NO>
<PG>213-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gladstone-2011" MODIFIED="2014-04-19 04:12:37 +0100" MODIFIED_BY="[Empty name]" NAME="Gladstone 2011" TYPE="JOURNAL_ARTICLE">
<AU>Gladstone M, Neilson JP, White S, Kafulafula G, van den Broek N</AU>
<TI>Post-neonatal mortality, morbidity, and developmental outcome after ultrasound-dated preterm birth in rural Malawi: a community-based cohort study</TI>
<SO>PLoS Medicine</SO>
<YR>2011</YR>
<VL>8</VL>
<PG>e1001121</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldenberg-2008" MODIFIED="2014-04-19 04:12:37 +0100" MODIFIED_BY="[Empty name]" NAME="Goldenberg 2008" TYPE="JOURNAL_ARTICLE">
<AU>Goldenberg RL, Culhane JF, Iams JD, Romero R</AU>
<TI>Epidemiology and causes of preterm birth</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<PG>75-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haas-2012" MODIFIED="2014-04-19 04:23:35 +0100" MODIFIED_BY="[Empty name]" NAME="Haas 2012" TYPE="JOURNAL_ARTICLE">
<AU>Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ</AU>
<TI>Tocolytic therapy for preterm delivery: systematic review and network meta-analysis</TI>
<SO>BMJ</SO>
<YR>2012</YR>
<VL>345</VL>
<PG>e6226</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-10-31 11:55:14 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keirse-1992" MODIFIED="2014-10-28 09:01:52 +0000" MODIFIED_BY="Lynn Hampaon" NAME="Keirse 1992" TYPE="BOOK_SECTION">
<AU>Keirse MJNC</AU>
<TI>Inhibitors of prostaglandin synthesis for treatment of preterm labour</TI>
<SO>Prostaglandins and the Uterus</SO>
<YR>1992</YR>
<ED>Drife JO, Calder AA</ED>
<PB>Springer-Verlag</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koren-2006" MODIFIED="2014-09-01 00:05:09 +0100" MODIFIED_BY="[Empty name]" NAME="Koren 2006" TYPE="JOURNAL_ARTICLE">
<AU>Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME</AU>
<TI>Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>5</NO>
<PG>824-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCain-1993" NAME="McCain 1993" TYPE="JOURNAL_ARTICLE">
<AU>McCain GC, Deatrick JA</AU>
<TI>The experience of high-risk pregnancy</TI>
<SO>Journal of Obstetric, Gynecologic and Neonatal Nursing</SO>
<YR>1993</YR>
<VL>23</VL>
<PG>421-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moise-1990" NAME="Moise 1990" TYPE="JOURNAL_ARTICLE">
<AU>Moise KJ, Ou C-N, Kirshon B, Cano LE, Carpenter RJ</AU>
<TI>Placental transfer of indomethacin in the human pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>162</VL>
<PG>549-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-2006" MODIFIED="2014-11-07 14:09:49 +0000" MODIFIED_BY="[Empty name]" NAME="Murray 2006" TYPE="BOOK">
<AU>Murray M</AU>
<SO>Antepartal and Intrapartal Fetal Monitoring</SO>
<YR>2006</YR>
<PB>Springer Publishing Company</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neilson-2014" MODIFIED="2014-04-19 04:23:35 +0100" MODIFIED_BY="[Empty name]" NAME="Neilson 2014" TYPE="COCHRANE_REVIEW">
<AU>Neilson JP, West HM, Dowswell T</AU>
<TI>Betamimetics for inhibiting preterm labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004352.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Norman-2009" MODIFIED="2014-11-07 14:08:15 +0000" MODIFIED_BY="[Empty name]" NAME="Norman 2009" TYPE="JOURNAL_ARTICLE">
<AU>Norman JE, Morris C, Chalmers J</AU>
<TI>The effect of changing patterns of obstetric care in Scotland (1980&#8211;2004) on rates of preterm birth and its neonatal consequences: perinatal database study</TI>
<SO>PLoS Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>9</NO>
<PG>e1000153</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norton-1993" NAME="Norton 1993" TYPE="JOURNAL_ARTICLE">
<AU>Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI</AU>
<TI>Neonatal complications after the administration of indomethacin for preterm labor</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>22</NO>
<PG>1602-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perron-2013" MODIFIED="2014-11-07 14:10:09 +0000" MODIFIED_BY="[Empty name]" NAME="Perron 2013" TYPE="JOURNAL_ARTICLE">
<AU>Perron N, Tremblay E, Ferretti E, Babakissa C, Seidman EG, Levy E, et al</AU>
<TI>Deleterious effects of indomethacin in the mid-gestation human intestine</TI>
<SO>Genomics</SO>
<YR>2013</YR>
<VL>101</VL>
<NO>3</NO>
<PG>171-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petrou-2011" MODIFIED="2014-11-07 14:10:17 +0000" MODIFIED_BY="[Empty name]" NAME="Petrou 2011" TYPE="JOURNAL_ARTICLE">
<AU>Petrou S, Eddama O, Mangham L</AU>
<TI>A structured review of the recent literature on the economic consequences of preterm birth</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>3</NO>
<PG>F225&#8211;32</PG>
<IDENTIFIERS MODIFIED="2014-08-13 12:38:47 +0100" MODIFIED_BY="Hanna E Reinebrant"/>
</REFERENCE>
<REFERENCE ID="REF-Powell-1995" NAME="Powell 1995" TYPE="JOURNAL_ARTICLE">
<AU>Powell SL, Holt VL, Hickok DE, Easterling T, Connell FA</AU>
<TI>Recent changes in delivery site of low-birth-weight infants in Washington: impact on birth weight-specific mortality</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<NO>5</NO>
<PG>1585-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-11-07 10:26:56 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-2006" MODIFIED="2014-04-19 04:15:47 +0100" MODIFIED_BY="[Empty name]" NAME="Roberts 2006" TYPE="COCHRANE_REVIEW">
<AU>Roberts D, Dalziel S</AU>
<TI>Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004454.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sanchez_x002d_Ramos-1999" NAME="Sanchez-Ramos 1999" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Ramos L, Kaunitz AM, Gaudier FL, Delke I</AU>
<TI>Efficacy of maintenance therapy after acute tocolysis: a meta-analysis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>181</VL>
<PG>484-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slater-1999" MODIFIED="2014-09-01 00:05:32 +0100" MODIFIED_BY="Hanna E Reinebrant" NAME="Slater 1999" TYPE="JOURNAL_ARTICLE">
<AU>Slater DM, Dennes WJB, Campa JS, Poston L, Bennett PR</AU>
<TI>Expression of cyclo-oxygenase types-1 and -2 in human myometrium throughout pregnancy</TI>
<SO>Molecular Human Reproduction</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>9</NO>
<PG>880-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Souter-1998" NAME="Souter 1998" TYPE="JOURNAL_ARTICLE">
<AU>Souter D, Harding J, McCowan L, O'Donnell C, McLeay E, Baxendale H</AU>
<TI>Antenatal indomethacin-adverse fetal effects confirmed</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>38</VL>
<NO>1</NO>
<PG>11-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Su-2010" MODIFIED="2014-04-19 04:23:35 +0100" MODIFIED_BY="[Empty name]" NAME="Su 2010" TYPE="COCHRANE_REVIEW">
<AU>Su LL, Samuel M, Chong YS</AU>
<TI>Progestational agents for treating threatened or established preterm labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006770.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Veyver-1993" NAME="Van den Veyver 1993" TYPE="JOURNAL_ARTICLE">
<AU>Van den Veyver IB, Moise KJ</AU>
<TI>Prostaglandin synthetase inhibitors in pregnancy</TI>
<SO>Obstetrical &amp; Gynecological Survey</SO>
<YR>1993</YR>
<VL>48</VL>
<NO>7</NO>
<PG>493-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vogel-2014" MODIFIED="2014-09-01 00:05:39 +0100" MODIFIED_BY="Hanna E Reinebrant" NAME="Vogel 2014" TYPE="COCHRANE_REVIEW">
<AU>Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT</AU>
<TI>Combination of tocolytic agents for inhibiting preterm labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2014-08-13 13:06:45 +0100" MODIFIED_BY="Hanna E Reinebrant">
<IDENTIFIER MODIFIED="2014-08-13 13:06:45 +0100" MODIFIED_BY="Hanna E Reinebrant" TYPE="DOI" VALUE="10.1002/14651858.CD006169.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walker-2011" MODIFIED="2014-04-19 04:44:21 +0100" MODIFIED_BY="[Empty name]" NAME="Walker 2011" TYPE="JOURNAL_ARTICLE">
<AU>Walker MW, Clark RH, Spitzer AR</AU>
<TI>Elevation in plasma creatinine and renal failure in premature neonates without major anomalies: terminology, occurrence and factors associated with increased risk</TI>
<SO>Journal of Perinatology</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>3</NO>
<PG>199-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2012" MODIFIED="2014-09-01 00:05:46 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2012" TYPE="BOOK">
<AU>Howson CP, Kinney MV, Lawn JE</AU>
<SO>Born Too Soon: The Global Action Report on Preterm Birth</SO>
<YR>2012</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yelland-2011" MODIFIED="2015-04-01 13:34:11 +0100" MODIFIED_BY="[Empty name]" NAME="Yelland 2011" TYPE="JOURNAL_ARTICLE">
<AU>Yelland LN, Saltera AB, Ryana P, Makrides M</AU>
<TI>Analysis of binary outcomes from randomised trials including multiple births: when should clustering be taken into account?</TI>
<SO>Paediatric and Perinatal Epidemiology</SO>
<YR>2011</YR>
<VL>25</VL>
<PG>283&#8211;97</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-04-13 11:58:21 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-King-2005" MODIFIED="2015-04-13 11:58:21 +0100" MODIFIED_BY="Heather Maxwell" NAME="King 2005" TYPE="COCHRANE_REVIEW">
<AU>King JF, Flenady V, Cole S, Thornton S</AU>
<TI>Cyclo-oxygenase (COX) inhibitors for treating preterm labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-10-31 11:56:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-31 11:56:37 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001992.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-10-27 10:32:31 +0000" MODIFIED_BY="Jill V Hampson"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-04-13 18:22:07 +0100" MODIFIED_BY="Heather Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-04-13 18:22:07 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-11-07 12:46:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asgharnia-2002">
<CHAR_METHODS MODIFIED="2014-05-20 09:56:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 12:35:58 +0000" MODIFIED_BY="[Empty name]">
<P>120 women in preterm labour between 24-32 weeks' gestation with intact membranes and cervical dilation &#8805; 2 cm.</P>
<P>Exclusion criteria: PROM, complete cervical dilatation, severe haemorrhage, chorioamnionitis, high-order multiple pregnancy (&#8805; triplets), fetal or placental abnormality or sensitivity to tocolytic drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 12:46:19 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: indomethacin. 25 mg every 6 h (p.o.) up to maximum of 4 doses.</P>
<P>Control group: MgSO<SUB>4</SUB>. Bolus dose of 4 g (i.v.) followed by 2 g/h (i.v.) given in 5% dextrose at 10-25 µg/min (i.v.).</P>
<P>Both groups: antibiotics as required and 5 mg dexamethasone every 12 h up to 4 doses.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-21 13:59:59 +0000" MODIFIED_BY="[Empty name]">
<P>Gestational age, mode of delivery, frequency of uterine contractions, dilatation and effacement and delivery delay.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-15 07:47:15 +0100" MODIFIED_BY="[Empty name]">
<P>This paper was published in a non-English language and has been translated for the purpose of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-13 13:54:50 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Besinger-1991">
<CHAR_METHODS MODIFIED="2014-05-20 06:56:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 12:46:44 +0000" MODIFIED_BY="[Empty name]">
<P>43 women with preterm labour between 23 to 34 weeks' gestation with intact membranes and contractions at a rate of &#8805; 4/20 min or &#8805; 8/60 min and cervical dilatation &gt; 2 cm or effacement &gt; 75%. Singleton and multiple pregnancies were included.</P>
<P>Exclusion criteria: cervical dilatation &gt; 4 cm, or with ruptured membranes or if they had a cervical cerclage.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 14:06:00 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: indomethacin. Initial dose of 50 mg (p.o.), then 25-50 mg (p.o.) every 4 h until contractions ceased, thereafter 25 mg (p.o.) every 4-6 h.</P>
<P>Control group: ritodrine. 100-350 &#956;g/min (i.v.) continued until 8-12 h after contractions ceased. Terbutaline (dosing as required to prevent recurrent uterine activity, 2.5-5 g) were then given every 4-6 h.</P>
<P>Both groups: maintenance fluid 125 mL/h. All tocolytic treatments were discontinued at 35 weeks' gestation. Patients with initial treatment failure (progressive preterm labour or patient intolerance) received MgSO<SUB>4</SUB> (bolus dose: 4 g (i.v.) followed by 2-4 g/h (i.v.)) for 8-12 h after contractions ceased.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-13 13:54:50 +0100" MODIFIED_BY="Heather Maxwell">
<P>Efficacy and side effects of treatment.</P>
<P>Maternal: birth (&gt; 35 weeks), delayed delivery &gt; 48 h and &gt; 7 days, side effects, interval from treatment to delivery, gestational age at delivery.<BR/>
</P>
<P>Neonatal: birth weight, 5 min Apgar score, umbilical cord pH, days in NICU, days on ventilator, primary pulmonary hypertension, PDA, IVH, neonatal death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-30 04:16:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-13 13:54:55 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Borna-2007">
<CHAR_METHODS MODIFIED="2014-05-15 07:47:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 14:06:07 +0000" MODIFIED_BY="[Empty name]">
<P>104 women with preterm labour (defined as progressive cervical dilatation or effacement associated with regular uterine contractions at a rate of &#8805; 4/20 min or &#8805; 8/60 min) with intact membranes and cervical dilatation &#8804; 4 cm between 24-34 weeks' gestation with a singleton pregnancy.</P>
<P>Exclusion criteria: cervical dilatation &gt; 4 cm, non-reassuring FHR or other contra-indications to tocolysis (including intra-amniotic infection), fetal anomaly, placenta previa, renal or hepatic dysfunction, thrombocytopenia, coagulation disorder, history of peptic ulcer disease or use of fluconazole.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 12:41:40 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: celecoxib. 100 mg every 12 h (p.o.) up to 48 h. Simultaneous administration of physiological saline (80 mL/h) for the duration of study.</P>
<P>Control group: MgSO<SUB>4</SUB>. Bolus dose of 4-6 g (i.v.) followed by 2-4 g/h (i.v.) up to 48 h. Simultaneous administration of placebo tablet (p.o.) every 12 h.</P>
<P>Both groups: electrical fetal monitoring. 12 mg betamethasone (12 mg) every 24 h up to 2 doses. Continuing treatment if required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-13 13:54:55 +0100" MODIFIED_BY="Heather Maxwell">
<P>Delay in delivery for 48 h, maternal and neonatal side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-15 07:47:40 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-07 12:54:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kashanian-2011">
<CHAR_METHODS MODIFIED="2014-05-15 07:47:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, block randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 12:54:24 +0000" MODIFIED_BY="[Empty name]">
<P>80 nulliparous women between 26-34 weeks' gestation documented by a definite LMP and sonography in the first trimester. Preterm labour defined as contraction rate of 4/20 min or 8/60 min, cervical dilation of &#8805; 1 cm and cervical effacement of &#8805; 50%.</P>
<P>Exclusions: PROM, vaginal bleeding, multiple pregnancy, fetal distress or fetal death, IUGR, a history of trauma, cervical dilation &gt; 4 cm, systemic disorders of the mother including pre-eclampsia, a known uterine or fetal anomaly, smoking, use of other drugs, polyhydramnios, suspected intrauterine infection, prior use of tocolytics and BP &lt; 90/50.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-23 08:21:25 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>COX group: indomethacin. 100 mg suppository, repeated after 1 h if contractions continued, maximum dose of 200 mg.</P>
<P>Control group: nifedipine. 10 mg (p.o.) every 20 mins until cessation of contractions or up to 40 mg total followed by 20 mg every 6 h for 24 h, then 20 mg every 8 h for 24 h, then 10 mg every 8 h for 24 h.</P>
<P>Both groups: 12 mg of betamethasone every 24 h up to 48 h. Alternative treatment was used if treatment failed. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-31 23:48:03 +0100" MODIFIED_BY="[Empty name]">
<P>Maternal: cessation of contractions after 2 h, delivery within 48 h, delivery within 7 days, adverse drug reactions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-15 07:48:03 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-13 13:55:11 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Klauser-2012">
<CHAR_METHODS MODIFIED="2014-11-07 12:42:08 +0000" MODIFIED_BY="[Empty name]">
<P>3-armed randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 13:59:20 +0000" MODIFIED_BY="[Empty name]">
<P>276 women in preterm labour (uterine contractions &#8804; 5 min apart, cervical dilatation &#8805; 1 cm or a change form the previous vaginal examination) between 20-32 weeks' gestation with intact membranes and vertex presentations with cervical dilatation from 1 to 6 cm as well as sufficient effacement and decrease in station.</P>
<P>Exclusion criteria: high-order multiple pregnancy (&#8805; triplets), women with prior significant medical/surgical reasons for early delivery such as severe pre-eclampsia, abruptio placenta, fetal malformations inconsistent with life, chorioamnionitis, IUGR (&lt; 5th percentile), non-reassuring FHR or refusal to participate in the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 14:01:39 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: indomethacin. 100 mg suppository, which was repeated after 2 h if required, then 50 mg (p.o.) every 6 h until contractions had been extinguished for 12 h or up to a maximum of 48 h. Pepcid (20 mg) was given p.o. twice daily.</P>
<P>Control group: MgSO<SUB>4</SUB>. 6 g over 20 min (i.v.), thereafter 4-6 g/h until contractions had been stopped for 1- 2 h.</P>
<P>CCB group: nifedipine. Bolus dose 30 mg (p.o.) followed by 20-30 mg every 4-6 h for 24 h until contractions abated.</P>
<P>All groups: antenatal steroids were started and no antibiotics were used.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-13 13:55:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>Maternal: proportion of women undelivered after 48 h and 7 days, delivery after 37, 34 and 30 weeks' gestation, maternal drug side effects, tachycardia, fetal ductal constriction, oligohydramnios.<BR/>Neonatal: composite measure of "adverse neonatal morbidity" (including RDS, PDA, sepsis, IVH, PVL, NEC), gestational age at birth, birthweight, acidosis, days of mechanical ventilation, neonatal length of stay.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-07 12:41:42 +0000" MODIFIED_BY="[Empty name]">
<P>For subgroup comparisons, the authors of this review have split data from the COX arm into 2 groups with smaller sample size, to achieve reasonably independent comparisons (i.e., (1) COX versus MgSO<SUB>4</SUB>, and (2) COX versus CCB).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-07 12:55:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kramer-1999">
<CHAR_METHODS MODIFIED="2014-08-31 23:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 12:55:48 +0000" MODIFIED_BY="[Empty name]">
<P>20 women &#8805; 17 years with preterm labour (defined as uterine contractions at a rate of 4/20 min or 8/60 min in conjunction with cervical dilatation &#8805; 2 cm, cervical effacement &#8805; 80%, or documented cervical change on serial examinations) between 24-35 weeks' gestation.</P>
<P>Exclusion criteria: maternal medical illness, contraindications to tocolytic therapy, ruptured membranes, fetal anomalies, IUGR, oligohydramnios, evidence of bacteria or white blood cells, glucose concentration &lt; 15 mg/dL, lecithin/sphingomyelin ratio &gt; 1.7 and presence of phosphatidylglycerol.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-15 07:49:11 +0100" MODIFIED_BY="[Empty name]">
<P>COX group: sulindac. 200 mg (p.o.) every 12 h for 6 doses. Every 4 h, when not receiving COX, a placebo tablet was given.</P>
<P>Control group: terbutaline. 5 mg (p.o.) every 4 h for 72 h.</P>
<P>Both groups: all study medications were ground to powder form and combined with glucose-based powder. 12 mg betamethasone (i.m.) was given with the first study medication and again at 24 h. No other medications given. After 72 h all women received 5 mg terbutaline (p.o.) every 4 h until delivery or until 36 weeks' gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-15 07:49:16 +0100" MODIFIED_BY="[Empty name]">
<P>Fetal cardiovascular function (by studying the waveforms in the ductus arteriosus, middle cerebral artery and umbilical artery), fetal urinary function (by studying the renal arteries, fetal urinary output and amniotic fluid output).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-15 07:49:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-07 14:06:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kurki-1991">
<CHAR_METHODS MODIFIED="2014-11-07 12:41:43 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial in 2 hospitals.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 12:57:24 +0000" MODIFIED_BY="[Empty name]">
<P>60 women with imminent preterm labour (defined as painful uterine contractions at least at 10 min intervals and cervical dilatation 2-4 cm), Bishop score of 1-9, between 25-34 weeks' gestation with intact membranes, normal amniotic fluid volume and lack of fetal abnormality as assessed by ultrasound.</P>
<P>Exclusion criteria: multiple pregnancies, IUGR (&lt; 10th percentile), cervical dilatation &gt; 4 cm, ruptured membranes, placenta previa, previous tocolysis in current pregnancy or contraindication to tocolysis (including suspected chorioamnionitis, cardiovascular disease or aspirin allergy).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 14:06:15 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: indomethacin. 100 mg suppository, then 50 mg (p.o.) every 8 h for 24 h followed by 50 mg 3 times daily for 48 h. Simultaneous infusion of physiological saline (i.v.; initial dose 30 mL/h, maintenance 90 mL/h).</P>
<P>Control group: nylidrin. Initial dose 50 &#956;g/min in physiological saline (initial 30 mL/h; i.v.), after 30 min increased to maintenance dose 100-150 &#956;g/min (in 90 mL/h). Simultaneous administration of placebo suppository and oral tablets.</P>
<P>Both treatments continued until cessation of contractions or up to a maximum of 3 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-07 13:58:36 +0000" MODIFIED_BY="[Empty name]">
<P>Maternal: vital signs (including BP, pulse rate, respiration rate and side effects), uterine activity, effect of tocolysis (by assessing postponed delivery and frequency of preterm deliveries), treatment failure (defined as delivery during tocolysis or recurrence of uterine contractions within 48 h of cessation of treatment).</P>
<P>Neonatal: placental histology, respiratory distress, PDA, septicaemia, IVH, NEC.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-15 07:49:57 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-07 13:38:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McWhorter-2004">
<CHAR_METHODS MODIFIED="2014-11-07 12:57:52 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 13:38:15 +0000" MODIFIED_BY="[Empty name]">
<P>214 women with preterm labour (defined as progressive cervical dilatation or effacement associated with regular uterine contractions) between 22-34 weeks' gestation with intact membranes and cervical dilatation of &#8804; 4 cm.<BR/>Exclusion criteria: non-reassuring fetal surveillance, IUGR, lethal congenital anomalies, allergy to NSAIDs, contraindications to tocolysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 12:58:41 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: rofecoxib. 50 mg (p.o.) daily. Simultaneous treatment with physiologic saline (80 mL/h) was given for the duration of the study.</P>
<P>Control group: MgSO<SUB>4</SUB>. Bolus dose (4-6 g; i.v.) followed by 2-4 g/h. Simultaneos placebo treatment with tablet identical in appearance to study drug (with lactose filler) was administered daily.</P>
<P>All women had urogenital cultures taken at randomisation and were started on ampicillin (2 g every 6 h, i.v.) until cultures returned. If cultures were positive women were treated appropriately for up to 7 days and if cultures were negative antibiotic treatment was terminated. Treatment was continued until cessation of contractions or up to 48 h, longer if required. All women were offered betamethasone (12 mg, i.m.) every 24 h for 2 doses. No participants received aspirin or other tocolysis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-15 07:50:13 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: delay in delivery for 48 h. Secondary: maternal and neonatal side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-15 07:50:15 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-13 13:55:17 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Morales-1989">
<CHAR_METHODS MODIFIED="2014-11-07 13:47:25 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 13:44:13 +0000" MODIFIED_BY="[Empty name]">
<P>106 women with preterm labour (defined as progressive cervical dilatation or effacement associated with regular uterine contractions at a rate of 4/20 min) less than 32 weeks' gestation with intact membranes.</P>
<P>Exclusion criteria: cervical dilatation &gt; 4 cm, clinical evidence of intra-amniotic infection or pyelonephritis, medical complications contraindicating tocolysis, IUGR and congenital anomalies inconsistent with life.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-13 13:55:17 +0100" MODIFIED_BY="Heather Maxwell">
<P>COX group: indomethacin. 100 mg suppository, which was repeated 1-2 h later if required, followed by 25 mg (p.o.) every 4 h up to 48 h.</P>
<P>Control group: ritodrine. 50 &#956;g/min (i.v.) increasing by 50 &#956;g/min every 20 min until contractions stopped or a maximum of 350 &#956;g/min reached. Treatment was discontinued if patients displayed changes in ECG, had persistent chest pain, persistent HR &gt; 140 bpm or persistent hypotension (defined as diastolic BP &lt; 40 mmHg).</P>
<P>Both groups: MgSO<SUB>4</SUB> (i.v.) was administered to women with persistent uterine contractions, progressive cervical dilatation or serious side effects as a bolus dose (5 g; i.v.) followed by 2-4 g/h as required. At admission a single dose of Vitamin K (10 mg; i.m.) and 2 doses of betamethasone (12 mg; i.m.) 24 h apart were administered.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-30 04:08:14 +0100" MODIFIED_BY="[Empty name]">
<P>Maternal: effectiveness of tocolysis, side effects.</P>
<P>Neonatal: RDS, IVH, PDA, platelet count, creatinine, blood urea nitrogen, glucose levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-31 23:51:26 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-13 13:38:29 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Morales-1993">
<CHAR_METHODS MODIFIED="2014-09-04 04:28:19 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 13:51:35 +0000" MODIFIED_BY="[Empty name]">
<P>114 women with singleton pregnancies with preterm labour (defined as contraction rate 4/20 min associated with progressive cervical dilatation or effacement or cervical dilatation &gt; 2 cm) less than 32 weeks' gestation.</P>
<P>Exclusion criteria: multiple pregnancy, ruptured membranes, IUGR, congenital anomalies incompatible with life, cervical dilatation &gt; 4 cm.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-13 13:38:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>COX group: indomethacin. 100 mg suppository, which was repeated 1-2 h later if required, followed by 25 mg (p.o.) every 4 h up to 48 h.</P>
<P>Control group: MgSO<SUB>4</SUB>. Bolus dose (6 g over 30 min) followed by 2 g/h (50 g MgSO<SUB>4</SUB> in 500 mL 5% dextrose in water) increasing by 1 g/h every 30 min up to 5 g/h. Serum magnesium concentration measurements were taken from patients with clinically relevant symptoms.</P>
<P>Both groups: at admission a single dose of Vitamin K (10 mg; i.m.) and 2 doses of betamethasone (12 mg; i.m.) 24 h apart were administered. Women &lt; 30 weeks' gestation with failure of tocolysis received phenobarbital (780 mg over 30 min, i.v.). After cessation of contractions (&lt; 4 contractions/h) all patients received terbutaline (5 mg every 6 h; p.o.).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-30 04:08:22 +0100" MODIFIED_BY="[Empty name]">
<P>Maternal: effectiveness of tocolysis, side effects.</P>
<P>Neonatal: RDS, IVH, pulmonary hypertension, death, blood urea nitrogen, creatinine, urine output.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-15 07:51:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-23 08:23:34 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Nevils-1994">
<CHAR_METHODS MODIFIED="2014-05-15 07:51:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial of a rescue tocolytic.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-30 04:08:31 +0100" MODIFIED_BY="[Empty name]">
<P>45 women between 24-34 weeks' gestation with preterm labour.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-23 08:23:34 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>COX group: indomethacin (p.o.).</P>
<P>Control group: terbutaline (i.v.).</P>
<P>Both groups: treatment up to 48 h. Alternative treatment was used if tocolysis was unsuccessful.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-15 13:16:04 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy of indomethacin as a rescue tocolytic including maternal side effects, cervical dilatation, delayed delivery and neonatal outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-15 07:51:49 +0100" MODIFIED_BY="[Empty name]">
<P>Only abstract available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-13 13:55:23 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Niebyl-1980">
<CHAR_METHODS MODIFIED="2014-11-07 13:52:29 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 14:06:28 +0000" MODIFIED_BY="[Empty name]">
<P>32 women between 24-33 weeks' gestation with preterm labour (defined as cervical dilatation of &#8805; 2 cm or 75% effaced or any cervical change during a period of observation together with painful/regular contractions).</P>
<P>Exclusion criteria: ruptured membranes, cervical dilatation &gt; 4 cm, FGR, salicylate sensitivity or peptic ulcer disease history, intrauterine infection and IUGR.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 13:52:45 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: indomethacin. Bolus dose 50 mg (p.o.) followed by 25 mg every 4 h up to 24 h. If contractions recurred after discontinuation, the protocol was repeated with the same study drug for another 24 h.</P>
<P>Control group: placebo. Lactose capsule (p.o.).</P>
<P>Both groups: alternative therapy was used for treatment failure (defined as cervical dilatation &gt; 4 cm &gt; 2 h after initial dose).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-13 13:55:23 +0100" MODIFIED_BY="Heather Maxwell">
<P>Maternal: mean plasma concentration of treatment drug, gestational age.</P>
<P>Fetal/neonatal: Side effects. Benign: Bleeding, NEC, respiratory distress, hyperbilirubinaemia, metabolic abnormality. Life-threatening: pneumothorax, BPD, severe RDS, persistent fetal circulation, PDA with congestive heart failure, bradycardia and premature atrial contractions, chronic hepatitis, hydrocephalus. Causes of death: NEC, sepsis, stillbirth.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-30 04:16:04 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-07 13:54:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Odeh-1997">
<CHAR_METHODS MODIFIED="2014-11-07 13:54:21 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 13:54:27 +0000" MODIFIED_BY="[Empty name]">
<P>25 women in preterm labour (&#8805; 6 uterine contractions/h and cervical dilatation &gt; 4 cm) with intact membranes and singleton pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-23 08:24:07 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>COX group: indomethacin. 100 mg suppository and 25 mg (p.o.) followed by 25 mg (p.o.) every 6 h.</P>
<P>Control group: ritodrine. 0.1 mg/min and increased by 0.05 mg/min every 10 min until inhibition of labour and then maintained for 24 h. Thereafter 20 mg every 4 h (p.o.).</P>
<P>Both groups: no antenatal steroid treatment. Treatment was continued up to 48 h.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-15 07:52:40 +0100" MODIFIED_BY="[Empty name]">
<P>Concentration of progesterone after drug administration.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-15 07:52:40 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not contribute with data to this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-13 13:55:28 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Panter-1999">
<CHAR_METHODS MODIFIED="2014-11-07 13:54:48 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised placebo-controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-30 04:15:55 +0100" MODIFIED_BY="[Empty name]">
<P>34 women between 23-30 weeks' gestation with preterm labour (defined as regular painful contractions with cervical dilatation or effacement).</P>
<P>Exclusion criteria: ruptured membranes, SGA, chorioamnionitis, oligohydramnios, maternal or fetal contraindications to indomethacin or tocolysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 14:00:19 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: indomethacin. Bolus dose 50 mg (p.o.) given followed by 25 mg every 6 h for 48 h.</P>
<P>Control group: placebo. Tablets of identical appearance distributed in the same fashion as treatment.</P>
<P>Both groups: analgesia and i.v. fluids as required, attempted completion of complete course of betamethasone (2 doses of 12 mg (i.m.) 12 h apart).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-13 13:55:28 +0100" MODIFIED_BY="Heather Maxwell">
<P>Maternal: side effects, prolongation of gestation, gestational age at delivery, postpartum haemorrhage, endometritis, wound infection, amniotic fluid volume.</P>
<P>Fetal/neonatal: oxygen dependency at 36 weeks' gestation, perinatal or neonatal death prior to discharge, NEC, IVH (grade 4), PVL, chronic lung disease, admission to NICU, PDA, RDS, surfactant use, days in oxygen, days ventilated, seizures, oliguria, time in hospital.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-30 04:15:56 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-07 13:59:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parilla-1997">
<CHAR_METHODS MODIFIED="2014-08-30 04:15:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 13:59:24 +0000" MODIFIED_BY="[Empty name]">
<P>24 women with preterm labour (defined as regular contractions and progressive cervical dilatation and effacement) &lt; 30 weeks' gestation. Multiples included.</P>
<P>Exclusion criteria: ruptured membranes, uterine bleeding, IUGR, chorioamnionitis, preeclampsia, or abnormal FHR.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-23 08:24:39 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>COX group: indomethacin. Bolus dose 50-100 mg (p.o. or rectally) followed 25-50 mg (p.o.) every 4-6 h up to 24-48 h.</P>
<P>Control group: MgSO<SUB>4</SUB>. 8 g (i.v.) over 60 min followed by 4 g over 60 min, then 2.5 g/h for 12 h after cessation of contractions.</P>
<P>Both groups: betamethasone (2 doses of 12.5 mg 24 h apart). Alternative treatment was used if tocolysis was unsuccessful.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-30 04:15:44 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Maternal: gestational age at delivery.</P>
<P>Fetal/neonatal: fetal cerebral blood flow, IVH, RDS, NEC, neonatal death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-30 04:15:44 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-04 04:28:21 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Purwaka-2004">
<CHAR_METHODS MODIFIED="2014-08-30 04:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-15 07:53:50 +0100" MODIFIED_BY="[Empty name]">
<P>32 women in threatened preterm labour between 24-32 weeks' gestation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-15 07:53:50 +0100" MODIFIED_BY="[Empty name]">
<P>COX group: nimesulide. 4 times 100 mg (p.o.) up to 24 h then 2 times 100 mg per day for 6 days.</P>
<P>Control group: isoxsuprine. Given parenterally and followed by 3 times 20 mg (p.o.) per day for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-15 07:53:50 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy of tocolysis (including delivery delay and time for omitting contractions).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-04 04:28:21 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Only abstract available. This study did not contribute with data to this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-07 13:55:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sawdy-2003">
<CHAR_METHODS MODIFIED="2014-11-07 12:42:12 +0000" MODIFIED_BY="[Empty name]">
<P>3-armed randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 13:55:52 +0000" MODIFIED_BY="[Empty name]">
<P>30 women between 28-32 weeks' gestation with preterm labour (contractions &#8805; 30 sec at least 5 min apart and cervical dilation &#8805; 2 cm).</P>
<P>Exclusion criteria: multiple pregnancy, ruptured membranes, advance cervical dilatation, maternal contraindications to NSAIDs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 12:42:36 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: sulindac. 200 mg (p.o.) and 1 placebo suppository.<BR/>COX group: indomethacin. 100 mg (rectally) and 1 placebo capsule (p.o.).</P>
<P>Control group: nimesulide. 200 mg (rectally) and 1 placebo capsule (p.o.).</P>
<P>All groups: 1 suppository and 1 oral capsule every 12 h for 4 doses. Genital tract swabs, a midstream urine specimen, a full blood count, and a C-reactive protein sample were taken and 2 doses of dexamethasone (12.5 mg, i.m.) was given 12 h apart. Antibiotic prophylaxis (i.v.) with either coamoxiclav (1.5 g twice daily) or cefuroxime (500 mg 3 times daily) was given for 24 h.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-30 04:15:27 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Maternal: amniotic fluid index, gestational age at delivery, prolongation of delivery.</P>
<P>Fetal neonatal: fetal urine output, Doppler pulsatile index, fetal side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-30 04:15:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-13 13:55:41 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Schorr-1998">
<CHAR_METHODS MODIFIED="2014-08-30 04:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-13 13:42:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>88 women &#8804; 32 weeks with preterm labour (defined as contraction rate &#8805; 12/60 min, cervical dilatation &#8805; 2 cm and 50% effaced or cervical change from earlier examination). Singleton and twin pregnancies included.</P>
<P>Exclusion criteria: ruptured membranes, cervical dilatation &gt; 4 cm, significant maternal disease/obstetric disorders or maternal history of peptic ulcer, asthma, bleeding diathesis, thrombocytopenia, NSAID sensitivity, fetal malformations, chorioamnionitis, oligohydramnios, FGR, non reassuring fetal status.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 14:06:40 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: ketorolac. Bolus dose 60 mg (i.m.) then 30 mg every 6 h for 24 h.</P>
<P>Control group: MgSO<SUB>4</SUB>. 6 g (i.v.) over 20 min, followed by 2-6 g/h continuous infusion until 2 h after cessation of uterine contractions, thereafter slow tapering for 3-4 h before stopping.</P>
<P>Both groups: oral tocolysis with magnesium gluconate (2 g every 4 h) after parenteral agents were discontinued up to 37 completed weeks. Betamethasone (12 mg, i.m.) was given and repeated 12 h later.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-13 13:55:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>Maternal: time to uterine quiescence, recurrent preterm labour, delivery during current admission, readmission for preterm labour, preterm delivery &lt; 37 weeks, amniotic fluid volume, oligohydramnios, side effects.</P>
<P>Neonatal: side effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-30 04:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-07 14:06:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stika-2002">
<CHAR_METHODS MODIFIED="2014-10-23 02:46:01 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 14:00:24 +0000" MODIFIED_BY="[Empty name]">
<P>24 women &#8805; 18 years old between 24-34 weeks' gestation with singleton pregnancy and intact membranes with preterm labour (regular, painful contraction unresponsive to initial i.v. hydration and progressive dilatation or effacement).</P>
<P>Exclusion criteria: cervical dilation &#8805; 4 cm, non-reassuring FHR or other contraindication to tocolysis (including intra-amniotic infection), fetal anomalies, amniotic fluid index &lt; 8, placenta previa, renal or hepatic dysfunction, thrombocytopenia (&lt; 150,000 platelets), platelet dysfunction or coagulation disorder, history of peptic ulcer disease, sensitivity to NSAIDs, use of fluconazole.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 14:06:46 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: indomethacin. 100 mg (rectally) followed by 50 mg (p.o.) every 6 h up to 48 h. Simultaneous administration of placebo capsule (p.o.).</P>
<P>Control group: celecoxib. 100 mg (p.o.) every 12 h up to 48 h. Placebo suppository at start of trial, thereafter 1 capsule every 12 h (p.o.; alternating with active drug).</P>
<P>Both groups: administration of MgSO<SUB>4</SUB> (i.v.) prior to and up to 2 h after study drug administration. All women received 1 course of corticosteroid treatment during the first 48 h. Continued cervical change and contraction within 6 h of trial entry was considered treatment failure and MgSO<SUB>4</SUB> (i.v.) was resumed. Recurrent preterm labour episodes after completion of study were treated with MgSO<SUB>4</SUB> (i.v.). Additional NSAIDs were prohibited.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-30 04:14:01 +0100" MODIFIED_BY="[Empty name]">
<P>Maternal: gestational age at delivery, mode of delivery, Apgar score.</P>
<P>Neonatal: weight, duration of stay in NICU, duration of ventilatory support, sepsis, hyaline membrane disease, transient hypertension, IVH, PVL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-30 04:14:01 +0100" MODIFIED_BY="Hanna E Reinebrant"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-13 13:55:51 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Zuckerman-1984a">
<CHAR_METHODS MODIFIED="2014-10-23 02:46:17 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-07 13:58:03 +0000" MODIFIED_BY="[Empty name]">
<P>36 women between 25-35 weeks' gestation with preterm labour (painful, regular uterine contractions at a rate of &gt; 2/10 min for at least 30 min, or accompanied by effacement and/or cervical dilatation &#8805; 1-2 cm and &#8804; 4 cm.</P>
<P>Exclusion criteria: pre-eclampsia, diabetes mellitus, twin pregnancy, cardiac disease, APH, ruptured membranes, intra-uterine infections, IUGR.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-23 08:25:47 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>COX group: indomethacin. 100 mg (rectally) followed by 25 mg (p.o.) 4 times daily up to 24 h. Additional 100 mg suppository if required. Indications of preterm labour and progressive cervical dilatation within 2 h after trial entry was considered treatment failure.</P>
<P>Control group: placebo. Treatment at the same time-intervals and fashion as the COX group.</P>
<P>Both groups: alternative treatment was given if tocolysis was unsuccessful.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-13 13:55:51 +0100" MODIFIED_BY="Heather Maxwell">
<P>Maternal: delivery within 48 h or 7 days, preterm delivery, gestational age at delivery, side effects.</P>
<P>Neonatal: weight, Apgar score, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-30 04:12:41 +0100" MODIFIED_BY="Hanna E Reinebrant"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BP: blood pressure<BR/>BPD: bronchopulmonary dysplasia<BR/>CCB: calcium channel blocker<BR/>cm: centimetre<BR/>COX: cyclo-oxygenase<BR/>FGR: fetal growth restriction<BR/>FHR: fetal heart rate<BR/>g: gram<BR/>h: hour/s<BR/>i.m.: intramuscular<BR/>IUGR: intrauterine growth restriction<BR/>i.v.: intravenous<BR/>IVH: intraventricular haemorrhage<BR/>LMP: last menstrual period<BR/>mg: milligram<BR/>MgSO<SUB>4</SUB>: magnesium sulphate<BR/>min: minutes<BR/>mL: millilitre<BR/>&#956;g: microgram<BR/>NEC: necrotising enterocolitis<BR/>NICU: neonatal intensive care unit<BR/>NSAID: nonsteroidal anti-inflammatory drug<BR/>p.o.: orally<BR/>PDA: patent ductus arteriosus<BR/>PROM: premature rupture of membranes<BR/>PVL: periventricular haemorrhage<BR/>RDS: respiratory distress syndrome<BR/>SGA: small for gestational age<BR/>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-04-13 13:24:48 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:46:30 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Abramov-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:46:30 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>This study compared different routes of administration of indomethacin for the treatment of women with preterm labour: intravaginal versus intrarectal plus oral.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-04-13 13:23:16 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bartfield-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-04-13 13:23:16 +0100" MODIFIED_BY="Heather Maxwell">
<P>This study included pregnant women with an episode of preterm labour successfully treated testing drugs for follow-up prevention of preterm labour.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:46:32 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Bivins-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:46:32 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>A study of maintenance therapy following successful tocolysis: indomethacin versus terbutaline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-30 04:12:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caballero-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-30 04:12:04 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-30 04:09:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carlan--1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-30 04:09:54 +0100" MODIFIED_BY="[Empty name]">
<P>Women were randomised following failed tocolysis to either indomethacin or sulindac.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:46:38 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Carlan-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:46:38 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>A study of maintenance therapy following successful tocolysis: sulindac versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:46:39 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Ehsanipoor-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:46:39 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>This study investigated the role of indomethacin for women with preterm premature rupture of the membranes and excluded women in preterm labour.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-30 04:11:24 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Gamissans-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-30 04:11:24 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Combination tocolytic therapy comparison: ritodrine versus ritodrine with indomethacin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-07 12:58:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gamissans-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-07 12:58:55 +0000" MODIFIED_BY="[Empty name]">
<P>This is a book chapter with no original data, summarising results from clinical studies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:46:48 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Groom-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:46:48 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>This randomised clinical trial was not a tocolytic study: high-risk women were enrolled from 16 to 26 weeks for prevention of preterm labour.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:46:50 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Hallak--1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:46:50 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>This was not a tocolytic study: women with a low-risk pregnancy were randomly assigned to either indomethacin or terbutaline to assess the effects on fetal breathing and body movements.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:46:51 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Humphrey-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:46:51 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>A study of maintenance therapy following successful tocolysis: sulindac versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:46:52 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Jain-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:46:52 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>This study is not described as a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:46:55 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Katz-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:46:55 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>This study assessed combination tocolytic therapy: ritodrine versus ritodrine with indomethacin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:46:57 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Mital-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:46:57 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Women were not in preterm labour at enrolment. This study assessed the effects of mefenamic acid in the prevention of preterm labour for women at increased risk of preterm birth.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-07 12:42:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newton-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-07 12:42:19 +0000" MODIFIED_BY="[Empty name]">
<P>3-armed combination tocolytic therapy comparison: indomethacin, MgSO<SUB>4</SUB> with antibiotics versus MgSO<SUB>4</SUB> alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-07 12:42:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rasanen-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-07 12:42:01 +0000" MODIFIED_BY="[Empty name]">
<P>2 non-selective COX inhibitors were compared for the treatment of women in preterm labour: indomethacin versus sulindac.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-30 04:11:01 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Rios_x002d_Anez-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-30 04:11:01 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Combination tocolytic therapy comparison: fenoterol alone versus fenoterol with indomethacin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-23 02:47:02 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Spearing-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-23 02:47:02 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Quasi-random combination tocolytic study comparing ethanol, ethanol with indomethacin versus salbutamol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-15 12:35:07 +0100" MODIFIED_BY="Hanna E Reinebrant" STUDY_ID="STD-Zuckerman-1984b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-15 12:35:07 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Prospective uncontrolled study to evaluate efficacy and safety in women treated with indomethacin for preterm labour. No comparison group included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>COX: cyclo-oxygenase<BR/>MgSO<SUB>4</SUB>: magnesium sulphate</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-04-13 13:25:00 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-11-07 14:03:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castillo-1988">
<CHAR_METHODS MODIFIED="2014-11-07 14:03:19 +0000" MODIFIED_BY="[Empty name]">
<P>Study of women in threatening preterm labour.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-20 07:03:00 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>35 pregnant women.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-07 14:03:28 +0000" MODIFIED_BY="[Empty name]">
<P>COX group: indomethacin (n = 10).</P>
<P>Betamimetics group: ritodrine (n = 10).</P>
<P>Combination group: ritodrine and indomethacin (n = 10).</P>
<P>Control group: bedrest with infusion of 1000 cc of physiologic serum (i.v.; n = 5).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-20 07:03:00 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Biophysical and biochemical modifications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-20 07:03:00 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>It is unclear why the number of participants was significantly different in the bedrest group. We will await further clarification if this was a randomised controlled trial.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-04-13 13:24:55 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Mesdaghinia-2012">
<CHAR_METHODS MODIFIED="2014-10-23 02:47:10 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Randomised clinical study in Iran.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-30 04:10:40 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>60 women between 24-32 weeks' gestation at risk of preterm labour.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-30 04:10:40 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>COX group: indomethacin (rectally).</P>
<P>Control group: MgSO<SUB>4</SUB> (i.v.).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-30 04:10:40 +0100" MODIFIED_BY="Hanna E Reinebrant">
<P>Maternal: delayed preterm labour, morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-04-13 13:24:55 +0100" MODIFIED_BY="Heather Maxwell">
<P>It is unclear whether women were in preterm labour at time of enrolment. This study is published in a non-English language and we are awaiting translation to enable inclusion assessment.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>COX: cyclo-oxygenase<BR/>i.v.: intravenous<BR/>MgSO<SUB>4</SUB>: magnesium sulphate</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-04-24 01:51:10 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-04-13 13:55:06 +0100" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-11-07 13:55:42 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:47:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asgharnia-2002">
<DESCRIPTION>
<P>Unable to determine how randomisation was performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:07:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Besinger-1991">
<DESCRIPTION>
<P>"...randomly assigned by a table of random numbers via a sealed envelope..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:47:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borna-2007">
<DESCRIPTION>
<P>"Each participant in the study was randomly assigned by the pharmacy with a random number table [...]."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 12:54:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kashanian-2011">
<DESCRIPTION>
<P>Block randomisation, 4 part, ABCD.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-30 04:07:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klauser-2012">
<DESCRIPTION>
<P>Drugs were distributed by the University pharmacy by opening consecutive opaque envelopes containing a card advising group allocation. The cards were "generated by random selection" but no details as to how. The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 12:57:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramer-1999">
<DESCRIPTION>
<P>"Computer-generated random table."</P>
<P>The authors consider this low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:13:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurki-1991">
<DESCRIPTION>
<P>"Subjects [...] were treated in randomized order (choice by a sealed envelope)..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:14:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McWhorter-2004">
<DESCRIPTION>
<P>"Each participant [...] was randomly assigned by the pharmacy with a random table number."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:16:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>"Patients were randomized by means of sealed envelopes..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-13 06:38:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-1993">
<DESCRIPTION>
<P>"Subjects were randomized [...] for tocolysis by means of random number tables. Subjects assigned odd integers were allocated to the MgSO<SUB>4</SUB> group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:51:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nevils-1994">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:18:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niebyl-1980">
<DESCRIPTION>
<P>"Capsules were placed in envelopes and allocated to patients according to a table of random numbers..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:52:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Odeh-1997">
<DESCRIPTION>
<P>"[...] randomly and consecutively selected for treatment [...] (the first with ritodrine, the second with indomethacin etc)."</P>
<P>The authors consider this approach high risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 12:41:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panter-1999">
<DESCRIPTION>
<P>"Women were randomised [...] in random blocks of 2 and four with stratification for study centre. Randomisation was centrally controlled."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:53:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parilla-1997">
<DESCRIPTION>
<P>"Randomization was based on a computer-generated series of random numbers balanced every six patients for a 1:1 ratio."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 13:55:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Purwaka-2004">
<DESCRIPTION>
<P>"[...] then simply randomized to [...]."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:39:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawdy-2003">
<DESCRIPTION>
<P>"To prevent observer bias, drugs were prepared by the pharmacy department in sealed boxes and divided into three equal groups; block randomization was performed to assign the package number. Blocks of 15 patients at a time were produced to ensure that drug expiration dates (1 year) were not violated."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:43:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schorr-1998">
<DESCRIPTION>
<P>"...randomised by pharmacy personnel who selected a sealed opaque envelope...". Random sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:28:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stika-2002">
<DESCRIPTION>
<P>"...women were stratified by gestational age [...]. Women were randomised [...] by sealed envelopes...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-30 04:12:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zuckerman-1984a">
<DESCRIPTION>
<P>"Indomethacin and placebo were allocated at random." Unclear how sequence generation was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-11-07 13:55:43 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:47:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asgharnia-2002">
<DESCRIPTION>
<P>Method of allocation concealment not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 12:53:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besinger-1991">
<DESCRIPTION>
<P>"... via a sealed envelope.."</P>
<P>The authors consider this approach unclear risk as it is not stated whether the envelopes were "Sequentially numbered, opaque, sealed envelopes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:47:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borna-2007">
<DESCRIPTION>
<P>"The hospital pharmacy supplied the patient with the medications [...]."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:48:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kashanian-2011">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:48:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klauser-2012">
<DESCRIPTION>
<P>Sequentially opened opaque envelopes. Probably low risk, but no details as to whether envelopes were sealed and tamper-proof.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:49:28 +0100" MODIFIED_BY="Jill V Hampson" RESULT="YES" STUDY_ID="STD-Kramer-1999">
<DESCRIPTION>
<P>"All study medications, including placebos, were contained in identical opaque capsules in previously prepared blister packs. [...] which was given to the pharmacist responsible for dispensing the medications."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 12:57:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kurki-1991">
<DESCRIPTION>
<P>"Choice by a sealed envelope."</P>
<P>The authors consider this approach unclear risk as it is not stated whether the envelopes were "Sequentially numbered, opaque, sealed envelopes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:15:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McWhorter-2004">
<DESCRIPTION>
<P>Not stated; however the hospital pharmacy supplied the patient with the medication.</P>
<P>The authors consider this approach to be low risk. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 13:51:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>"Patients were randomized by means of sealed envelopes..." The authors consider this approach unclear risk as it is not stated whether the envelopes were "Sequentially numbered, opaque, sealed envelopes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 13:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morales-1993">
<DESCRIPTION>
<P>Sealed envelopes are mentioned. The authors consider this approach unclear risk as it is not stated whether the envelopes were "Sequentially numbered, opaque, sealed envelopes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:51:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nevils-1994">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:19:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niebyl-1980">
<DESCRIPTION>
<P>"Capsules were placed in envelopes..."</P>
<P>The authors consider this approach unclear risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 13:54:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Odeh-1997">
<DESCRIPTION>
<P>"[...] randomly and consecutively selected for treatment [...] (the first with ritodrine, the second with indomethacin etc)."</P>
<P>The authors consider this approach high risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:53:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Panter-1999">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:53:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parilla-1997">
<DESCRIPTION>
<P>"...randomised by opaque sealed envelopes..."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 13:55:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Purwaka-2004">
<DESCRIPTION>
<P>"[...] then simply randomized to [...]."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:41:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawdy-2003">
<DESCRIPTION>
<P>"To prevent observer bias, drugs were prepared by the pharmacy department in sealed boxes and divided into three equal groups;.."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:43:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schorr-1998">
<DESCRIPTION>
<P>"...sealed opaque envelope..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-20 07:45:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stika-2002">
<DESCRIPTION>
<P>"Women were randomized to tocolytic therapy with either celecoxib or indomethacin by sealed envelopes that were kept in each institution&#8217;s pharmacy."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-30 04:12:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zuckerman-1984a">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-05-13 04:20:41 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-11-07 13:55:45 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:47:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asgharnia-2002">
<DESCRIPTION>
<P>Not stated, but there is no mention of simultaneous placebo treatment to adjust for differences in drug administration and it is likely that participants and personnel were not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:47:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Besinger-1991">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:47:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borna-2007">
<DESCRIPTION>
<P>"The hospital pharmacy supplied the patient with the medications and the investigators and patients were blinded as to which preparation the patient was taking."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:48:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kashanian-2011">
<DESCRIPTION>
<P>Intervention not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:48:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klauser-2012">
<DESCRIPTION>
<P>Not blinded, diverging treatment regimens.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-20 06:58:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramer-1999">
<DESCRIPTION>
<P>"Both the principal investigator and the patient were unaware of the type of medication given."</P>
<P>Although it is not known if other personnel involved in patient care were blinded, the authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:50:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kurki-1991">
<DESCRIPTION>
<P>"The double-dummy technique was followed..."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:50:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McWhorter-2004">
<DESCRIPTION>
<P>"The pharmacy supplied the patient with the medications, and the investigators and patients were blinded as to which preparation the patient was taking."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:51:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>Not stated, however considering the different administration routes for the treatment drugs it is likely that participants and personnel were not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:51:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morales-1993">
<DESCRIPTION>
<P>Not stated, however considering the different administration routes for the treatment drugs it is likely that participants and personnel were not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:51:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nevils-1994">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:52:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niebyl-1980">
<DESCRIPTION>
<P>"Capsules were allocated to patients [...] in a double-blind fashion."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:52:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Odeh-1997">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:53:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panter-1999">
<DESCRIPTION>
<P>"...double-blind fashion...". In addition, the appearance of the placebo and COX inhibitor tablets was identical.</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:53:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Parilla-1997">
<DESCRIPTION>
<P>Not blinded; the drugs were administered via different routes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-07 13:55:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Purwaka-2004">
<DESCRIPTION>
<P>Not blinded, different administration routes for the treatment drugs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:54:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawdy-2003">
<DESCRIPTION>
<P>"Placebo and active suppository or capsule were designed to have identical appearance". In addition, drugs were prepared by the pharmacy in order to "avoid observer bias". </P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-20 07:27:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schorr-1998">
<DESCRIPTION>
<P>Not blinded. Drugs were administered via different routes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-15 07:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stika-2002">
<DESCRIPTION>
<P>Both groups were administered simultaneous placebo to ensure blinding of participants and personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-23 06:20:24 +0100" MODIFIED_BY="Hanna E Reinebrant" RESULT="YES" STUDY_ID="STD-Zuckerman-1984a">
<DESCRIPTION>
<P>Placebo controlled trial. "If uterine contractions continued after the insertion of the first suppository, the patient received an additional 100 mg suppository (from the same envelope) after 1 h, and then the treatment was continued orally." Participants and personnel were likely to be blinded to treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-11-07 13:58:22 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:47:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asgharnia-2002">
<DESCRIPTION>
<P>Not stated, but there is no mention of simultaneous placebo treatment to adjust for differences in drug administration and it is likely that participants and personnel were not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:47:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Besinger-1991">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:47:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borna-2007">
<DESCRIPTION>
<P>"At no time before data analysis did any clinical investigator have access to or knowledge of the identity of the assigned drug."</P>
<P>The authors consider this approach low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:48:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kashanian-2011">
<DESCRIPTION>
<P>Outcome assessment not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-07 12:55:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klauser-2012">
<DESCRIPTION>
<P>"Those assessing outcomes were not privy to group assignment as they were not involved in their clinical care."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:49:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kramer-1999">
<DESCRIPTION>
<P>"All infants were assessed at birth by a neonatologist and managed accordingly."</P>
<P>It is unknown if the neonatologist was blinded to study medications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-20 07:14:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kurki-1991">
<DESCRIPTION>
<P>Not stated; however the concomitant placebo treatment to all participants which was identical in appearance to study drugs suggests low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:50:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McWhorter-2004">
<DESCRIPTION>
<P>"At no time before data analysis did any clinical investigator have access to or knowledge of the identity of the assigned drug."</P>
<P>The authors consider this approach low risk. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:50:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:51:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morales-1993">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:51:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nevils-1994">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:52:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niebyl-1980">
<DESCRIPTION>
<P>Based on blinding of participants and personnel, the authors consider this low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:52:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Odeh-1997">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:53:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panter-1999">
<DESCRIPTION>
<P>Not stated, however based on the blinded approach of participants and personnel the authors consider this low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:53:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parilla-1997">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:53:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Purwaka-2004">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:54:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawdy-2003">
<DESCRIPTION>
<P>Participants and personnel were blinded in this study; the authors consider this low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-20 07:26:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schorr-1998">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 07:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stika-2002">
<DESCRIPTION>
<P>Outcome assessment was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-07 13:58:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zuckerman-1984a">
<DESCRIPTION>
<P>Unclear. "The code key was not available to the investigators before completion of the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-11-07 13:57:04 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-20 07:06:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asgharnia-2002">
<DESCRIPTION>
<P>All randomised women were included in reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-15 07:47:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Besinger-1991">
<DESCRIPTION>
<P>Postrandomisation exclusions: 3 women - 1 in indomethacin group for 'evidence of a concealed abruptio placentae' and 2 in ritodrine group for protocol errors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-20 06:58:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borna-2007">
<DESCRIPTION>
<P>All women randomised have been included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-15 07:48:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kashanian-2011">
<DESCRIPTION>
<P>2 women in nifedipine group excluded post-randomisation due to hypotension, 1 woman in indomethacin group excluded - unexplained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-15 07:49:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klauser-2012">
<DESCRIPTION>
<P>25 of 301 women were lost to attrition, reasons for each loss are provided (e.g., delivered elsewhere, no medications available).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-20 06:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramer-1999">
<DESCRIPTION>
<P>All randomised women appear to be included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-20 07:14:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kurki-1991">
<DESCRIPTION>
<P>All randomised women were included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-20 07:00:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McWhorter-2004">
<DESCRIPTION>
<P>4 women in the COX group and 3 women in the control group were excluded post-randomisation (2 membrane rupture prior to medication start, 1 chorioamnionitis, 1 patient refusal, 1 physician error). However all women randomised were included in analyses. In addition there was no information available for 13 patients in the COX group and 7 patients in the control group for neonatal outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-07 13:51:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>All women randomised were included in data analyses. For neonatal outcomes data from 7 infants in the COX group and 8 infants in the control group were missing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-15 07:51:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-1993">
<DESCRIPTION>
<P>7 women in the COX group and 6 in the control group were excluded due to failure to adhere to the study protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-07 12:43:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nevils-1994">
<DESCRIPTION>
<P>13 women did not meet inclusion criteria and only 9 women the COX group and 13 in the control group were included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-07 12:41:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niebyl-1980">
<DESCRIPTION>
<P>2 women were excluded from the indomethacin group: 1 woman vomited the initial capsule treatment and no detectable levels of indomethacin were achieved and 1 woman was treated in error.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-20 07:20:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Odeh-1997">
<DESCRIPTION>
<P>It is unknown how many women were randomised; only how many women were included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-15 07:53:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panter-1999">
<DESCRIPTION>
<P>All women randomised were included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-15 07:53:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parilla-1997">
<DESCRIPTION>
<P>It is unknown how many women were randomised and thus the authors consider this unclear risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-15 07:53:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Purwaka-2004">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-15 07:54:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawdy-2003">
<DESCRIPTION>
<P>All women randomised were included in analyses. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-07 13:57:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schorr-1998">
<DESCRIPTION>
<P>All women randomised were included in analyses. However, 7 eligible women did not participate; 4 declined entry to the study, 1 had placental abruption and 2 had advanced cervical dilatation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-30 04:13:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stika-2002">
<DESCRIPTION>
<P>Number of women randomised not reported; only how many women were enrolled. All women enrolled were included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-20 07:29:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zuckerman-1984a">
<DESCRIPTION>
<P>It is unknown how many women were randomised; only how many women were included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-04-13 13:55:06 +0100" MODIFIED_BY="Heather Maxwell" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:47:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asgharnia-2002">
<DESCRIPTION>
<P>Unable to determine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:47:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Besinger-1991">
<DESCRIPTION>
<P>All outcomes reported as expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-13 13:55:06 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Borna-2007">
<DESCRIPTION>
<P>Maternal and neonatal side effects: Although maternal side effects were reported in the text, it was stated: "There were no severe maternal or neonatal complications in either group believed to be related to study medications."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:48:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kashanian-2011">
<DESCRIPTION>
<P>Minimal neonatal outcome data reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:49:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klauser-2012">
<DESCRIPTION>
<P>Neonatal and maternal outcomes reported in separate papers, all as expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:49:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kramer-1999">
<DESCRIPTION>
<P>Minimal data were reported for neonatal outcomes and efficacy of drug treatment; however this was not the aim of this study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:50:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kurki-1991">
<DESCRIPTION>
<P>All outcomes were reported as expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:50:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McWhorter-2004">
<DESCRIPTION>
<P>All outcomes were reported as expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:50:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>All outcomes were reported as expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:51:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-1993">
<DESCRIPTION>
<P>All outcomes were reported as expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:51:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nevils-1994">
<DESCRIPTION>
<P>Unable to determine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:52:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niebyl-1980">
<DESCRIPTION>
<P>All outcomes were reported as expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:52:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Odeh-1997">
<DESCRIPTION>
<P>No neonatal or maternal outcomes were reported and no measures of efficacy of treatment were included; these were not within the scope of this study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:53:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panter-1999">
<DESCRIPTION>
<P>All outcomes were reported as expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:53:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parilla-1997">
<DESCRIPTION>
<P>No data on tocolytic efficacy and pregnancy prolongation were included. Only minimal data on neonatal and maternal outcomes were included; it appears this was outside the scope of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:53:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Purwaka-2004">
<DESCRIPTION>
<P>Unable to determine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 13:56:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sawdy-2003">
<DESCRIPTION>
<P>The objective of this study was to establish fetal side effects of 2 different drugs after acute maternal exposure for tocolysis; however very limited data on side effects were reported form this study. It is also stated: "There were no reports of adverse neonatal complications related to the study drugs".</P>
<P>The authors consider this to be high risk of reporting bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 13:57:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schorr-1998">
<DESCRIPTION>
<P>The aim of this study was to evaluate safety and efficacy of tocolysis; however, limited data were available in the report for pregnancy prolongation and maternal, fetal and neonatal side effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stika-2002">
<DESCRIPTION>
<P>All outcomes were reported as expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:55:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zuckerman-1984a">
<DESCRIPTION>
<P>All outcomes were reported as expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-05-15 07:55:26 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:47:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asgharnia-2002">
<DESCRIPTION>
<P>Unable to determine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:47:31 +0100" MODIFIED_BY="Hanna E Reinebrant" RESULT="YES" STUDY_ID="STD-Besinger-1991">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:47:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borna-2007">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:48:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kashanian-2011">
<DESCRIPTION>
<P>Unable to determine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:49:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klauser-2012">
<DESCRIPTION>
<P>None evident.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:49:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramer-1999">
<DESCRIPTION>
<P>None evident.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:50:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kurki-1991">
<DESCRIPTION>
<P>None evident.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:50:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McWhorter-2004">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:50:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-1989">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:51:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morales-1993">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:51:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nevils-1994">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:52:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niebyl-1980">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:52:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Odeh-1997">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:53:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panter-1999">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:53:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parilla-1997">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:53:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purwaka-2004">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:54:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawdy-2003">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:54:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schorr-1998">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stika-2002">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-15 07:55:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zuckerman-1984a">
<DESCRIPTION>
<P>None apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-04-13 18:02:35 +0100" MODIFIED_BY="Heather Maxwell">
<COMPARISON ID="CMP-001" MODIFIED="2015-04-13 18:01:32 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>COX inhibitors compared with placebo</NAME>
<DICH_OUTCOME CHI2="2.8132572357982606" CI_END="1.2799934800043853" CI_START="0.03180934331213872" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2017814462302188" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="22" I2="64.45401482398567" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.1072077574562049" LOG_CI_START="-1.4974452965907923" LOG_EFFECT_SIZE="-0.6951187695672936" METHOD="MH" MODIFIED="2014-09-08 05:49:08 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.09348848228532158" P_Q="1.0" P_Z="0.0894942810055118" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.179156863160476" TOTALS="YES" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.00000000000001" Z="1.698071430324016">
<NAME>Birth less than 48 hours after trial entry</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3234819532405666" CI_START="0.13447747828311277" EFFECT_SIZE="0.421875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12171802371709954" LOG_CI_START="-0.8713504433668994" LOG_EFFECT_SIZE="-0.3748162098248999" MODIFIED="2014-03-13 05:48:56 +0000" MODIFIED_BY="[Empty name]" ORDER="38800" O_E="0.0" SE="0.5833333333333334" STUDY_ID="STD-Panter-1999" TOTAL_1="16" TOTAL_2="18" VAR="0.3402777777777778" WEIGHT="58.47301324752439"/>
<DICH_DATA CI_END="0.4875437910881784" CI_START="0.01046478472208409" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3119863699678647" LOG_CI_START="-1.9802697013886117" LOG_EFFECT_SIZE="-1.146128035678238" MODIFIED="2014-05-10 02:03:10 +0100" MODIFIED_BY="[Empty name]" ORDER="38801" O_E="0.0" SE="0.9799578870122228" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" VAR="0.9603174603174602" WEIGHT="41.52698675247562"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.977065787753471" CI_END="2.5842643884842236" CI_START="0.24814138705123626" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8007889546351087" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.41233694298636026" LOG_CI_START="-0.6053007944986438" LOG_EFFECT_SIZE="-0.09648192575614176" METHOD="MH" MODIFIED="2014-09-08 05:49:18 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="0.6135258939366008" P_Q="1.0" P_Z="0.7101555545310896" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="0.3716471838170052">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.237149233206586" CI_START="0.12066944458197347" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5101627209237998" LOG_CI_START="-0.9184026862356492" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="38788" O_E="0.0" SE="0.8391463916782737" STUDY_ID="STD-Niebyl-1980" TOTAL_1="16" TOTAL_2="15" VAR="0.7041666666666666" WEIGHT="55.452240067624686"/>
<DICH_DATA CI_END="72.88490151495549" CI_START="0.13613930723311707" EFFECT_SIZE="3.15" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8626375712827092" LOG_CI_START="-0.8660164637035079" LOG_EFFECT_SIZE="0.4983105537896005" ORDER="38789" O_E="0.0" SE="1.602824887206216" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="2.5690476190476192" WEIGHT="8.734854888701044"/>
<DICH_DATA CI_END="5.036404963596798" CI_START="0.04963858184697284" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7021206432754832" LOG_CI_START="-1.3041806346034457" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="38790" O_E="0.0" SE="1.1785113019775793" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" VAR="1.3888888888888888" WEIGHT="35.81290504367428"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6198056810464001" CI_START="0.07408510239760323" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.20774444740006628" LOG_CI_START="-1.1302691145170851" LOG_EFFECT_SIZE="-0.6690067809585756" METHOD="MH" MODIFIED="2014-09-08 05:49:24 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.004473353199562362" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="2.8426973127767017">
<NAME>Preterm birth (before completion of 37 weeks of gestation)</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6198056810464001" CI_START="0.07408510239760323" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.20774444740006628" LOG_CI_START="-1.1302691145170851" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="38799" O_E="0.0" SE="0.5418955560352877" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" VAR="0.2936507936507936" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.3578700363102865" CI_END="1.6588809452216497" CI_START="0.1028953916187648" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41314792085582175" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" I2="81.3358668048497" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.21981521864122816" LOG_CI_START="-0.9876040755714696" LOG_EFFECT_SIZE="-0.38389442846512073" METHOD="MH" MODIFIED="2014-09-08 05:49:30 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="4" P_CHI2="0.02062902194516547" P_Q="1.0" P_Z="0.2126446242300315" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.8261795277171586" TOTALS="YES" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.0" Z="1.2463263710687058">
<NAME>Birth less than 7 days after trial entry</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3514982806777682" CI_START="0.41620474701448357" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.13081549754297" LOG_CI_START="-0.3806929707595699" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-03-13 05:59:57 +0000" MODIFIED_BY="[Empty name]" ORDER="38802" O_E="0.0" SE="0.3004626062886657" STUDY_ID="STD-Panter-1999" TOTAL_1="16" TOTAL_2="18" VAR="0.09027777777777776" WEIGHT="54.8882253606346"/>
<DICH_DATA CI_END="0.5735048277595051" CI_START="0.0697465793902152" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.24146292185950846" LOG_CI_START="-1.156477086812529" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2014-03-13 05:59:57 +0000" MODIFIED_BY="[Empty name]" ORDER="38803" O_E="0.0" SE="0.5374838498865699" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" VAR="0.28888888888888886" WEIGHT="45.1117746393654"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.4728314030857326" CI_END="6.524064396058655" CI_START="0.6594952874969033" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.5917798417777793" ESTIMABLE="YES" I2="32.10356610370355" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2014-09-08 05:49:35 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="5" P_CHI2="0.22489981564910955" P_Q="1.0" P_Z="0.01636033649445518" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.4446604746666567" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" UNITS="" WEIGHT="100.0" Z="2.4007762548160603">
<NAME>Gestational age (weeks)</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COX inhibitor</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.438794702612092" CI_START="-1.038794702612086" EFFECT_SIZE="2.200000000000003" ESTIMABLE="YES" MEAN_1="35.2" MEAN_2="33.0" MODIFIED="2014-08-20 06:02:51 +0100" MODIFIED_BY="[Empty name]" ORDER="38804" SD_1="4.4" SD_2="4.6476" SE="1.6524766414889702" STUDY_ID="STD-Niebyl-1980" TOTAL_1="15" TOTAL_2="15" WEIGHT="53.607338607407414"/>
<CONT_DATA CI_END="8.803349943309161" CI_START="1.5966500566908364" EFFECT_SIZE="5.199999999999999" ESTIMABLE="YES" MEAN_1="36.4" MEAN_2="31.2" MODIFIED="2014-05-05 12:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="38805" SD_1="7.2" SD_2="3.0" SE="1.8384776310850237" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" WEIGHT="46.392661392592586"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1571062133375922" CI_END="1007.1596371233148" CI_START="425.51693702825344" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="716.3382870757841" ESTIMABLE="YES" I2="13.577510130589507" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2015-04-13 18:01:32 +0100" MODIFIED_BY="Heather Maxwell" NO="6" P_CHI2="0.2820665435182512" P_Q="1.0" P_Z="1.3812130642896981E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="33" UNITS="" WEIGHT="100.0" Z="4.8276966020073395">
<NAME>Birthweight (g)</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COX inhibitor</GRAPH_LABEL_2>
<CONT_DATA CI_END="1027.8970169288218" CI_START="-169.8970169288218" EFFECT_SIZE="429.0" ESTIMABLE="YES" MEAN_1="2358.0" MEAN_2="1929.0" ORDER="38806" SD_1="848.2" SD_2="852.1" SE="305.56531734911715" STUDY_ID="STD-Niebyl-1980" TOTAL_1="16" TOTAL_2="15" WEIGHT="23.58024279899361"/>
<CONT_DATA CI_END="1137.67752315809" CI_START="472.32247684190986" EFFECT_SIZE="805.0" ESTIMABLE="YES" MEAN_1="2833.0" MEAN_2="2028.0" ORDER="38807" SD_1="496.3" SD_2="521.8" SE="169.73654913162076" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" WEIGHT="76.41975720100639"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.338934927225216" CI_START="0.05188456387373051" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.7274546275596815" LOG_CI_START="-1.2849618294653393" LOG_EFFECT_SIZE="-0.278753600952829" METHOD="MH" MODIFIED="2014-09-08 05:49:52 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5871462613301085" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.5429760987306437">
<NAME>Apgar score less than 7 at 5 minutes</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.338934927225216" CI_START="0.05188456387373051" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7274546275596815" LOG_CI_START="-1.2849618294653393" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="38808" O_E="0.0" SE="1.1821033884786185" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="1.3973684210526316" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1499223708951847" CI_START="0.5634730228357667" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.804953560371517" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.060668522936384195" LOG_CI_START="-0.2491268716569541" LOG_EFFECT_SIZE="-0.09422917436028494" METHOD="MH" MODIFIED="2014-09-08 05:49:58 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.23314045861645127" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="1.1923081573342083">
<NAME>Admission to neonatal intensive care unit</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.149922370895185" CI_START="0.5634730228357666" EFFECT_SIZE="0.804953560371517" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.06066852293638428" LOG_CI_START="-0.24912687165695419" LOG_EFFECT_SIZE="-0.09422917436028494" ORDER="38809" O_E="0.0" SE="0.1819753482960624" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="0.033115027387473225" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7093529879857607" CI_END="2.4920122656375003" CI_START="0.400536910734479" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9990710156895126" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="26.181637871893596" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.3965501755816641" LOG_CI_START="-0.3973574561348716" LOG_EFFECT_SIZE="-4.036402766037424E-4" METHOD="MH" MODIFIED="2014-09-08 05:50:11 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="9" P_CHI2="0.25803096066523845" P_Q="1.0" P_Z="0.9984098343087959" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="0.0019929784605864317">
<NAME>Respiratory distress syndrome</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.283585774714819" CI_START="0.2715062503094403" EFFECT_SIZE="1.40625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8623452390351622" LOG_CI_START="-0.5662201681242868" LOG_EFFECT_SIZE="0.1480625354554377" ORDER="38791" O_E="0.0" SE="0.8391463916782737" STUDY_ID="STD-Niebyl-1980" TOTAL_1="16" TOTAL_2="15" VAR="0.7041666666666666" WEIGHT="25.763831544178363"/>
<DICH_DATA CI_END="10.190052314463278" CI_START="0.4349470274748403" EFFECT_SIZE="2.1052631578947367" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0081764136260931" LOG_CI_START="-0.3615636328758263" LOG_EFFECT_SIZE="0.3233063903751334" ORDER="38792" O_E="0.0" SE="0.8045920836378093" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="0.6473684210526316" WEIGHT="24.318744838976052"/>
<DICH_DATA CI_END="2.0245641737004374" CI_START="0.03087084164181588" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.30633154738858576" LOG_CI_START="-1.5104515300445105" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="38793" O_E="0.0" SE="1.0671873729054748" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" VAR="1.1388888888888888" WEIGHT="49.91742361684558"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5070578480454344" CI_END="12.369211080002493" CI_START="0.07407714821008687" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9572230055818725" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="60.11260766162116" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="1.0923420007990658" LOG_CI_START="-1.1303157452848485" LOG_EFFECT_SIZE="-0.018986872242891265" METHOD="MH" MODIFIED="2014-09-08 05:50:18 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="10" P_CHI2="0.11333763992725432" P_Q="1.0" P_Z="0.9732872975034284" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.167183012639175" TOTALS="YES" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="0.03348566448495861">
<NAME>Chronic lung disease</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.627555752732273" CI_START="0.00976760341308864" EFFECT_SIZE="0.18823529411764706" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5596140959320776" LOG_CI_START="-2.010211982048814" LOG_EFFECT_SIZE="-0.725298943058368" MODIFIED="2014-05-05 13:11:53 +0100" MODIFIED_BY="[Empty name]" ORDER="38797" O_E="0.0" SE="1.5095285590502205" STUDY_ID="STD-Niebyl-1980" TOTAL_1="16" TOTAL_2="15" VAR="2.2786764705882354" WEIGHT="38.34110795550905"/>
<DICH_DATA CI_END="11.970348053953002" CI_START="0.5785301918556793" EFFECT_SIZE="2.6315789473684212" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0781067782855762" LOG_CI_START="-0.23767397151919653" LOG_EFFECT_SIZE="0.4202164033831899" ORDER="38798" O_E="0.0" SE="0.7728961256550789" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="0.5973684210526315" WEIGHT="61.658892044490955"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 05:50:23 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Persistent pulmonary hypertension of the newborn</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38812" O_E="0.0" SE="0.0" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38811" O_E="0.0" SE="0.0" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38810" O_E="0.0" SE="0.0" STUDY_ID="STD-Niebyl-1980" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="72.88490151495543" CI_START="0.13613930723311712" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1500000000000004" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="1.8626375712827088" LOG_CI_START="-0.8660164637035078" LOG_EFFECT_SIZE="0.49831055378960054" METHOD="MH" MODIFIED="2014-09-08 05:50:28 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.4740761754003553" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.7158626385178655">
<NAME>Intraventricular haemorrhage Grades III or IV</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.88490151495549" CI_START="0.13613930723311707" EFFECT_SIZE="3.15" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8626375712827092" LOG_CI_START="-0.8660164637035079" LOG_EFFECT_SIZE="0.4983105537896005" ORDER="38794" O_E="0.0" SE="1.602824887206216" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="2.5690476190476192" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.004854804804712497" CI_END="4.43261225808823" CI_START="0.21420421194779038" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.974414806750136" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.6466597431338498" LOG_CI_START="-0.6691719937856802" LOG_EFFECT_SIZE="-0.011256125325915177" METHOD="MH" MODIFIED="2014-09-08 05:50:32 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="13" P_CHI2="0.9444512029031669" P_Q="1.0" P_Z="0.9732499050423211" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="35" WEIGHT="99.99999999999999" Z="0.033532555303630154">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.838474302896339" CI_START="0.15053697325755022" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.766299373071226" LOG_CI_START="-0.8223568202717129" LOG_EFFECT_SIZE="-0.028028723600243537" ORDER="38795" O_E="0.0" SE="0.9331845119446279" STUDY_ID="STD-Niebyl-1980" TOTAL_1="16" TOTAL_2="15" VAR="0.8708333333333333" WEIGHT="67.93685356559607"/>
<DICH_DATA CI_END="15.658996795910493" CI_START="0.07076016780887293" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.194763935247068" LOG_CI_START="-1.1502111458247635" LOG_EFFECT_SIZE="0.022276394711152208" ORDER="38796" O_E="0.0" SE="1.3774499704354535" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="1.8973684210526316" WEIGHT="32.06314643440392"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.154313167730004" CI_START="0.013757251170205428" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3137254901960784" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.8545679467215713" LOG_CI_START="-1.8614683336055944" LOG_EFFECT_SIZE="-0.5034501934420116" METHOD="MH" MODIFIED="2014-09-08 05:50:37 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.4674673036900284" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="0.72660608718909">
<NAME>Neonatal sepsis</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.154313167730004" CI_START="0.013757251170205428" EFFECT_SIZE="0.3137254901960784" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8545679467215713" LOG_CI_START="-1.8614683336055944" LOG_EFFECT_SIZE="-0.5034501934420116" ORDER="38814" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Niebyl-1980" TOTAL_1="16" TOTAL_2="15" VAR="2.545343137254902" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38815" O_E="0.0" SE="0.0" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 05:50:42 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Premature closure of the ductus arteriosus</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38820" O_E="0.0" SE="0.0" STUDY_ID="STD-Niebyl-1980" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38821" O_E="0.0" SE="0.0" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38822" O_E="0.0" SE="0.0" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.462303046774549" CI_START="0.3606238716555902" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4035087719298245" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.7373757909869798" LOG_CI_START="-0.4429455283480755" LOG_EFFECT_SIZE="0.14721513131945216" METHOD="MH" MODIFIED="2014-09-08 05:50:46 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.6249043290080961" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.48891153728886355">
<NAME>Patent ductus arteriosus</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.462303046774549" CI_START="0.3606238716555902" EFFECT_SIZE="1.4035087719298245" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7373757909869798" LOG_CI_START="-0.4429455283480755" LOG_EFFECT_SIZE="0.14721513131945216" ORDER="38813" O_E="0.0" SE="0.6933265856621719" STUDY_ID="STD-Panter-1999" TOTAL_1="19" TOTAL_2="20" VAR="0.4807017543859649" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2709623085197904" CI_END="3.7760364957644894" CI_START="0.658194327407109" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5765042979942696" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.5770361831452409" LOG_CI_START="-0.18164586495627097" LOG_EFFECT_SIZE="0.1976951590944849" METHOD="MH" MODIFIED="2014-09-08 05:50:50 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="17" P_CHI2="0.873295628324075" P_Q="1.0" P_Z="0.3070444183715758" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0" Z="1.0214434168113131">
<NAME>Maternal adverse effects</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.38881850957007" CI_START="0.12381526053184887" EFFECT_SIZE="2.823529411764706" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8088104561608964" LOG_CI_START="-0.9072258241662695" LOG_EFFECT_SIZE="0.45079231599731334" ORDER="38816" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Niebyl-1980" TOTAL_1="16" TOTAL_2="15" VAR="2.545343137254902" WEIGHT="8.28080229226361"/>
<DICH_DATA CI_END="3.5871593475343757" CI_START="0.5080621805252925" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5547506691816229" LOG_CI_START="-0.29408313219161053" LOG_EFFECT_SIZE="0.13033376849500614" ORDER="38817" O_E="0.0" SE="0.4986091767217197" STUDY_ID="STD-Panter-1999" TOTAL_1="16" TOTAL_2="18" VAR="0.24861111111111114" WEIGHT="75.64469914040114"/>
<DICH_DATA CI_END="20.145619854387196" CI_START="0.19855432738789142" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3041806346034457" LOG_CI_START="-0.7021206432754833" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="38818" O_E="0.0" SE="1.1785113019775793" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" VAR="1.3888888888888888" WEIGHT="16.074498567335244"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.287638572855496" CI_START="0.9518817709915516" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.9375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="1.2118581236505244" LOG_CI_START="-0.0214169900552107" LOG_EFFECT_SIZE="0.5952205667976569" METHOD="MH" MODIFIED="2014-09-08 05:50:55 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.05850554197548624" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="18" WEIGHT="100.0" Z="1.8918907238393907">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.287638572855496" CI_START="0.9518817709915518" EFFECT_SIZE="3.9375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2118581236505244" LOG_CI_START="-0.0214169900552106" LOG_EFFECT_SIZE="0.5952205667976569" ORDER="38819" O_E="0.0" SE="0.7244319066010187" STUDY_ID="STD-Panter-1999" TOTAL_1="16" TOTAL_2="18" VAR="0.5248015873015872" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7303020835548986" CI_END="8.601883215506817" CI_START="0.4367528273038323" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9382716049382716" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.9345935420072784" LOG_CI_START="-0.3597642749461106" LOG_EFFECT_SIZE="0.287414633530584" METHOD="MH" MODIFIED="2014-09-08 05:50:59 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="19" P_CHI2="0.392785316005955" P_Q="1.0" P_Z="0.3840668235295528" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="0.8704275169839045">
<NAME>Chorioamnionitis or endometritis</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="96.12715085961011" CI_START="0.260072204121721" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="38823" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Niebyl-1980" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="20.987654320987655"/>
<DICH_DATA CI_END="7.088135988724078" CI_START="0.17855540610583326" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8505320410722685" LOG_CI_START="-0.7482269961775061" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="38824" O_E="0.0" SE="0.9391189724653871" STUDY_ID="STD-Panter-1999" TOTAL_1="16" TOTAL_2="18" VAR="0.8819444444444444" WEIGHT="79.01234567901234"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.786473993825217" CI_START="0.06762937536140103" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="1.169864623787869" LOG_CI_START="-1.169864623787869" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-09-08 05:51:03 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.0">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.786473993825217" CI_START="0.06762937536140103" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.169864623787869" LOG_CI_START="-1.169864623787869" LOG_EFFECT_SIZE="0.0" ORDER="38825" O_E="0.0" SE="1.3743685418725535" STUDY_ID="STD-Zuckerman-1984a" TOTAL_1="18" TOTAL_2="18" VAR="1.8888888888888888" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-04-13 18:02:02 +0100" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)</NAME>
<DICH_OUTCOME CHI2="5.494092733574757" CI_END="1.1357149648973706" CI_START="0.6002362989354173" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8256496515929532" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="87" I2="0.0" I2_Q="46.72841774495365" ID="CMP-002.01" LOG_CI_END="0.05526934836015613" LOG_CI_START="-0.2216777444148835" LOG_EFFECT_SIZE="-0.08320419802736369" METHOD="MH" MODIFIED="2014-09-08 05:52:09 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.4821711917028818" P_Q="0.15302212084382305" P_Z="0.23892507242271332" Q="3.7543469056816736" RANDOM="NO" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="385" TOTAL_2="492" WEIGHT="300.0" Z="1.177677872420469">
<NAME>Birth less than 48 hours after trial entry</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0468566710741218" CI_END="0.9565601421821556" CI_START="0.07725548663098471" DF="1" EFFECT_SIZE="0.27184466019417475" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="4.475939483295721" ID="CMP-002.01.01" LOG_CI_END="-0.019287719210428822" LOG_CI_START="-1.112070667515477" LOG_EFFECT_SIZE="-0.565679193362953" MODIFIED="2014-05-08 03:32:12 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.30623248622366483" P_Z="0.04244290528607493" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="48" WEIGHT="99.99999999999999" Z="2.0291510725249027">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="1.0912771015330225" CI_START="0.01870117428161628" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.03793504241817489" LOG_CI_START="-1.7281311224466887" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="38860" O_E="0.0" SE="1.0373960074101287" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="1.076190476190476" WEIGHT="67.96116504854368"/>
<DICH_DATA CI_END="2.9186487379152517" CI_START="0.10193781022430927" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4651818303889811" LOG_CI_START="-0.991664699938144" LOG_EFFECT_SIZE="-0.26324143477458145" ORDER="38859" O_E="0.0" SE="0.8557588634207841" STUDY_ID="STD-Besinger-1991" TOTAL_1="22" TOTAL_2="18" VAR="0.7323232323232323" WEIGHT="32.03883495145631"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5947257927738074" CI_END="1.2941553960583783" CI_START="0.5867285766402077" DF="3" EFFECT_SIZE="0.8713885203975185" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="53" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.11198642749087484" LOG_CI_START="-0.23156275893738001" LOG_EFFECT_SIZE="-0.05978816572325262" MODIFIED="2014-05-08 03:42:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6605863513346562" P_Z="0.4951197721046733" STUDIES="4" TAU2="0.0" TOTAL_1="249" TOTAL_2="298" WEIGHT="100.0" Z="0.6821884967191395">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="1.8896976175003382" CI_START="0.2327996089065436" EFFECT_SIZE="0.6632653061224489" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.27639231551854365" LOG_CI_START="-0.6330177536178222" LOG_EFFECT_SIZE="-0.1783127190496393" ORDER="38862" O_E="0.0" SE="0.5341919762631452" STUDY_ID="STD-Morales-1993" TOTAL_1="49" TOTAL_2="52" VAR="0.28536106750392465" WEIGHT="17.51586468585803"/>
<DICH_DATA CI_END="1.4921219972839475" CI_START="0.4190024766533986" EFFECT_SIZE="0.7906976744186046" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" LOG_CI_END="0.17380433290957703" LOG_CI_START="-0.37778340998423987" LOG_EFFECT_SIZE="-0.10198953853733142" MODIFIED="2014-05-08 03:09:16 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="191" O_E="0.0" SE="0.3240053705791907" STUDY_ID="STD-Klauser-2012" TOTAL_1="43" TOTAL_2="85" VAR="0.1049794801641587" WEIGHT="37.90228412521994"/>
<DICH_DATA CI_END="1.7413278484754635" CI_START="0.3661905625808961" EFFECT_SIZE="0.7985347985347986" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.24088054560291114" LOG_CI_START="-0.4362928524752135" LOG_EFFECT_SIZE="-0.09770615343615117" ORDER="38861" O_E="0.0" SE="0.39777500609347227" STUDY_ID="STD-McWhorter-2004" TOTAL_1="105" TOTAL_2="109" VAR="0.1582249554726619" WEIGHT="28.78629464185363"/>
<DICH_DATA CI_END="3.465223907571751" CI_START="0.5889421235006747" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5397313020592628" LOG_CI_START="-0.22992738208777638" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2013-12-05 23:57:49 +0000" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.45210132093990213" STUDY_ID="STD-Borna-2007" TOTAL_1="52" TOTAL_2="52" VAR="0.2043956043956044" WEIGHT="15.795556547068403"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.014880102884881" CI_START="0.5824719343998428" DF="0" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.30424920819190965" LOG_CI_START="-0.2347249956734859" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2014-08-19 08:16:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8004051694986822" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="146" WEIGHT="100.0" Z="0.2528227726157568">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-19 08:16:40 +0100" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.0" STUDY_ID="STD-Kashanian-2011" TOTAL_1="40" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.014880102884881" CI_START="0.5824719343998428" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="0.30424920819190965" LOG_CI_START="-0.2347249956734859" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2014-05-08 03:09:55 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="192" O_E="0.0" SE="0.3165961153158709" STUDY_ID="STD-Klauser-2012" TOTAL_1="44" TOTAL_2="104" VAR="0.10023310023310023" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.733614392522655" CI_END="3.163867235742387" CI_START="0.8639215018786701" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6532794482625373" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.5002182510600839" LOG_CI_START="-0.0635257168378867" LOG_EFFECT_SIZE="0.2183462671110986" METHOD="MH" MODIFIED="2014-09-08 05:52:16 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="0.8803225483818806" P_Q="0.5141022237313508" P_Z="0.12895256717279158" Q="1.330666459665553" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="468" TOTAL_2="588" WEIGHT="300.0" Z="1.5182453172571015">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6277675373348872" CI_END="3.574894122973509" CI_START="0.2743327869423942" DF="2" EFFECT_SIZE="0.9903083700440529" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.5532631839023369" LOG_CI_START="-0.5617222844945352" LOG_EFFECT_SIZE="-0.004229550296099216" MODIFIED="2014-05-08 03:32:31 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.7306039875774978" P_Z="0.9881361094743728" STUDIES="4" TAU2="0.0" TOTAL_1="119" TOTAL_2="118" WEIGHT="99.99999999999999" Z="0.014869729671139528">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="12.008089728571122" CI_START="0.05329740320620968" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0794739244448837" LOG_CI_START="-1.2732939504609964" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="38826" O_E="0.0" SE="1.3820274961085253" STUDY_ID="STD-Besinger-1991" TOTAL_1="25" TOTAL_2="20" VAR="1.91" WEIGHT="24.669603524229075"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38827" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="38828" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="11.101321585903083"/>
<DICH_DATA CI_END="4.122163903559417" CI_START="0.12438290433946707" EFFECT_SIZE="0.7160493827160493" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6151252560012337" LOG_CI_START="-0.9052393066326588" LOG_EFFECT_SIZE="-0.1450570253157125" ORDER="38829" O_E="0.0" SE="0.8930696700171101" STUDY_ID="STD-Morales-1989" TOTAL_1="54" TOTAL_2="58" VAR="0.7975734355044699" WEIGHT="64.22907488986783"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6036420289566895" CI_END="4.289199512976716" CI_START="0.5918003730000235" DF="3" EFFECT_SIZE="1.5932199696373188" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.6323762480039635" LOG_CI_START="-0.2278247654481115" LOG_EFFECT_SIZE="0.2022757412779259" MODIFIED="2014-05-08 03:43:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6585643488179498" P_Z="0.35664926859504553" STUDIES="5" TAU2="0.0" TOTAL_1="259" TOTAL_2="311" WEIGHT="100.00000000000001" Z="0.9217686602341226">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="4.404641533209657" CI_START="0.27279251793330384" EFFECT_SIZE="1.0961538461538463" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.6439105696189529" LOG_CI_START="-0.5641675455435682" LOG_EFFECT_SIZE="0.03987151203769228" MODIFIED="2014-05-08 02:27:00 +0100" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.7096310649295804" STUDY_ID="STD-Klauser-2012" TOTAL_1="52" TOTAL_2="95" VAR="0.5035762483130903" WEIGHT="58.923940756452076"/>
<DICH_DATA CI_END="148.10682562375757" CI_START="0.4058163669351805" EFFECT_SIZE="7.752688172043011" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.170575073797546" LOG_CI_START="-0.3916704414665584" LOG_EFFECT_SIZE="0.8894523161654939" ORDER="38830" O_E="0.0" SE="1.5050756989859895" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" VAR="2.265252859678165" WEIGHT="7.9037401303125625"/>
<DICH_DATA CI_END="15.880747965636855" CI_START="0.06515940093125934" EFFECT_SIZE="1.0172413793103448" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008709533617878" LOG_CI_START="-1.1860229172033738" LOG_EFFECT_SIZE="0.007424018079206875" ORDER="38831" O_E="0.0" SE="1.4020732748851903" STUDY_ID="STD-Morales-1993" TOTAL_1="58" TOTAL_2="59" VAR="1.9658094681472824" WEIGHT="16.51497432246911"/>
<DICH_DATA CI_END="14.207980025005401" CI_START="0.07038298183415555" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.152532337860481" LOG_CI_START="-1.152532337860481" LOG_EFFECT_SIZE="0.0" ORDER="38832" O_E="0.0" SE="1.3540064007726602" STUDY_ID="STD-Parilla-1997" TOTAL_1="12" TOTAL_2="12" VAR="1.8333333333333335" WEIGHT="16.65734479076626"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38833" O_E="0.0" SE="0.0" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.22681727981415706" CI_END="9.622088014176235" CI_START="0.8204628342547547" DF="1" EFFECT_SIZE="2.809726962457338" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.9832693251186393" LOG_CI_START="-0.08594108705896744" LOG_EFFECT_SIZE="0.448664119029836" MODIFIED="2014-05-08 03:46:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6338938958573463" P_Z="0.09999297707161832" STUDIES="2" TAU2="0.0" TOTAL_1="90" TOTAL_2="159" WEIGHT="100.0" Z="1.6448876749393249">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="103.44997807039977" CI_START="0.25389686387488375" EFFECT_SIZE="5.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.014730402938869" LOG_CI_START="-0.5953426634832854" LOG_EFFECT_SIZE="0.7096938697277919" MODIFIED="2013-12-06 00:13:52 +0000" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="1.5331698392864246" STUDY_ID="STD-Kashanian-2011" TOTAL_1="39" TOTAL_2="40" VAR="2.350609756097561" WEIGHT="17.064846416382252"/>
<DICH_DATA CI_END="8.969423059443171" CI_START="0.6070005181339322" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.9527645088012268" LOG_CI_START="-0.21681093821203798" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2014-05-08 02:27:03 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="177" O_E="0.0" SE="0.6870144070674262" STUDY_ID="STD-Klauser-2012" TOTAL_1="51" TOTAL_2="119" VAR="0.47198879551820727" WEIGHT="82.93515358361775"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22288876669539476" CI_END="1.07242674688863" CI_START="0.7282603331553443" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8837453592374988" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="130" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.030367636979327553" LOG_CI_START="-0.13771334453001094" LOG_EFFECT_SIZE="-0.05367285377534171" METHOD="MH" MODIFIED="2014-10-23 05:14:54 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="0.6368476018484686" P_Q="0.6368564274271565" P_Z="0.21066457258371984" Q="0.22287709133770478" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="87" TOTAL_2="189" WEIGHT="200.0" Z="1.2517401957378476">
<NAME>Very preterm birth (before completion of 34 weeks of gestation)</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1103831012844974" CI_START="0.639315335986316" DF="0" EFFECT_SIZE="0.8425467022493328" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="61" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.045472843713500015" LOG_CI_START="-0.19428487752398574" LOG_EFFECT_SIZE="-0.07440601690524287" MODIFIED="2014-05-08 03:43:24 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.22379301112897876" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="85" WEIGHT="100.0" Z="1.216503999242663">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="1.1103831012844974" CI_START="0.639315335986316" EFFECT_SIZE="0.8425467022493328" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="61" LOG_CI_END="0.045472843713500015" LOG_CI_START="-0.19428487752398574" LOG_EFFECT_SIZE="-0.07440601690524287" MODIFIED="2014-05-08 03:07:56 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="189" O_E="0.0" SE="0.14083487227476005" STUDY_ID="STD-Klauser-2012" TOTAL_1="43" TOTAL_2="85" VAR="0.019834461248647975" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2133937541215891" CI_START="0.7049996759373633" DF="0" EFFECT_SIZE="0.924901185770751" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="69" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.08400175510653791" LOG_CI_START="-0.15181108263788815" LOG_EFFECT_SIZE="-0.03390466376567509" MODIFIED="2014-05-08 03:46:49 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="1.0" P_Z="0.573027184962191" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="104" WEIGHT="100.0" Z="0.5635988313807064">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="1.2133937541215891" CI_START="0.7049996759373635" EFFECT_SIZE="0.924901185770751" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="69" LOG_CI_END="0.08400175510653791" LOG_CI_START="-0.1518110826378881" LOG_EFFECT_SIZE="-0.03390466376567509" MODIFIED="2014-05-08 03:08:10 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="190" O_E="0.0" SE="0.13851762818344854" STUDY_ID="STD-Klauser-2012" TOTAL_1="44" TOTAL_2="104" VAR="0.0191871333175681" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-10-23 05:15:03 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="87" TOTAL_2="189" WEIGHT="0.0" Z="0.0">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-08 03:43:29 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-05-08 03:16:01 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="195" O_E="0.0" SE="0.0" STUDY_ID="STD-Klauser-2012" TOTAL_1="43" TOTAL_2="85" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-08 03:46:54 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="104" WEIGHT="0.0" Z="0.0">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-05-08 03:16:08 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="196" O_E="0.0" SE="0.0" STUDY_ID="STD-Klauser-2012" TOTAL_1="44" TOTAL_2="104" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.861660162596019" CI_END="1.182727690098148" CI_START="0.9088296565101441" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0367728778941587" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="187" I2="66.14629826742136" I2_Q="61.32669303070728" ID="CMP-002.05" LOG_CI_END="0.07288476466087057" LOG_CI_START="-0.04151750970461854" LOG_EFFECT_SIZE="0.015683627478126034" METHOD="MH" MODIFIED="2014-10-23 05:15:03 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="5" P_CHI2="0.031187897143445165" P_Q="0.07533869243087499" P_Z="0.5909979390543006" Q="5.171525676839674" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0247954087965231" TOTALS="SUB" TOTAL_1="172" TOTAL_2="272" WEIGHT="300.0" Z="0.5373904526734254">
<NAME>Preterm birth (before completion of 37 weeks of gestation)</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9938710793373499" CI_START="0.2820052041315734" DF="0" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-0.0026699467531850667" LOG_CI_START="-0.5497428771247131" LOG_EFFECT_SIZE="-0.27620641193894907" MODIFIED="2014-05-08 03:32:54 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.047805324025515954" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.979094887154185">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38856" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9938710793373499" CI_START="0.2820052041315734" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="-0.0026699467531850667" LOG_CI_START="-0.5497428771247131" LOG_EFFECT_SIZE="-0.27620641193894907" ORDER="38857" O_E="0.0" SE="0.32135334735491583" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.10326797385620917" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.45444513338599" CI_END="1.474569125977307" CI_START="0.5219765370558135" DF="1" EFFECT_SIZE="0.8773200590588661" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="85" I2="31.24525793063288" ID="CMP-002.05.02" LOG_CI_END="0.16866513655334092" LOG_CI_START="-0.28234901817820396" LOG_EFFECT_SIZE="-0.056841940812431505" MODIFIED="2014-05-08 03:43:18 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="0.22781632282855757" P_Z="0.6212821903918568" STUDIES="2" TAU2="0.07986757088981274" TOTAL_1="88" TOTAL_2="128" WEIGHT="100.0" Z="0.4940339704860757">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="1.0920631630892639" CI_START="0.8492414245730622" EFFECT_SIZE="0.9630292188431724" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="78" LOG_CI_END="0.0382477579546338" LOG_CI_START="-0.07096882983256184" LOG_EFFECT_SIZE="-0.016360535938964013" MODIFIED="2014-05-08 02:30:01 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="178" O_E="0.0" SE="0.06415436429702746" STUDY_ID="STD-Klauser-2012" TOTAL_1="43" TOTAL_2="85" VAR="0.004115782458355713" WEIGHT="83.57229656537784"/>
<DICH_DATA CI_END="1.7334308141555324" CI_START="0.17200032746604071" EFFECT_SIZE="0.546031746031746" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.23890651248788783" LOG_CI_START="-0.7644707262519911" LOG_EFFECT_SIZE="-0.2627821068820516" ORDER="38858" O_E="0.0" SE="0.5893887568332401" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="0.3473791066814323" WEIGHT="16.427703434622167"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2467914922582946" CI_START="0.9433195999263094" DF="0" EFFECT_SIZE="1.0844919786096257" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="85" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="0.09579383011596486" LOG_CI_START="-0.02534114186636608" LOG_EFFECT_SIZE="0.03522634412479939" MODIFIED="2014-05-08 03:46:43 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="1.0" P_Z="0.2543177443254253" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="104" WEIGHT="100.0" Z="1.1399245760620083">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="1.2467914922582946" CI_START="0.9433195999263094" EFFECT_SIZE="1.0844919786096257" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="85" LOG_CI_END="0.09579383011596486" LOG_CI_START="-0.02534114186636608" LOG_EFFECT_SIZE="0.03522634412479939" MODIFIED="2014-05-08 02:31:03 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="179" O_E="0.0" SE="0.0711552821702032" STUDY_ID="STD-Klauser-2012" TOTAL_1="44" TOTAL_2="104" VAR="0.005063074180721237" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.281770739163059" CI_END="1.286646198564152" CI_START="0.47678750242182655" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7832348482504717" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="26" I2="0.0" I2_Q="16.095381476925905" ID="CMP-002.06" LOG_CI_END="0.10945914120493049" LOG_CI_START="-0.3216751368675933" LOG_EFFECT_SIZE="-0.10610799783133142" METHOD="MH" MODIFIED="2014-09-08 05:52:39 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="6" P_CHI2="0.5268258102581517" P_Q="0.27496089425091663" P_Z="0.3346713194940161" Q="1.1918295054580292" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="113" TOTAL_2="112" WEIGHT="200.0" Z="0.9647474803016253">
<NAME>Birth less than 7 days after trial entry</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.049152882030137" CI_END="1.4635015037718655" CI_START="0.5249942197968871" DF="1" EFFECT_SIZE="0.8765442545269928" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.16539317301476306" LOG_CI_START="-0.27984547816382493" LOG_EFFECT_SIZE="-0.057226152574530946" MODIFIED="2014-05-08 03:33:12 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.824543933644095" P_Z="0.614384308521283" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="72" WEIGHT="100.00000000000001" Z="0.5038250732409401">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="2.336056482660195" CI_START="0.3900406653506101" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.3684833392156578" LOG_CI_START="-0.4088901113922317" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="38863" O_E="0.0" SE="0.4566330129477155" STUDY_ID="STD-Besinger-1991" TOTAL_1="22" TOTAL_2="18" VAR="0.2085137085137085" WEIGHT="29.598916906413947"/>
<DICH_DATA CI_END="1.5762703228260713" CI_START="0.45164465269105625" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.19763069896849528" LOG_CI_START="-0.3452031272903326" LOG_EFFECT_SIZE="-0.07378621416091867" ORDER="38864" O_E="0.0" SE="0.31886327661521197" STUDY_ID="STD-Morales-1989" TOTAL_1="52" TOTAL_2="54" VAR="0.10167378917378918" WEIGHT="70.40108309358607"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.193465872553432" CI_START="0.029973668801984914" DF="0" EFFECT_SIZE="0.2564102564102564" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.3411308817420919" LOG_CI_START="-1.5232600957950904" LOG_EFFECT_SIZE="-0.5910646070264992" MODIFIED="2014-09-04 04:21:23 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="1.0" P_Z="0.21396814298841205" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="1.242727900173133">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="2.193465872553433" CI_START="0.029973668801984904" EFFECT_SIZE="0.2564102564102564" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3411308817420921" LOG_CI_START="-1.5232600957950906" LOG_EFFECT_SIZE="-0.5910646070264992" MODIFIED="2013-12-06 00:09:42 +0000" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="1.0951524890895215" STUDY_ID="STD-Kashanian-2011" TOTAL_1="39" TOTAL_2="40" VAR="1.1993589743589745" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.061365216132587" CI_START="-4.661365216132588" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2014-09-08 05:52:43 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.9357327849941702" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="49" TOTAL_2="52" UNITS="" WEIGHT="100.00000000000001" Z="0.08063430322148386">
<NAME>Pregnancy prolongation (days)</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other tocolytic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COX inhibitor</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.061365216132587" CI_START="-4.661365216132588" DF="0" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" MODIFIED="2014-09-04 04:21:29 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.9357327849941702" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="52" WEIGHT="100.00000000000001" Z="0.08063430322148386">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<CONT_DATA CI_END="5.061365216132587" CI_START="-4.661365216132588" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="22.9" MEAN_2="22.7" ORDER="38865" SD_1="11.5" SD_2="13.4" SE="2.4803339522962746" STUDY_ID="STD-Morales-1993" TOTAL_1="49" TOTAL_2="52" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.602098994477869" CI_END="0.48563130042177616" CI_START="-0.4706237234310531" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="0.007503788495361541" ESTIMABLE="YES" I2="6.999442750709881" I2_Q="64.40923557723134" ID="CMP-002.08" MODIFIED="2014-09-08 05:52:49 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="8" P_CHI2="0.3769654132442608" P_Q="0.06022204385359309" P_Z="0.9754610191956916" Q="5.619435357562956" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="380" TOTAL_2="488" UNITS="" WEIGHT="300.0" Z="0.030759901556926313">
<NAME>Gestational age (weeks)</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other tocolytic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COX inhibitor</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.007183855916522348" CI_END="3.4979676306012566" CI_START="-0.4052479969053431" DF="1" EFFECT_SIZE="1.5463598168479569" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.01" MODIFIED="2014-08-19 08:44:09 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.9324540785322107" P_Z="0.12042771130305714" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="48" WEIGHT="100.0" Z="1.55298084318137">
<NAME>COX inhibitor versus betamimetics</NAME>
<CONT_DATA CI_END="5.753560789335688" CI_START="-2.353560789335682" EFFECT_SIZE="1.7000000000000028" ESTIMABLE="YES" MEAN_1="35.5" MEAN_2="33.8" MODIFIED="2014-08-19 08:44:09 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="38866" SD_1="5.7" SD_2="7.1" SE="2.0681812631811884" STUDY_ID="STD-Besinger-1991" TOTAL_1="22" TOTAL_2="18" WEIGHT="23.17990842397812"/>
<CONT_DATA CI_END="3.7266663089117222" CI_START="-0.7266663089117222" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="36.7" MEAN_2="35.2" ORDER="38867" SD_1="4.4" SD_2="4.4" SE="1.136075114887509" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" WEIGHT="76.82009157602188"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.560916184028165" CI_END="0.8016258080316359" CI_START="-0.387889443347383" DF="4" EFFECT_SIZE="0.2068681823421264" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.02" MODIFIED="2014-08-19 08:44:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8157990427320367" P_Z="0.4954202570143672" STUDIES="5" TAU2="0.0" TOTAL_1="244" TOTAL_2="294" WEIGHT="99.99999999999999" Z="0.6817133054288876">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<CONT_DATA CI_END="0.7731738527710642" CI_START="-1.17317385277107" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="35.5" MEAN_2="35.7" MODIFIED="2013-12-11 12:08:16 +0000" MODIFIED_BY="[Empty name]" ORDER="165" SD_1="2.1" SD_2="2.9" SE="0.4965263956110103" STUDY_ID="STD-Borna-2007" TOTAL_1="52" TOTAL_2="52" WEIGHT="37.35073690043631"/>
<CONT_DATA CI_END="2.104422360821376" CI_START="-0.9044223608213731" EFFECT_SIZE="0.6000000000000014" ESTIMABLE="YES" MEAN_1="31.8" MEAN_2="31.2" MODIFIED="2014-08-19 08:44:30 +0100" MODIFIED_BY="[Empty name]" ORDER="180" SD_1="4.2" SD_2="3.9" SE="0.7675765333894224" STUDY_ID="STD-Klauser-2012" TOTAL_1="43" TOTAL_2="85" WEIGHT="15.62933422151775"/>
<CONT_DATA CI_END="1.6709967598605524" CI_START="-0.4709967598605638" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" MEAN_1="35.3" MEAN_2="34.7" ORDER="38868" SD_1="3.4" SD_2="4.2" SE="0.5464369592035587" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" WEIGHT="30.83924407871275"/>
<CONT_DATA CI_END="2.9467835232921615" CI_START="-3.546783523292163" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="30.8" MEAN_2="31.1" ORDER="38869" SD_1="3.8" SD_2="4.3" SE="1.6565526453049015" STUDY_ID="STD-Parilla-1997" TOTAL_1="12" TOTAL_2="12" WEIGHT="3.3556246144286965"/>
<CONT_DATA CI_END="1.760773143225283" CI_START="-1.5607731432252803" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="34.9" MEAN_2="34.8" ORDER="38870" SD_1="3.6" SD_2="4.3" SE="0.8473488065725944" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" WEIGHT="12.825060184904478"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4145635969702257" CI_END="0.1366083169673712" CI_START="-1.6278353256615046" DF="1" EFFECT_SIZE="-0.7456135043470666" ESTIMABLE="YES" I2="29.306819280388396" ID="CMP-002.08.03" MODIFIED="2014-08-20 06:02:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.23430052006556223" P_Z="0.09762630060464453" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="146" WEIGHT="100.00000000000001" Z="1.6564718527701123">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<CONT_DATA CI_END="-0.043924205193318855" CI_START="-2.2160757948066863" EFFECT_SIZE="-1.1300000000000026" ESTIMABLE="YES" MEAN_1="34.07" MEAN_2="35.2" MODIFIED="2014-08-20 06:02:57 +0100" MODIFIED_BY="[Empty name]" ORDER="173" SD_1="2.77" SD_2="2.2" SE="0.5541304857505092" STUDY_ID="STD-Kashanian-2011" TOTAL_1="40" TOTAL_2="42" WEIGHT="65.98349595991726"/>
<CONT_DATA CI_END="1.5126308606144432" CI_START="-1.5126308606144432" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="31.8" MEAN_2="31.8" MODIFIED="2014-08-20 05:14:28 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="180" SD_1="4.2" SD_2="4.5" SE="0.7717646204450094" STUDY_ID="STD-Klauser-2012" TOTAL_1="44" TOTAL_2="104" WEIGHT="34.01650404008275"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.4757686930381295" CI_END="50.735479485519015" CI_START="-146.68415167579715" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-47.97433609513907" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2015-04-13 18:02:02 +0100" MODIFIED_BY="Heather Maxwell" NO="9" P_CHI2="0.4854187623836459" P_Q="0.38945757042148155" P_Z="0.34080819070872725" Q="1.8860010410753716" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="365" TOTAL_2="488" UNITS="" WEIGHT="300.0" Z="0.9525696140305326">
<NAME>Birthweight (g)</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other tocolytic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COX inhibitor</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0874602574981438" CI_END="575.6518318030719" CI_START="-176.8532403766016" DF="1" EFFECT_SIZE="199.39929571323512" ESTIMABLE="YES" I2="8.042616444609983" ID="CMP-002.09.01" MODIFIED="2014-05-08 03:33:36 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.29703507716990407" P_Z="0.29894191101524603" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="50" WEIGHT="100.0" Z="1.038705126620805">
<NAME>COX inhibitor versus betamimetics</NAME>
<CONT_DATA CI_END="576.3575175409858" CI_START="-774.3575175409858" EFFECT_SIZE="-99.0" ESTIMABLE="YES" MEAN_1="2090.0" MEAN_2="2189.0" ORDER="38871" SD_1="1202.0" SD_2="1104.0" SE="344.57649368463893" STUDY_ID="STD-Besinger-1991" TOTAL_1="25" TOTAL_2="20" WEIGHT="31.037833207017492"/>
<CONT_DATA CI_END="786.7790556477619" CI_START="-119.37905564776224" EFFECT_SIZE="333.6999999999998" ESTIMABLE="YES" MEAN_1="2892.0" MEAN_2="2558.3" ORDER="38872" SD_1="952.5" SD_2="834.2" SE="231.1670312422023" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" WEIGHT="68.9621667929825"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.5023073944646135" CI_END="40.29539544193284" CI_START="-190.1644804644062" DF="4" EFFECT_SIZE="-74.93454251123669" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.02" MODIFIED="2014-08-20 06:04:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.47752763316211355" P_Z="0.20246033153225362" STUDIES="5" TAU2="0.0" TOTAL_1="259" TOTAL_2="319" WEIGHT="100.0" Z="1.2745733194762148">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<CONT_DATA CI_END="184.19286494514216" CI_START="-310.19286494514216" EFFECT_SIZE="-63.0" ESTIMABLE="YES" MEAN_1="2448.0" MEAN_2="2511.0" MODIFIED="2013-12-06 00:00:49 +0000" MODIFIED_BY="[Empty name]" ORDER="166" SD_1="632.0" SD_2="654.0" SE="126.12112615077008" STUDY_ID="STD-Borna-2007" TOTAL_1="52" TOTAL_2="52" WEIGHT="21.729953356538473"/>
<CONT_DATA CI_END="249.8252457139202" CI_START="-295.8252457139202" EFFECT_SIZE="-23.0" ESTIMABLE="YES" MEAN_1="1746.0" MEAN_2="1769.0" MODIFIED="2014-08-19 08:49:17 +0100" MODIFIED_BY="[Empty name]" ORDER="181" SD_1="808.0" SD_2="805.0" SE="139.19911175201733" STUDY_ID="STD-Klauser-2012" TOTAL_1="52" TOTAL_2="95" WEIGHT="17.838631986919335"/>
<CONT_DATA CI_END="291.4636538789191" CI_START="-181.46365387891908" EFFECT_SIZE="55.0" ESTIMABLE="YES" MEAN_1="2585.0" MEAN_2="2530.0" ORDER="38873" SD_1="778.0" SD_2="902.0" SE="120.64693828259814" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" WEIGHT="23.746623350324207"/>
<CONT_DATA CI_END="-19.598677572921645" CI_START="-424.40132242707836" EFFECT_SIZE="-222.0" ESTIMABLE="YES" MEAN_1="1808.0" MEAN_2="2030.0" ORDER="38874" SD_1="390.0" SD_2="627.0" SE="103.26787840164113" STUDY_ID="STD-Morales-1993" TOTAL_1="49" TOTAL_2="52" WEIGHT="32.41186076724476"/>
<CONT_DATA CI_END="598.4454969258568" CI_START="-516.4454969258568" EFFECT_SIZE="41.0" ESTIMABLE="YES" MEAN_1="1622.0" MEAN_2="1581.0" MODIFIED="2014-08-20 06:04:07 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="38875" SD_1="589.0" SD_2="1005.0" SE="284.4161940336229" STUDY_ID="STD-Parilla-1997" TOTAL_1="14" TOTAL_2="18" WEIGHT="4.2729305389732275"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="188.19786717348344" CI_START="-256.1978671734835" DF="0" EFFECT_SIZE="-34.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.03" MODIFIED="2014-09-01 00:07:16 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="1.0" P_Z="0.764247821467327" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0" Z="0.2999073587971611">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<CONT_DATA CI_END="188.19786717348344" CI_START="-256.1978671734835" EFFECT_SIZE="-34.0" ESTIMABLE="YES" MEAN_1="1746.0" MEAN_2="1780.0" MODIFIED="2014-08-19 08:48:46 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="196" SD_1="808.0" SD_2="78.0" SE="113.36834193186806" STUDY_ID="STD-Klauser-2012" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.193465872553432" CI_START="0.029973668801984914" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2564102564102564" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.3411308817420919" LOG_CI_START="-1.5232600957950904" LOG_EFFECT_SIZE="-0.5910646070264992" METHOD="MH" MODIFIED="2014-09-08 05:57:13 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.21396814298841205" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="1.242727900173133">
<NAME>Antenatal corticosteroids - any</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.193465872553432" CI_START="0.029973668801984914" DF="0" EFFECT_SIZE="0.2564102564102564" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.3411308817420919" LOG_CI_START="-1.5232600957950904" LOG_EFFECT_SIZE="-0.5910646070264992" MODIFIED="2014-09-04 04:20:26 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.21396814298841205" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="1.242727900173133">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="2.193465872553433" CI_START="0.029973668801984904" EFFECT_SIZE="0.2564102564102564" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3411308817420921" LOG_CI_START="-1.5232600957950906" LOG_EFFECT_SIZE="-0.5910646070264992" MODIFIED="2013-12-09 19:37:38 +0000" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="1.0951524890895215" STUDY_ID="STD-Kashanian-2011" TOTAL_1="39" TOTAL_2="40" VAR="1.1993589743589745" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8389341670383095" CI_END="1.4772206728929869" CI_START="0.8836862519875819" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1425408525682472" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.1694453767345104" LOG_CI_START="-0.053701901521603465" LOG_EFFECT_SIZE="0.05787173760645346" METHOD="MH" MODIFIED="2014-09-08 05:53:15 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="11" P_CHI2="0.8709523721844963" P_Q="0.4184805543647543" P_Z="0.3093405269645628" Q="1.742251453146716" RANDOM="NO" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="350" TOTAL_2="470" WEIGHT="300.0" Z="1.0166068106931374">
<NAME>Respiratory distress syndrome</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.3444766693104" CI_START="0.26963943805788637" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="0.9213991047351494" LOG_CI_START="-0.569216586623787" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2014-05-08 03:33:52 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.6433114807050054" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.46307378587542436">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38834" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.3444766693104" CI_START="0.26963943805788637" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9213991047351494" LOG_CI_START="-0.569216586623787" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="38835" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03385655233669106" CI_END="1.3971243212087119" CI_START="0.7309281145966426" DF="3" EFFECT_SIZE="1.0105431440360169" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="64" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="0.14523505293784178" LOG_CI_START="-0.1361253329862482" LOG_EFFECT_SIZE="0.00455485997579678" MODIFIED="2014-08-20 06:03:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.998359878562432" P_Z="0.9494013624559539" STUDIES="5" TAU2="0.0" TOTAL_1="259" TOTAL_2="311" WEIGHT="99.99999999999999" Z="0.06345855318518963">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38839" O_E="0.0" SE="0.0" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4805163385092064" CI_START="0.6536370996232479" EFFECT_SIZE="0.9837278106508875" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="39" LOG_CI_END="0.1704132044880587" LOG_CI_START="-0.18466330576512144" LOG_EFFECT_SIZE="-0.007125050638531344" MODIFIED="2014-05-08 02:50:42 +0100" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="0.20857369977979087" STUDY_ID="STD-Klauser-2012" TOTAL_1="52" TOTAL_2="95" VAR="0.043502988239830336" WEIGHT="53.50394883208795"/>
<DICH_DATA CI_END="14.207980025005401" CI_START="0.07038298183415555" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.152532337860481" LOG_CI_START="-1.152532337860481" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 05:40:03 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="38838" O_E="0.0" SE="1.3540064007726602" STUDY_ID="STD-Parilla-1997" TOTAL_1="12" TOTAL_2="12" VAR="1.8333333333333335" WEIGHT="1.9391224058966787"/>
<DICH_DATA CI_END="3.328505728276704" CI_START="0.3108842550548826" EFFECT_SIZE="1.0172413793103448" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5222493086984821" LOG_CI_START="-0.5074012725400683" LOG_EFFECT_SIZE="0.007424018079206875" MODIFIED="2014-08-20 06:03:57 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="38837" O_E="0.0" SE="0.6048218482721026" STUDY_ID="STD-Morales-1993" TOTAL_1="58" TOTAL_2="59" VAR="0.3658094681472823" WEIGHT="9.612743550598921"/>
<DICH_DATA CI_END="1.8755977198624214" CI_START="0.5881969944491723" EFFECT_SIZE="1.0503432494279177" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.27313969610148314" LOG_CI_START="-0.23047719896780433" LOG_EFFECT_SIZE="0.021331248566839423" ORDER="38836" O_E="0.0" SE="0.29582705710753576" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" VAR="0.08751364771690523" WEIGHT="34.94418521141644"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.224212884938349" CI_START="0.9338088244348667" DF="0" EFFECT_SIZE="1.4411764705882353" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="34" I2="0.0" ID="CMP-002.11.03" LOG_CI_END="0.3471763523027029" LOG_CI_START="-0.02974202633018573" LOG_EFFECT_SIZE="0.15871716298625854" MODIFIED="2014-05-08 03:47:19 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="1.0" P_Z="0.09881032059187511" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0" Z="1.6506487389113307">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="2.224212884938349" CI_START="0.9338088244348667" EFFECT_SIZE="1.4411764705882353" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="34" LOG_CI_END="0.3471763523027029" LOG_CI_START="-0.02974202633018573" LOG_EFFECT_SIZE="0.15871716298625854" MODIFIED="2014-05-08 02:51:00 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="181" O_E="0.0" SE="0.22140372138502384" STUDY_ID="STD-Klauser-2012" TOTAL_1="51" TOTAL_2="119" VAR="0.04901960784313726" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3372324350136557" CI_END="1.3045065286782245" CI_START="0.21267151909045745" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5267175572519084" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="25.21868496333713" I2_Q="24.900781080560563" ID="CMP-002.12" LOG_CI_END="0.11544625696006625" LOG_CI_START="-0.6722906667970842" LOG_EFFECT_SIZE="-0.27842220491850894" METHOD="MH" MODIFIED="2014-09-08 05:53:20 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="12" P_CHI2="0.24752277497579933" P_Q="0.24852593620407726" P_Z="0.16590526474759873" Q="1.3315717718352327" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="122" TOTAL_2="132" WEIGHT="200.0" Z="1.3854815679675825">
<NAME>Apgar score less than 7 at 5 minutes</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-05-08 03:34:05 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.6810488185180525">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="38876" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1500761368559596" CI_START="0.1581071100808152" DF="0" EFFECT_SIZE="0.42642140468227424" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="0.06072659228568465" LOG_CI_START="-0.801048599394596" LOG_EFFECT_SIZE="-0.3701610035544557" MODIFIED="2014-05-08 03:44:16 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="1.0" P_Z="0.0922321270657463" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="102" WEIGHT="100.0" Z="1.6837389668490204">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="1.1500761368559596" CI_START="0.1581071100808152" EFFECT_SIZE="0.42642140468227424" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.06072659228568465" LOG_CI_START="-0.801048599394596" LOG_EFFECT_SIZE="-0.3701610035544557" ORDER="38877" O_E="0.0" SE="0.5062110134489946" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" VAR="0.25624959013705817" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4301424648763568" CI_START="0.48346819958687154" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8315217391304348" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.15537930223979088" LOG_CI_START="-0.31563208662366615" LOG_EFFECT_SIZE="-0.08012639219193765" METHOD="MH" MODIFIED="2014-09-08 05:53:30 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.5048737317679081" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="92" TOTAL_2="102" WEIGHT="100.0" Z="0.6668409580765166">
<NAME>Admission to neonatal intensive care unit</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4301424648763568" CI_START="0.48346819958687154" DF="0" EFFECT_SIZE="0.8315217391304348" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="0.15537930223979088" LOG_CI_START="-0.31563208662366615" LOG_EFFECT_SIZE="-0.08012639219193765" MODIFIED="2014-09-04 04:20:54 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.5048737317679081" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="102" WEIGHT="100.0" Z="0.6668409580765166">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="1.4301424648763568" CI_START="0.48346819958687154" EFFECT_SIZE="0.8315217391304348" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.15537930223979088" LOG_CI_START="-0.31563208662366615" LOG_EFFECT_SIZE="-0.08012639219193765" ORDER="38878" O_E="0.0" SE="0.2766744213623722" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" VAR="0.07654873543620347" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6496755747208722" CI_END="1.7263267824396946" CI_START="-7.2645070193806065" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.769090118470456" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.14" MODIFIED="2014-09-08 05:53:35 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="14" P_CHI2="0.7226446232442847" P_Q="0.8760285158658567" P_Z="0.22731664620729142" Q="0.02433779004957855" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="195" TOTAL_2="316" UNITS="" WEIGHT="200.0" Z="1.2073000172796033">
<NAME>Duration of neonatal intensive care unit stay</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6253377846712936" CI_END="2.2795267881463195" CI_START="-7.5095294893075275" DF="1" EFFECT_SIZE="-2.615001350580604" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.01" MODIFIED="2014-08-20 05:18:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4290708332722034" P_Z="0.2950301035148768" STUDIES="2" TAU2="0.0" TOTAL_1="144" TOTAL_2="197" WEIGHT="100.0" Z="1.0471506795739225">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<CONT_DATA CI_END="5.4299711234288655" CI_START="-20.229971123428868" EFFECT_SIZE="-7.400000000000002" ESTIMABLE="YES" MEAN_1="31.2" MEAN_2="38.6" MODIFIED="2014-08-20 05:15:46 +0100" MODIFIED_BY="[Empty name]" ORDER="191" SD_1="32.4" SD_2="46.4" SE="6.546023919128128" STUDY_ID="STD-Klauser-2012" TOTAL_1="52" TOTAL_2="95" WEIGHT="14.553595546082207"/>
<CONT_DATA CI_END="3.4949752366370683" CI_START="-7.094975236637068" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="8.5" ORDER="38879" SD_1="17.1" SD_2="20.5" SE="2.701567619815036" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" WEIGHT="85.4464044539178"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.765859947299555" CI_START="-14.96585994729955" DF="0" EFFECT_SIZE="-3.599999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.02" MODIFIED="2014-08-20 05:18:15 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="1.0" P_Z="0.5347344406297012" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0" Z="0.6207951159930152">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<CONT_DATA CI_END="7.765859947299555" CI_START="-14.96585994729955" EFFECT_SIZE="-3.599999999999998" ESTIMABLE="YES" MEAN_1="31.2" MEAN_2="34.8" MODIFIED="2014-08-20 05:16:46 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="197" SD_1="32.4" SD_2="39.4" SE="5.799014694633169" STUDY_ID="STD-Klauser-2012" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.78265312007099" CI_START="0.4704501755641861" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.6796688831713416" LOG_CI_START="-0.3274863650599791" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2014-09-08 05:53:42 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.4931160751078578" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.6853611225231462">
<NAME>Use of mechanical ventilation</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.78265312007099" CI_START="0.4704501755641861" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="0.6796688831713416" LOG_CI_START="-0.3274863650599791" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2014-05-08 03:34:24 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.4931160751078578" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.6853611225231462">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="4.78265312007099" CI_START="0.4704501755641861" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6796688831713416" LOG_CI_START="-0.3274863650599791" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="38880" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.35" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.0475660854267614" CI_END="3.746862196762335" CI_START="-3.6726467966407115" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.03710770006081157" ESTIMABLE="YES" I2="51.161527478045905" I2_Q="51.161527478045905" ID="CMP-002.16" MODIFIED="2014-09-08 05:56:48 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="16" P_CHI2="0.15245017384524662" P_Q="0.15245017384524662" P_Z="0.9843584711418762" Q="2.0475660854267614" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="214" UNITS="" WEIGHT="200.0" Z="0.019605005057065666">
<NAME>Duration of mechanical ventilation (days)</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8956925361788396E-32" CI_END="2.6217069838795957" CI_START="-10.021706983879593" DF="0" EFFECT_SIZE="-3.699999999999999" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-002.16.01" MODIFIED="2014-08-20 06:02:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.251324843153489" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="95" WEIGHT="100.0" Z="1.1471374363428293">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<CONT_DATA CI_END="2.621706983879595" CI_START="-10.021706983879593" EFFECT_SIZE="-3.6999999999999993" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="9.6" MODIFIED="2014-08-20 06:02:25 +0100" MODIFIED_BY="[Empty name]" ORDER="192" SD_1="13.5" SD_2="25.6" SE="3.2254199739099354" STUDY_ID="STD-Klauser-2012" TOTAL_1="52" TOTAL_2="95" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.581574899086094" CI_START="-2.581574899086094" DF="0" EFFECT_SIZE="2.0000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-002.16.02" MODIFIED="2014-08-20 06:02:36 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="1.0" P_Z="0.39222723251897973" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0" Z="0.8555852638929975">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<CONT_DATA CI_END="6.581574899086094" CI_START="-2.581574899086094" EFFECT_SIZE="2.0000000000000004" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="3.9" MODIFIED="2014-08-20 06:02:36 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="198" SD_1="13.5" SD_2="15.0" SE="2.3375811674219387" STUDY_ID="STD-Klauser-2012" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.6653976562443972" CI_END="14.380126385303129" CI_START="0.564662918330479" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8495480572691494" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="1.1577627030286815" LOG_CI_START="-0.248210731641962" LOG_EFFECT_SIZE="0.45477598569335964" METHOD="MH" MODIFIED="2014-09-08 05:53:54 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="17" P_CHI2="0.7169861646486289" P_Q="0.5215601190981463" P_Z="0.20481961944593807" Q="0.41080716599179995" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="239" TOTAL_2="249" WEIGHT="200.0" Z="1.2679393948883395">
<NAME>Persistent pulmonary hypertension of the newborn</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="103.46055304405698" CI_START="0.3089677697522916" DF="0" EFFECT_SIZE="5.653846153846154" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.17.01" LOG_CI_END="2.0147747955822486" LOG_CI_START="-0.5100868220275321" LOG_EFFECT_SIZE="0.7523439867773581" MODIFIED="2014-05-08 03:34:44 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.24279146999265877" STUDIES="3" TAU2="0.0" TOTAL_1="89" TOTAL_2="88" WEIGHT="100.0" Z="1.1680379691183507">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="103.46055304405698" CI_START="0.3089677697522916" EFFECT_SIZE="5.653846153846154" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0147747955822486" LOG_CI_START="-0.5100868220275321" LOG_EFFECT_SIZE="0.7523439867773581" ORDER="38881" O_E="0.0" SE="1.4831162124505617" STUDY_ID="STD-Besinger-1991" TOTAL_1="25" TOTAL_2="20" VAR="2.1996336996337" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38882" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38883" O_E="0.0" SE="0.0" STUDY_ID="STD-Morales-1989" TOTAL_1="54" TOTAL_2="58" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2233227187748999" CI_END="13.435583340780614" CI_START="0.23460912592522967" DF="1" EFFECT_SIZE="1.775418391218283" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.17.02" LOG_CI_END="1.1282565272025529" LOG_CI_START="-0.6296550985210664" LOG_EFFECT_SIZE="0.2493007143407432" MODIFIED="2014-05-12 13:36:49 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="0.6365197712591473" P_Z="0.5782723099823756" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="161" WEIGHT="100.0" Z="0.5559101086516011">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="17.472512640157113" CI_START="0.07035084618134721" EFFECT_SIZE="1.108695652173913" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2423553633280626" LOG_CI_START="-1.1527306744953383" LOG_EFFECT_SIZE="0.04481234441636231" ORDER="38885" O_E="0.0" SE="1.4068853944845618" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" VAR="1.9793265132139812" WEIGHT="65.67092555935457"/>
<DICH_DATA CI_END="73.39016164239492" CI_START="0.12682449529220188" EFFECT_SIZE="3.0508474576271185" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8656378442376154" LOG_CI_START="-0.8967968573152918" LOG_EFFECT_SIZE="0.48442049346116184" ORDER="38886" O_E="0.0" SE="1.6226678179644862" STUDY_ID="STD-Morales-1993" TOTAL_1="58" TOTAL_2="59" VAR="2.633050847457627" WEIGHT="34.329074440645435"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.4383437598296585" CI_END="1.9333940730190766" CI_START="0.8222235906838457" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2608260058091325" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" I2="0.0" I2_Q="31.232973437170347" ID="CMP-002.18" LOG_CI_END="0.28632038289292244" LOG_CI_START="-0.08501006689300616" LOG_EFFECT_SIZE="0.10065515799995817" METHOD="MH" MODIFIED="2014-09-08 05:53:59 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="18" P_CHI2="0.7281284834165856" P_Q="0.23359063882301778" P_Z="0.2879814451255587" Q="2.9083706246520356" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="375" TOTAL_2="490" WEIGHT="300.0" Z="1.0625602325467174">
<NAME>Intraventricular haemorrhage - all grades</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.003339152235274467" CI_END="43.10473833679086" CI_START="0.6623933164726716" DF="1" EFFECT_SIZE="5.3434343434343425" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-002.18.01" LOG_CI_END="1.6345250130937408" LOG_CI_START="-0.17888405821846912" LOG_EFFECT_SIZE="0.7278204774376358" MODIFIED="2014-05-08 03:34:50 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.9539196035903675" P_Z="0.11565353593617349" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="60" WEIGHT="99.99999999999999" Z="1.573281997488052">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="103.46055304405698" CI_START="0.3089677697522916" EFFECT_SIZE="5.653846153846154" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0147747955822486" LOG_CI_START="-0.5100868220275321" LOG_EFFECT_SIZE="0.7523439867773581" ORDER="38844" O_E="0.0" SE="1.4831162124505617" STUDY_ID="STD-Besinger-1991" TOTAL_1="25" TOTAL_2="20" VAR="2.1996336996337" WEIGHT="52.52525252525252"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38845" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="38846" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="47.47474747474747"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2002686029213" CI_END="1.6623289067174318" CI_START="0.5996025565280952" DF="4" EFFECT_SIZE="0.9983669977810393" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" I2="0.0" ID="CMP-002.18.02" LOG_CI_END="0.22071695701739769" LOG_CI_START="-0.2221365241164906" LOG_EFFECT_SIZE="-7.097835495464321E-4" MODIFIED="2014-05-08 03:44:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8780544082873571" P_Z="0.9949871909929957" STUDIES="5" TAU2="0.0" TOTAL_1="259" TOTAL_2="311" WEIGHT="100.00000000000001" Z="0.006282665726678211">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="2.817675549867239" CI_START="0.4796895412498357" EFFECT_SIZE="1.1625874125874125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.44989098344523815" LOG_CI_START="-0.3190397504250775" LOG_EFFECT_SIZE="0.06542561651008036" MODIFIED="2014-05-08 02:52:59 +0100" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.4516737193439428" STUDY_ID="STD-Klauser-2012" TOTAL_1="52" TOTAL_2="95" VAR="0.20400914874599083" WEIGHT="31.256263076219806"/>
<DICH_DATA CI_END="2.724846851715956" CI_START="0.33142785914371" EFFECT_SIZE="0.9503105590062112" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.435342098053485" LOG_CI_START="-0.47961098848198686" LOG_EFFECT_SIZE="-0.022134445214250897" ORDER="38847" O_E="0.0" SE="0.5374479721217588" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" VAR="0.28885032273779077" WEIGHT="26.665055807976866"/>
<DICH_DATA CI_END="3.8758867434459616" CI_START="0.26697891147903186" EFFECT_SIZE="1.0172413793103448" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5883710781271568" LOG_CI_START="-0.5735230419687432" LOG_EFFECT_SIZE="0.007424018079206875" ORDER="38848" O_E="0.0" SE="0.6825023576129846" STUDY_ID="STD-Morales-1993" TOTAL_1="58" TOTAL_2="59" VAR="0.4658094681472823" WEIGHT="15.927971967476546"/>
<DICH_DATA CI_END="1.7762721743685985" CI_START="0.2502119049421176" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2495095125517467" LOG_CI_START="-0.6016920306631093" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="38849" O_E="0.0" SE="0.5" STUDY_ID="STD-Parilla-1997" TOTAL_1="12" TOTAL_2="12" VAR="0.25" WEIGHT="24.09792310596667"/>
<DICH_DATA CI_END="68.57796147055588" CI_START="0.12007362657458794" EFFECT_SIZE="2.869565217391304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8361845712535962" LOG_CI_START="-0.9205523722050446" LOG_EFFECT_SIZE="0.45781609952427577" ORDER="38850" O_E="0.0" SE="1.6193209266555566" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="2.622200263504611" WEIGHT="2.0527860423601236"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.737111782185081E-32" CI_END="4.0515323365749465" CI_START="0.6584614304307993" DF="0" EFFECT_SIZE="1.6333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="100.0" ID="CMP-002.18.03" LOG_CI_END="0.6076193095000788" LOG_CI_START="-0.18146965888237637" LOG_EFFECT_SIZE="0.21307482530885127" MODIFIED="2014-05-08 03:47:33 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="0.0" P_Z="0.2898349034794435" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0" Z="1.0584838981429043">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="4.0515323365749465" CI_START="0.6584614304307992" EFFECT_SIZE="1.6333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.6076193095000788" LOG_CI_START="-0.18146965888237646" LOG_EFFECT_SIZE="0.21307482530885122" MODIFIED="2014-05-08 02:53:13 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="182" O_E="0.0" SE="0.46351476608124376" STUDY_ID="STD-Klauser-2012" TOTAL_1="51" TOTAL_2="119" VAR="0.21484593837535013" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2787099899362592" CI_END="4.401908535278418" CI_START="0.08328586236420998" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6054888507718696" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.6436410143562306" LOG_CI_START="-1.0794287130986135" LOG_EFFECT_SIZE="-0.21789384937119152" METHOD="MH" MODIFIED="2014-09-08 05:54:04 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="19" P_CHI2="0.5975480447047852" P_Q="1.0" P_Z="0.6201050525940259" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="125" TOTAL_2="124" WEIGHT="100.0" Z="0.49570146862384923">
<NAME>Intraventricular haemorrhage Grades III or IV</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.19.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-08 03:34:56 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38840" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2787099899362592" CI_END="4.401908535278418" CI_START="0.08328586236420998" DF="1" EFFECT_SIZE="0.6054888507718696" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.19.02" LOG_CI_END="0.6436410143562306" LOG_CI_START="-1.0794287130986135" LOG_EFFECT_SIZE="-0.21789384937119152" MODIFIED="2014-08-20 06:03:55 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="0.5975480447047852" P_Z="0.6201050525940259" STUDIES="3" TAU2="0.0" TOTAL_1="115" TOTAL_2="114" WEIGHT="100.0" Z="0.49570146862384923">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="15.880747965636855" CI_START="0.06515940093125934" EFFECT_SIZE="1.0172413793103448" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008709533617878" LOG_CI_START="-1.1860229172033738" LOG_EFFECT_SIZE="0.007424018079206875" MODIFIED="2014-08-20 06:03:55 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="38841" O_E="0.0" SE="1.4020732748851903" STUDY_ID="STD-Morales-1993" TOTAL_1="58" TOTAL_2="59" VAR="1.9658094681472824" WEIGHT="39.79416809605489"/>
<DICH_DATA CI_END="7.450631558527997" CI_START="0.014912978884848133" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="38842" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Parilla-1997" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="60.20583190394511"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38843" O_E="0.0" SE="0.0" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.011121276150708395" CI_END="57.89798943448268" CI_START="0.6465062145715774" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="6.118121442125238" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="1.7626634826795868" LOG_CI_START="-0.1894272960872662" LOG_EFFECT_SIZE="0.7866180932961604" METHOD="MH" MODIFIED="2014-09-08 05:56:26 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="20" P_CHI2="0.9160128237484302" P_Q="0.9160302226982842" P_Z="0.11420276398500787" Q="0.011116651705682642" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="214" WEIGHT="200.0" Z="1.5795813895724362">
<NAME>Other major cerebral abnormality</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="131.05980472454146" CI_START="0.22530131149117474" DF="0" EFFECT_SIZE="5.433962264150943" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.20.01" LOG_CI_END="2.117469516533921" LOG_CI_START="-0.6472362802170369" LOG_EFFECT_SIZE="0.7351166181584418" MODIFIED="2014-09-04 04:21:14 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.29728078491210486" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="95" WEIGHT="99.99999999999999" Z="1.0422823996105766">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="131.05980472454146" CI_START="0.22530131149117474" EFFECT_SIZE="5.433962264150943" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.117469516533921" LOG_CI_START="-0.6472362802170369" LOG_EFFECT_SIZE="0.7351166181584418" MODIFIED="2014-05-08 02:53:36 +0100" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="1.6240018705259234" STUDY_ID="STD-Klauser-2012" TOTAL_1="52" TOTAL_2="95" VAR="2.637382075471698" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8682035039846648E-32" CI_END="167.14864833381634" CI_START="0.28674473027816644" DF="0" EFFECT_SIZE="6.923076923076924" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="100.0" ID="CMP-002.20.02" LOG_CI_END="2.2231028689720307" LOG_CI_START="-0.5425045547070543" LOG_EFFECT_SIZE="0.8402991571324882" MODIFIED="2014-09-04 04:21:14 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="0.0" P_Z="0.2336431410456643" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0" Z="1.1910266584605103">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="167.14864833381634" CI_START="0.2867447302781664" EFFECT_SIZE="6.923076923076923" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.2231028689720307" LOG_CI_START="-0.5425045547070544" LOG_EFFECT_SIZE="0.8402991571324882" MODIFIED="2014-05-08 02:53:55 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="183" O_E="0.0" SE="1.6245314906466308" STUDY_ID="STD-Klauser-2012" TOTAL_1="51" TOTAL_2="119" VAR="2.639102564102564" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 05:54:13 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Retinopathy of prematurity Grades III or IV</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.21.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-08 03:35:20 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38851" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8964869836000582" CI_END="4.035863873488631" CI_START="0.69490958727717" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.674682208251113" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.6059365094009146" LOG_CI_START="-0.1580716965622398" LOG_EFFECT_SIZE="0.22393240641933734" METHOD="MH" MODIFIED="2014-09-08 05:54:18 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="22" P_CHI2="0.7547903822496583" P_Q="0.9173053683746594" P_Z="0.25058111151102647" Q="0.17262978925027106" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="247" TOTAL_2="368" WEIGHT="300.0" Z="1.1489391033437513">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.82882080128432" CI_START="0.12706691849706483" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.22.01" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-05-08 03:35:25 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6810488185180525">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38852" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="38853" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6757576384245705" CI_END="4.8423102374029625" CI_START="0.45709570696915974" DF="2" EFFECT_SIZE="1.4877497173011685" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-002.22.02" LOG_CI_END="0.6850526104002224" LOG_CI_START="-0.33999285757385" LOG_EFFECT_SIZE="0.17252987641318615" MODIFIED="2014-05-08 03:45:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4326274960513673" P_Z="0.5093949053650982" STUDIES="3" TAU2="0.0" TOTAL_1="156" TOTAL_2="209" WEIGHT="100.0" Z="0.659780184571373">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="3.636177183018221" CI_START="0.14686403928088704" EFFECT_SIZE="0.7307692307692307" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.5606450372925801" LOG_CI_START="-0.8330845313285581" LOG_EFFECT_SIZE="-0.13621974701798903" MODIFIED="2014-05-08 02:54:42 +0100" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.818683647680688" STUDY_ID="STD-Klauser-2012" TOTAL_1="52" TOTAL_2="95" VAR="0.670242914979757" WEIGHT="78.40180927252167"/>
<DICH_DATA CI_END="113.8588416776912" CI_START="0.2693281820848077" EFFECT_SIZE="5.537634408602151" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0563667612817307" LOG_CI_START="-0.5697182003072189" LOG_EFFECT_SIZE="0.743324280487256" ORDER="38854" O_E="0.0" SE="1.5425753057675593" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" VAR="2.3795385739638792" WEIGHT="10.516396532227668"/>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="38855" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Parilla-1997" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="11.08179419525066"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2196039026158675E-32" CI_END="7.539680076898857" CI_START="0.4061843432035429" DF="0" EFFECT_SIZE="1.7500000000000002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="100.0" ID="CMP-002.22.03" LOG_CI_END="0.8773529183120576" LOG_CI_START="-0.3912768209394688" LOG_EFFECT_SIZE="0.2430380486862945" MODIFIED="2014-05-08 03:47:46 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="0.0" P_Z="0.45267604455482957" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.00000000000001" Z="0.7509611473857876">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="7.539680076898857" CI_START="0.406184343203543" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.8773529183120576" LOG_CI_START="-0.3912768209394687" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2014-05-08 02:54:59 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="184" O_E="0.0" SE="0.7451993886548355" STUDY_ID="STD-Klauser-2012" TOTAL_1="51" TOTAL_2="119" VAR="0.5553221288515405" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.39695247695482094" CI_END="2.492057833281363" CI_START="0.6974005176870399" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3183180280328664" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.23" LOG_CI_END="0.3965581167927188" LOG_CI_START="-0.15651773457899645" LOG_EFFECT_SIZE="0.12002019110686113" METHOD="MH" MODIFIED="2014-09-08 05:54:23 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="23" P_CHI2="0.8199793261064974" P_Q="0.8202273395484931" P_Z="0.39496729953376786" Q="0.39634764073561335" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="143" TOTAL_2="254" WEIGHT="300.0" Z="0.8506437278128918">
<NAME>Neonatal sepsis</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.259760455310136" CI_START="0.0655318281652329" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.23.01" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-05-08 03:35:30 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.0">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38892" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" ORDER="38893" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.845639559837552" CI_START="0.4222436570661333" DF="0" EFFECT_SIZE="1.0961538461538463" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-002.23.02" LOG_CI_END="0.4541798897443993" LOG_CI_START="-0.37443686566901485" LOG_EFFECT_SIZE="0.03987151203769228" MODIFIED="2014-05-08 03:45:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8503908809211336" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="95" WEIGHT="100.0" Z="0.18861971373978087">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="2.845639559837552" CI_START="0.42224365706613337" EFFECT_SIZE="1.0961538461538463" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.4541798897443993" LOG_CI_START="-0.3744368656690148" LOG_EFFECT_SIZE="0.03987151203769228" MODIFIED="2014-05-08 02:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.4867335838489304" STUDY_ID="STD-Klauser-2012" TOTAL_1="52" TOTAL_2="95" VAR="0.23690958164642376" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.737111782185081E-32" CI_END="4.0515323365749465" CI_START="0.6584614304307993" DF="0" EFFECT_SIZE="1.6333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="100.0" ID="CMP-002.23.03" LOG_CI_END="0.6076193095000788" LOG_CI_START="-0.18146965888237637" LOG_EFFECT_SIZE="0.21307482530885127" MODIFIED="2014-05-08 03:47:52 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="0.0" P_Z="0.2898349034794435" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0" Z="1.0584838981429043">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="4.0515323365749465" CI_START="0.6584614304307992" EFFECT_SIZE="1.6333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.6076193095000788" LOG_CI_START="-0.18146965888237646" LOG_EFFECT_SIZE="0.21307482530885122" MODIFIED="2014-05-08 02:55:41 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="185" O_E="0.0" SE="0.46351476608124376" STUDY_ID="STD-Klauser-2012" TOTAL_1="51" TOTAL_2="119" VAR="0.21484593837535013" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5177157234534134" CI_END="8.647345447123943" CI_START="0.9374356149682409" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8471616738547616" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="0.9368828086671962" LOG_CI_START="-0.02805855082609375" LOG_EFFECT_SIZE="0.4544121289205511" METHOD="MH" MODIFIED="2014-09-08 05:54:28 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="24" P_CHI2="0.7719327487581971" P_Q="0.6499720085559402" P_Z="0.06489505486780298" Q="0.20593543216799662" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="162" TOTAL_2="165" WEIGHT="200.0" Z="1.8459803760306028">
<NAME>Oligohydramnios</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2849782553957686" CI_END="8.3284694266329" CI_START="0.7512606303848486" DF="1" EFFECT_SIZE="2.5013698630136987" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-002.24.01" LOG_CI_END="0.9205651958073263" LOG_CI_START="-0.12420936965167771" LOG_EFFECT_SIZE="0.39817791307782424" MODIFIED="2014-05-08 03:35:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5934567702331912" P_Z="0.13519174670426704" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="70" WEIGHT="100.0" Z="1.4939382999412778">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="7.873068262524477" CI_START="0.5478943308529723" EFFECT_SIZE="2.076923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.896144016958237" LOG_CI_START="-0.2613031932539358" LOG_EFFECT_SIZE="0.3174204118521506" ORDER="38906" O_E="0.0" SE="0.6798902207347244" STUDY_ID="STD-Morales-1989" TOTAL_1="52" TOTAL_2="54" VAR="0.46225071225071224" WEIGHT="85.47945205479452"/>
<DICH_DATA CI_END="96.58711188336108" CI_START="0.2588337047513139" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9849191801281645" LOG_CI_START="-0.5869791714561268" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-12-09 19:25:58 +0000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="1.5107458228227775" STUDY_ID="STD-Purwaka-2004" TOTAL_1="16" TOTAL_2="16" VAR="2.282352941176471" WEIGHT="14.52054794520548"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="107.70356726654825" CI_START="0.2608084459308758" DF="0" EFFECT_SIZE="5.3" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.24.02" LOG_CI_END="2.0322300878710617" LOG_CI_START="-0.5836783486694836" LOG_EFFECT_SIZE="0.724275869600789" MODIFIED="2014-05-08 03:45:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2777780221151015" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="95" WEIGHT="100.0" Z="1.085324393973277">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="107.70356726654825" CI_START="0.2608084459308758" EFFECT_SIZE="5.3" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0322300878710617" LOG_CI_START="-0.5836783486694836" LOG_EFFECT_SIZE="0.724275869600789" ORDER="38907" O_E="0.0" SE="1.5365975645795154" STUDY_ID="STD-Morales-1993" TOTAL_1="49" TOTAL_2="52" VAR="2.361132075471698" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38908" O_E="0.0" SE="0.0" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="73.39016164239492" CI_START="0.12682449529220188" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0508474576271185" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.25" LOG_CI_END="1.8656378442376154" LOG_CI_START="-0.8967968573152918" LOG_EFFECT_SIZE="0.48442049346116184" METHOD="MH" MODIFIED="2014-09-08 05:54:32 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.49183165393336326" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="180" TOTAL_2="179" WEIGHT="100.0" Z="0.6873984894725403">
<NAME>Premature closure of the ductus arteriosus</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytiic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.25.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-08 03:35:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38909" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38910" O_E="0.0" SE="0.0" STUDY_ID="STD-Morales-1989" TOTAL_1="54" TOTAL_2="58" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-12-09 19:43:27 +0000" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.0" STUDY_ID="STD-Nevils-1994" TOTAL_1="13" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.39016164239492" CI_START="0.12682449529220188" DF="0" EFFECT_SIZE="3.0508474576271185" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.25.02" LOG_CI_END="1.8656378442376154" LOG_CI_START="-0.8967968573152918" LOG_EFFECT_SIZE="0.48442049346116184" MODIFIED="2014-05-08 03:45:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49183165393336326" STUDIES="2" TAU2="0.0" TOTAL_1="103" TOTAL_2="102" WEIGHT="100.0" Z="0.6873984894725403">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="73.39016164239492" CI_START="0.12682449529220188" EFFECT_SIZE="3.0508474576271185" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8656378442376154" LOG_CI_START="-0.8967968573152918" LOG_EFFECT_SIZE="0.48442049346116184" ORDER="38911" O_E="0.0" SE="1.6226678179644862" STUDY_ID="STD-Morales-1993" TOTAL_1="58" TOTAL_2="59" VAR="2.633050847457627" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38912" O_E="0.0" SE="0.0" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0223152647865144" CI_END="1.68074017600559" CI_START="0.5393500488726698" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9521067671594792" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.26" LOG_CI_END="0.2255005814653414" LOG_CI_START="-0.2681292775781395" LOG_EFFECT_SIZE="-0.021314348056399025" METHOD="MH" MODIFIED="2014-09-08 05:54:39 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="26" P_CHI2="0.5540980378837375" P_Q="0.42684969616531765" P_Z="0.8655938596149855" Q="1.7026480686069099" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="213" TOTAL_2="317" WEIGHT="300.0" Z="0.16925781039843318">
<NAME>Patent ductus arteriosus</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6164802900064912" CI_END="7.663304268496128" CI_START="0.3588620976136875" DF="1" EFFECT_SIZE="1.6583333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-002.26.01" LOG_CI_END="0.8844160693914148" LOG_CI_START="-0.44507240866725106" LOG_EFFECT_SIZE="0.21967183036208185" MODIFIED="2014-05-08 03:36:00 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.43235844223684416" P_Z="0.5171848157923302" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="60" WEIGHT="100.0" Z="0.6476910225748856">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="79.62095080666157" CI_START="0.20483517758078085" EFFECT_SIZE="4.038461538461538" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9010273594779326" LOG_CI_START="-0.6885954572796923" LOG_EFFECT_SIZE="0.6062159510991201" ORDER="38888" O_E="0.0" SE="1.5211572614031115" STUDY_ID="STD-Besinger-1991" TOTAL_1="25" TOTAL_2="20" VAR="2.313919413919414" WEIGHT="21.666666666666668"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38889" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.64261094358732" CI_START="0.1505432138796847" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8223388166442885" LOG_CI_START="-0.8223388166442885" LOG_EFFECT_SIZE="0.0" ORDER="38890" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.9333333333333333" WEIGHT="78.33333333333333"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4097228231107874" CI_END="1.4891897788204036" CI_START="0.27963999895821645" DF="1" EFFECT_SIZE="0.6453193226596614" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="29.064069645028944" ID="CMP-002.26.02" LOG_CI_END="0.17295004673979344" LOG_CI_START="-0.5534007081609701" LOG_EFFECT_SIZE="-0.19022533071058834" MODIFIED="2014-05-08 03:45:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23510264037931583" P_Z="0.30461022434917717" STUDIES="2" TAU2="0.0" TOTAL_1="97" TOTAL_2="138" WEIGHT="100.0" Z="1.0265971216369485">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="2.087089857129812" CI_START="0.34065531708422603" EFFECT_SIZE="0.8431952662721893" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.3195411474916877" LOG_CI_START="-0.46768482802997685" LOG_EFFECT_SIZE="-0.07407184026914454" MODIFIED="2014-05-08 02:56:15 +0100" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.4624204348528519" STUDY_ID="STD-Klauser-2012" TOTAL_1="52" TOTAL_2="95" VAR="0.21383265856950065" WEIGHT="71.994035997018"/>
<DICH_DATA CI_END="2.5698834530964527" CI_START="0.007265745498578278" EFFECT_SIZE="0.13664596273291926" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40991342806872133" LOG_CI_START="-2.1387198184880085" LOG_EFFECT_SIZE="-0.8644031952096435" MODIFIED="2014-05-01 13:59:22 +0100" MODIFIED_BY="[Empty name]" ORDER="38891" O_E="0.0" SE="1.4970797849654607" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="2.24124788255223" WEIGHT="28.005964002982005"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2080868246163606E-31" CI_END="3.2551473635194093" CI_START="0.4976225435743295" DF="0" EFFECT_SIZE="1.2727272727272725" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="100.0" ID="CMP-002.26.03" LOG_CI_END="0.5125706542604752" LOG_CI_START="-0.3030999532204494" LOG_EFFECT_SIZE="0.1047353505200129" MODIFIED="2014-05-08 03:47:57 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="0.0" P_Z="0.6147292261386079" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="119" WEIGHT="100.0" Z="0.5033343436546581">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="3.2551473635194097" CI_START="0.4976225435743296" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.5125706542604753" LOG_CI_START="-0.30309995322044936" LOG_EFFECT_SIZE="0.10473535052001298" MODIFIED="2014-05-08 02:56:25 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="186" O_E="0.0" SE="0.4791289524689203" STUDY_ID="STD-Klauser-2012" TOTAL_1="51" TOTAL_2="119" VAR="0.22956455309396487" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.27" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 05:54:44 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="27" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal renal failure</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.27.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-08 03:36:05 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38887" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.287880916913355" CI_END="0.429123497751586" CI_START="0.23933764494694126" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.32047684369273644" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="146" I2="34.588710794203294" I2_Q="80.71020328431901" ID="CMP-002.28" LOG_CI_END="-0.36741770391420076" LOG_CI_START="-0.6209889866899045" LOG_EFFECT_SIZE="-0.4942033453020527" METHOD="MH" MODIFIED="2014-09-08 05:54:51 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="28" P_CHI2="0.12191345139316534" P_Q="0.005605081045088611" P_Z="2.1750858591390986E-14" Q="10.368175618845003" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="504" TOTAL_2="606" WEIGHT="300.0" Z="7.639830088236198">
<NAME>Maternal adverse effects</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0661098535525353" CI_END="0.3119813580681161" CI_START="0.11446307810808679" DF="4" EFFECT_SIZE="0.1889718141861843" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="75" I2="0.0" ID="CMP-002.28.01" LOG_CI_END="-0.5058713557572898" LOG_CI_START="-0.9413345793486315" LOG_EFFECT_SIZE="-0.7236029675529606" MODIFIED="2014-05-08 03:36:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7236009822668767" P_Z="7.332779795275514E-11" STUDIES="5" TAU2="0.0" TOTAL_1="123" TOTAL_2="125" WEIGHT="100.0" Z="6.513687855491765">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="1.0570974471925993" CI_START="0.0038198807148802695" EFFECT_SIZE="0.06354515050167224" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.024115024040935438" LOG_CI_START="-2.417950198784137" LOG_EFFECT_SIZE="-1.1969175873716007" ORDER="38894" O_E="0.0" SE="1.43448120030526" STUDY_ID="STD-Besinger-1991" TOTAL_1="22" TOTAL_2="18" VAR="2.0577363140292197" WEIGHT="9.44241554926965"/>
<DICH_DATA CI_END="1.4534097911536128" CI_START="0.0056862578332829376" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.16238808156913231" LOG_CI_START="-2.2451734518855826" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="38895" O_E="0.0" SE="1.4142135623730951" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="2.0" WEIGHT="7.294976561475885"/>
<DICH_DATA CI_END="0.49969119388865557" CI_START="0.1152711928976575" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="25" LOG_CI_END="-0.3012983041080696" LOG_CI_START="-0.9382792124687184" LOG_EFFECT_SIZE="-0.619788758288394" ORDER="38896" O_E="0.0" SE="0.37416573867739417" STUDY_ID="STD-Kurki-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.14" WEIGHT="33.15898437034493"/>
<DICH_DATA CI_END="0.37599760241423646" CI_START="0.07966971360836778" EFFECT_SIZE="0.17307692307692307" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="36" LOG_CI_END="-0.4248149243850699" LOG_CI_START="-1.0987067440058786" LOG_EFFECT_SIZE="-0.7617608341954742" MODIFIED="2014-05-06 12:55:27 +0100" MODIFIED_BY="[Empty name]" ORDER="38897" O_E="0.0" SE="0.3958473906635696" STUDY_ID="STD-Morales-1989" TOTAL_1="52" TOTAL_2="54" VAR="0.15669515669515668" WEIGHT="46.84801414436657"/>
<DICH_DATA CI_END="3.922148101035621" CI_START="0.05910649242143361" EFFECT_SIZE="0.48148148148148145" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5935239886811181" LOG_CI_START="-1.2283648123854192" LOG_EFFECT_SIZE="-0.3174204118521506" MODIFIED="2014-05-06 12:53:58 +0100" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="1.0701865002414976" STUDY_ID="STD-Nevils-1994" TOTAL_1="9" TOTAL_2="13" VAR="1.1452991452991452" WEIGHT="3.255609374542957"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1253234626809974" CI_END="0.619882583944442" CI_START="0.24569678421750013" DF="3" EFFECT_SIZE="0.3902603713773459" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="53" I2="4.009935745130557" ID="CMP-002.28.02" LOG_CI_END="-0.2076905652988188" LOG_CI_START="-0.6096005277109418" LOG_EFFECT_SIZE="-0.4086455465048803" MODIFIED="2014-05-08 03:45:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.37270375777378917" P_Z="6.730364194946299E-5" STUDIES="5" TAU2="0.0" TOTAL_1="298" TOTAL_2="337" WEIGHT="100.0" Z="3.985621798401554">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="2.012954946894688" CI_START="0.0061331124332369685" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.30383405480222114" LOG_CI_START="-2.212319073680871" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2013-12-05 23:58:55 +0000" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="1.4780008028298286" STUDY_ID="STD-Borna-2007" TOTAL_1="52" TOTAL_2="52" VAR="2.184486373165618" WEIGHT="8.389532648081685"/>
<DICH_DATA CI_END="15.66563250421922" CI_START="0.02709574557806637" EFFECT_SIZE="0.6515151515151515" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.1949479343308238" LOG_CI_START="-1.5670988942553883" LOG_EFFECT_SIZE="-0.18607547996228216" MODIFIED="2014-05-08 03:10:45 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="193" O_E="0.0" SE="1.6224399794638473" STUDY_ID="STD-Klauser-2012" TOTAL_1="43" TOTAL_2="85" VAR="2.6323114869626494" WEIGHT="1.8930227513620212"/>
<DICH_DATA CI_END="0.8639134783445486" CI_START="0.3031469748301827" EFFECT_SIZE="0.5117545871559633" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="32" LOG_CI_END="-0.06352975029783428" LOG_CI_START="-0.5183467613268009" LOG_EFFECT_SIZE="-0.2909382558123176" ORDER="38898" O_E="0.0" SE="0.2671617636589294" STUDY_ID="STD-McWhorter-2004" TOTAL_1="109" TOTAL_2="105" VAR="0.07137540796134967" WEIGHT="60.77401843511717"/>
<DICH_DATA CI_END="0.6409480733020146" CI_START="0.061772364434360946" EFFECT_SIZE="0.1989795918367347" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" LOG_CI_END="-0.1931771536198455" LOG_CI_START="-1.2092057750401082" LOG_EFFECT_SIZE="-0.7011914643299768" ORDER="38899" O_E="0.0" SE="0.5968202416450518" STUDY_ID="STD-Morales-1993" TOTAL_1="49" TOTAL_2="52" VAR="0.35619440083725795" WEIGHT="28.943426165439124"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38900" O_E="0.0" SE="0.0" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.009302228036094116" CI_END="1.2303536604502427" CI_START="0.3642645581241584" DF="1" EFFECT_SIZE="0.6694581633383437" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" I2="0.0" ID="CMP-002.28.03" LOG_CI_END="0.09002996567115712" LOG_CI_START="-0.43858308228509635" LOG_EFFECT_SIZE="-0.17427655830696961" MODIFIED="2014-05-08 03:48:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9231647252263525" P_Z="0.19623695733803984" STUDIES="2" TAU2="0.0" TOTAL_1="83" TOTAL_2="144" WEIGHT="100.0" Z="1.2923471297270102">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="1.2299496346608443" CI_START="0.35808899013941564" EFFECT_SIZE="0.6636500754147813" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.08988732783231153" LOG_CI_START="-0.4460090316694829" LOG_EFFECT_SIZE="-0.17806085191858573" MODIFIED="2013-12-06 00:12:05 +0000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.3147881743011163" STUDY_ID="STD-Kashanian-2011" TOTAL_1="39" TOTAL_2="40" VAR="0.09909159467982998" WEIGHT="94.91088683701955"/>
<DICH_DATA CI_END="18.731096908615406" CI_START="0.032295934111936375" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2725632107660492" LOG_CI_START="-1.4908521496161853" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2014-05-08 03:10:55 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="194" O_E="0.0" SE="1.6232438618151726" STUDY_ID="STD-Klauser-2012" TOTAL_1="44" TOTAL_2="104" VAR="2.634920634920635" WEIGHT="5.0891131629804605"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.06427636416505" CI_END="1.24148479821385" CI_START="0.15971252093744895" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.44528717343783225" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="33" I2="64.44893522755493" I2_Q="64.04857625688507" ID="CMP-002.29" LOG_CI_END="0.09394140605549618" LOG_CI_START="-0.7966610352648674" LOG_EFFECT_SIZE="-0.3513598146046856" METHOD="MH" MODIFIED="2014-09-08 05:54:56 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="29" P_CHI2="0.015206254026016053" P_Q="0.06194364382124584" P_Z="0.1219869791954821" Q="5.563062020271231" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.856303639030438" TOTALS="SUB" TOTAL_1="265" TOTAL_2="366" WEIGHT="300.0" Z="1.5464870750160797">
<NAME>Maternal adverse effects requiring cessation of treatment</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9236502504824001" CI_END="0.48516564822179487" CI_START="0.017245392280544274" DF="2" EFFECT_SIZE="0.09147060688893127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="19" I2="0.0" ID="CMP-002.29.01" LOG_CI_END="-0.3141099566015533" LOG_CI_START="-1.763326922297572" LOG_EFFECT_SIZE="-1.0387184394495625" MODIFIED="2014-05-08 03:36:15 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.6301325586594579" P_Z="0.004960507645203667" STUDIES="3" TAU2="0.0" TOTAL_1="84" TOTAL_2="82" WEIGHT="100.00000000000001" Z="2.809587217909817">
<NAME>COX inhibitor versus betamimetics</NAME>
<DICH_DATA CI_END="6.377231921964282" CI_START="0.011889861865633084" EFFECT_SIZE="0.2753623188405797" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8046322113416227" LOG_CI_START="-1.9248231909104754" LOG_EFFECT_SIZE="-0.5600954897844264" ORDER="38901" O_E="0.0" SE="1.6032956143050265" STUDY_ID="STD-Besinger-1991" TOTAL_1="22" TOTAL_2="18" VAR="2.5705568268497325" WEIGHT="28.191281230676026"/>
<DICH_DATA CI_END="1.4534097911536128" CI_START="0.0056862578332829376" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.16238808156913231" LOG_CI_START="-2.2451734518855826" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="38902" O_E="0.0" SE="1.4142135623730951" STUDY_ID="STD-Kramer-1999" TOTAL_1="10" TOTAL_2="10" VAR="2.0" WEIGHT="36.23364521257749"/>
<DICH_DATA CI_END="0.6303692530608849" CI_START="0.0023434251668639316" EFFECT_SIZE="0.03843466107617051" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.20040497818291544" LOG_CI_START="-2.63014891034815" LOG_EFFECT_SIZE="-1.4152769442655324" ORDER="38903" O_E="0.0" SE="1.4272436131802986" STUDY_ID="STD-Morales-1989" TOTAL_1="52" TOTAL_2="54" VAR="2.0370243313639538" WEIGHT="35.57507355674649"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.809972547080196" CI_END="186.10072092036904" CI_START="0.004441710648785998" DF="1" EFFECT_SIZE="0.9091785049476004" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="85.31565299145363" ID="CMP-002.29.02" LOG_CI_END="2.2697480555119154" LOG_CI_START="-2.3524497365864208" LOG_EFFECT_SIZE="-0.041350840537252645" MODIFIED="2014-08-30 04:34:38 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="0.00906507141850077" P_Z="0.9720253309697392" STUDIES="3" TAU2="12.578992150618543" TOTAL_1="137" TOTAL_2="180" WEIGHT="100.0" Z="0.03506823456236458">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="259.0190437779198" CI_START="0.7226964706148289" EFFECT_SIZE="13.681818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.4133316957554567" LOG_CI_START="-0.14104406621218252" LOG_EFFECT_SIZE="1.1361438147716372" MODIFIED="2014-05-08 02:58:34 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="188" O_E="0.0" SE="1.5004529669437388" STUDY_ID="STD-Klauser-2012" TOTAL_1="43" TOTAL_2="85" VAR="2.2513591060102685" WEIGHT="49.707373754514364"/>
<DICH_DATA CI_END="1.0522451585135428" CI_START="0.003694851187387394" EFFECT_SIZE="0.06235294117647059" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.022116936191796943" LOG_CI_START="-2.4324030484188044" LOG_EFFECT_SIZE="-1.2051430561135037" MODIFIED="2014-08-30 04:34:38 +0100" MODIFIED_BY="[Empty name]" ORDER="38904" O_E="0.0" SE="1.4417971890301449" STUDY_ID="STD-Morales-1993" TOTAL_1="49" TOTAL_2="52" VAR="2.0787791342952273" WEIGHT="50.292626245485636"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38905" O_E="0.0" SE="0.0" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.514907950078463" CI_START="0.309351647989138" DF="0" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-002.29.03" LOG_CI_END="0.6546489003459801" LOG_CI_START="-0.5095475660487565" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2014-05-08 03:48:09 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="1.0" P_Z="0.8070116596603985" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="104" WEIGHT="100.0" Z="0.24428298619731179">
<NAME>COX inhibitor versus calcium channel blocker</NAME>
<DICH_DATA CI_END="4.514907950078463" CI_START="0.309351647989138" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.6546489003459801" LOG_CI_START="-0.5095475660487565" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2014-05-08 02:58:48 +0100" MODIFIED_BY="Hanna E Reinebrant" ORDER="187" O_E="0.0" SE="0.6838547672257193" STUDY_ID="STD-Klauser-2012" TOTAL_1="44" TOTAL_2="104" VAR="0.46765734265734266" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.30" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 05:55:01 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="30" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Chorioamnionitis or endometritis</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.30.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-09-04 04:20:36 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38913" O_E="0.0" SE="0.0" STUDY_ID="STD-Schorr-1998" TOTAL_1="45" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1300856162980835" CI_START="0.7049511391272042" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2254004576659039" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.31" LOG_CI_END="0.3283970597479168" LOG_CI_START="-0.15184098335301155" LOG_EFFECT_SIZE="0.0882780381974526" METHOD="MH" MODIFIED="2014-09-08 05:55:06 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="31" P_CHI2="1.0" P_Q="1.0" P_Z="0.47117614188817314" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="92" TOTAL_2="102" WEIGHT="100.0" Z="0.720566718853198">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>COX inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Other tocolytic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COX inhibitor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other tocolytic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1300856162980835" CI_START="0.7049511391272042" DF="0" EFFECT_SIZE="1.2254004576659039" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" I2="0.0" ID="CMP-002.31.01" LOG_CI_END="0.3283970597479168" LOG_CI_START="-0.15184098335301155" LOG_EFFECT_SIZE="0.0882780381974526" MODIFIED="2014-09-04 04:20:43 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="1.0" P_Z="0.47117614188817314" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="102" WEIGHT="100.0" Z="0.720566718853198">
<NAME>COX inhibitor versus magnesium sulphate</NAME>
<DICH_DATA CI_END="2.1300856162980835" CI_START="0.7049511391272042" EFFECT_SIZE="1.2254004576659039" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.3283970597479168" LOG_CI_START="-0.15184098335301155" LOG_EFFECT_SIZE="0.0882780381974526" ORDER="38914" O_E="0.0" SE="0.2820942037341379" STUDY_ID="STD-McWhorter-2004" TOTAL_1="92" TOTAL_2="102" VAR="0.0795771397803973" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-04-13 18:02:35 +0100" MODIFIED_BY="Heather Maxwell" NO="3">
<NAME>Non-selective COX inhibitors compared with selective COX-2 inhibitors</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 06:01:04 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Birth less than 48 hours after trial entry</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-13 06:04:08 +0000" MODIFIED_BY="[Empty name]" ORDER="38921" O_E="0.0" SE="0.0" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 06:01:35 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38915" O_E="0.0" SE="0.0" STUDY_ID="STD-Sawdy-2003" TOTAL_1="20" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38916" O_E="0.0" SE="0.0" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1884354133806605" CI_START="0.31363345037612406" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.5035776241156603" LOG_CI_START="-0.5035776241156603" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-09-08 06:02:09 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="22" WEIGHT="100.0" Z="0.0">
<NAME>Preterm birth (before completion of 37 weeks of gestation)</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1884354133806605" CI_START="0.31363345037612406" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5035776241156603" LOG_CI_START="-0.5035776241156603" LOG_EFFECT_SIZE="0.0" ORDER="38938" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Sawdy-2003" TOTAL_1="20" TOTAL_2="10" VAR="0.35" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38939" O_E="0.0" SE="0.0" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="67.05568402675195" CI_START="0.13421680996363317" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2014-09-08 06:03:04 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4882790296766242" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6930486441661347">
<NAME>Birth less than 7 days after trial entry</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-03-13 06:04:11 +0000" MODIFIED_BY="[Empty name]" ORDER="38922" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.8051003816361253" CI_START="-2.8051003816361253" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2014-09-08 06:03:32 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Gestational age (weeks)</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours selective COX-2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-selective</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.8051003816361253" CI_START="-2.8051003816361253" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="35.7" MEAN_2="35.7" ORDER="38923" SD_1="3.3" SD_2="3.7" SE="1.4311999627352334" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="603.5829076395514" CI_START="-549.5829076395514" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="27.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2015-04-13 18:02:35 +0100" MODIFIED_BY="Heather Maxwell" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.926872492492283" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.09178043067427102">
<NAME>Birthweight (g)</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours selective COX-2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-selective</GRAPH_LABEL_2>
<CONT_DATA CI_END="603.5829076395514" CI_START="-549.5829076395514" EFFECT_SIZE="27.0" ESTIMABLE="YES" MEAN_1="2547.0" MEAN_2="2520.0" ORDER="38924" SD_1="732.0" SD_2="709.0" SE="294.18035851044397" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.207980025005394" CI_START="0.07038298183415558" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="1.1525323378604808" LOG_CI_START="-1.1525323378604808" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-09-08 06:04:26 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>Respiratory distress syndrome</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.207980025005401" CI_START="0.07038298183415555" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.152532337860481" LOG_CI_START="-1.152532337860481" LOG_EFFECT_SIZE="0.0" ORDER="38917" O_E="0.0" SE="1.3540064007726602" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="1.8333333333333335" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 06:04:51 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Intraventricular haemorrhage Grades III or IV</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38918" O_E="0.0" SE="0.0" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.806764937105011" CI_START="0.05201003237544802" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.6818528845554626" LOG_CI_START="-1.283912875883425" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2014-09-08 06:05:15 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.5483176049619031" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6002830669264718">
<NAME>Intraventricular haemorrhage - all grades</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.8067649371050125" CI_START="0.052010032375448" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6818528845554627" LOG_CI_START="-1.283912875883425" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="38919" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 06:05:40 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38920" O_E="0.0" SE="0.0" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="67.05568402675195" CI_START="0.13421680996363317" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2014-09-08 06:06:06 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.4882790296766242" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6930486441661347">
<NAME>Apgar score less than 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="38925" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.911692862790177" CI_START="0.3434428173312668" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.46414556190805994" LOG_CI_START="-0.46414556190805994" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-09-08 06:06:39 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="22" WEIGHT="100.0" Z="0.0">
<NAME>Admission to neonatal intensive care unit</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1884354133806605" CI_START="0.31363345037612406" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5035776241156603" LOG_CI_START="-0.5035776241156603" LOG_EFFECT_SIZE="0.0" ORDER="38926" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Sawdy-2003" TOTAL_1="20" TOTAL_2="10" VAR="0.35" WEIGHT="80.0"/>
<DICH_DATA CI_END="14.207980025005401" CI_START="0.07038298183415555" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.152532337860481" LOG_CI_START="-1.152532337860481" LOG_EFFECT_SIZE="0.0" ORDER="38927" O_E="0.0" SE="1.3540064007726602" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="1.8333333333333335" WEIGHT="20.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.207980025005394" CI_START="0.07038298183415558" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="1.1525323378604808" LOG_CI_START="-1.1525323378604808" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-09-08 06:07:09 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>Use of mechanical ventilation</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.207980025005401" CI_START="0.07038298183415555" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.152532337860481" LOG_CI_START="-1.152532337860481" LOG_EFFECT_SIZE="0.0" ORDER="38928" O_E="0.0" SE="1.3540064007726602" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="1.8333333333333335" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.450631558527997" CI_START="0.014912978884848133" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2014-09-08 06:07:33 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.4882790296766242" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6930486441661347">
<NAME>Neonatal sepsis</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.450631558527997" CI_START="0.014912978884848133" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="38929" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 06:08:01 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Premature closure of the ductus arteriosus</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38934" O_E="0.0" SE="0.0" STUDY_ID="STD-Sawdy-2003" TOTAL_1="20" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38935" O_E="0.0" SE="0.0" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="30.762288933068753" CI_START="0.5201173435049682" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="1.488018646929696" LOG_CI_START="-0.2838986642737713" LOG_EFFECT_SIZE="0.6020599913279624" METHOD="MH" MODIFIED="2014-09-08 06:08:25 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.18289024441209284" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="1.331908540059185">
<NAME>Oligohydramnios</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="30.762288933068753" CI_START="0.520117343504968" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.488018646929696" LOG_CI_START="-0.28389866427377153" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="38933" O_E="0.0" SE="1.0408329997330665" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="1.0833333333333335" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-08 06:08:53 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Maternal adverse effects</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38930" O_E="0.0" SE="0.0" STUDY_ID="STD-Sawdy-2003" TOTAL_1="20" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38931" O_E="0.0" SE="0.0" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.450631558527997" CI_START="0.014912978884848133" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2014-09-08 06:09:16 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.4882790296766242" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6930486441661347">
<NAME>Antepartum haemorrhage</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.450631558527997" CI_START="0.014912978884848133" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="38932" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.227059748420047" CI_START="0.20804012950179213" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="1.283912875883425" LOG_CI_START="-0.6818528845554624" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2014-09-08 06:09:48 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.5483176049619031" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6002830669264718">
<NAME>Chorioamnionitis or endometritis</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.227059748420054" CI_START="0.20804012950179201" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2839128758834253" LOG_CI_START="-0.6818528845554628" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="38936" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.303025227094487" CI_START="0.13455678170384452" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="0.5189118906596526" LOG_CI_START="-0.8710944087710152" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" MODIFIED="2014-09-08 06:10:12 +0100" MODIFIED_BY="Hanna E Reinebrant" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.6194772830713247" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.4965913116837106">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Non-selective</GROUP_LABEL_1>
<GROUP_LABEL_2>Selective COX-2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-selective</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selective COX-2</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.303025227094486" CI_START="0.13455678170384458" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5189118906596525" LOG_CI_START="-0.871094408771015" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="38937" O_E="0.0" SE="0.8164965809277259" STUDY_ID="STD-Stika-2002" TOTAL_1="12" TOTAL_2="12" VAR="0.6666666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-04-13 13:55:07 +0100" MODIFIED_BY="Heather Maxwell">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-04-13 13:55:07 +0100" MODIFIED_BY="Heather Maxwell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-04-13 13:55:07 +0100" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU8AAAOtCAIAAACOvHAFAAAxOElEQVR42u3dvW5dRdvGcUtIiMJF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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-02-25 17:18:40 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2013-10-31 11:54:33 +0000" MODIFIED_BY="Jill V Hampson"/>
<EXTENSIONS MODIFIED="2014-02-25 17:18:40 +0000" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>